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Abstract
Clostridium difficile infection is the most common nosocomial infection in the US
and other developed countries, yet standard antibiotic therapy for this infection fails to
cure nearly a quarter of patients. These individuals experience a recurrence of the
infection, and a large subset of patients with a single recurrence go on to develop
recurrent C. difficile infection syndrome (R-CDI), characterized by vicious cycles of
repeated antibiotic use and recurrence of disease. Although fecal microbiota
transplantation (FMT) is now widely recognized as an extremely effective therapy for R-
CDI, its mechanisms were heretofore unknown. This substantial gap in our knowledge
limited both our ability to design novel therapies for R-CDI and our understanding of the
role our native intestinal microbes play in our health.
The work herein summarizes our efforts to identify and test the mechanisms
behind this important treatment. Our findings indicate that fecal bile acid composition,
which is significantly altered following FMT, also dramatically impacts C. difficile
physiology. Bile acids present after FMT, compared to those present prior to the
procedure, prevent germination of C. difficile spores and limit the growth of vegetative
cells. With this knowledge, we demonstrated that a bile acid already clinically available,
ursodeoxycholic acid (UDCA), can also prevent C. difficile germination and growth.
Although unfortunately UDCA is a poor treatment option for many patients due to its
absorption in the small intestine, we showed both that a non-absorbed derivative of
UDCA, C7-sulfated UDCA, may be a promising novel therapy for R-CDI, and that
UDCA may still have clinical utility in patients with altered gastrointestinal anatomy.
These findings have paved the way for novel treatments for this widespread infection.
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1Chapter 1
Introduction
2Clostridium difficile infection and basic biology
Each year in the US, nearly half a million individuals suffer from hospital-
acquired infections with the bacterium Clostridium difficile (Lessa et al., 2015). This
bacterium enters the gastrointestinal tract through the fecal-oral route and, typically in
patients who have recently received antibiotics (Kelly and Lamont, 2008; Miller et al.,
2011; Ananthrakishnan, 2011; Lessa et al., 2012; Khanna et al., 2012; Chitnis et al.,
2013; Borody and Khoruts, 2011; Hu et al., 2009; Fashner et al., 2011), colonizes the
colon and causes inflammation, abdominal pain, and diarrhea (Cohen et al., 2010;
Kachrimanidou and Malisiovas, 2011). Some unlucky patients may experience more
severe clinical sequelae, including toxic megacolon, ileus, and pseudomembranous colitis
(Cohen et al., 2010).
Unfortunately, in addition to causing debilitating symptoms, Clostridium difficile
infection (CDI) is extremely common. CDI has surpassed methicillin-resistant
Staphylococcus aureus as the most common nosocomial infection in the US (Zilberberg
et al., 2008; Miller et al., 2011; Dubberke and Olsen, 2012; Magill et al., 2014).
Furthermore, it is increasingly recognized that CDI can occur in a community (rather than
hospital) setting; between 32% and 41% of CDI cases are predicted to be community-
associated (Khanna et al., 2012; Lessa et al., 2014; Lessa et al., 2015). Unsurprisingly the
costs associated with this common infection are staggering; in 2008 alone it is estimated
that excess healthcare costs associated with treating CDI may have been as high as $4.8
billion (Dubberke and Olsen, 2012). Furthermore, CDI was responsible for the deaths of
2600 individuals in the US in 2000, which rose to over 14,000 in 2007 (Hall et al., 2012).
3The most recent epidemiological data, from 2011, estimates over 29,000 deaths are due to
CDI each year (Lessa et al., 2015). The healthcare and economic burden of CDI,
complicated by its increasing resistance to standard antibiotic therapies (McDonald et al.,
2005; Vardakas et al., 2012), make this an important disease to understand and treat
effectively.
The causative agent of CDI, the bacterium Clostridium difficile, is a Gram-
positive, anaerobic, spore-forming rod which possesses a Pathogenicity Locus (PaLoc)
encoding the toxins responsible for disease symptoms. These toxins, Toxin A and Toxin
B (TcdA and TcdB), are Rho-glucosylating exotoxins which bind to human epithelial
cells and cause inflammation, edema, neutrophil recruitment, and cytoskeleton
depolymerization (Linevsky et al., 1997; Voth and Ballard, 2005; Nam et al., 2010;
Kachrimanidou and Malisiovas, 2011). The relative importance of each toxin in CDI
pathogenesis is not entirely clear, though evidence suggests that TcdB, but not TcdA, is
essential for virulence (Lyras et al., 2009). The PaLoc also encodes a sigma factor (TcdR)
which promotes transcription of tcdA and tcdB, a putative holin (TcdE), and a negative
transcriptional regulator (TcdC) (Kachrimanidou and Malisiovas, 2011).
Mutations in some of these PaLoc genes as well as other mechanisms may
account for the emergence of hypervirulent strains of C. difficile, particularly the North
American pulsed-field gel electrophoresis type 1 (NAP1) strain, which is also described
as restriction endonuclease analysis group BI and polymerase chain reaction ribotype 027
(McDonald et al., 2005; Loo et al., 2005; Warny et al., 2005). NAP1/BI/027 isolates
contain mutations in tcdC, which may increase toxin production (McDonald et al., 2005).
These isolates also produce another toxin, the binary toxin or CDT, which is encoded at a
4separate locus from TcdA and TcdB and also causes cytoskeleton disruption
(Kachrimanidou and Malisiovas, 2011; Perelle et al., 1997). In addition to increased or
alternative toxin production, hypervirulent strains of C. difficile are also resistant to
fluoroquinolone antibiotics (McDonald et al., 2005) and sporulate with greater efficiency
than other strains (Merrigan et al., 2010). Together, these characteristics may help explain
why NAP1/BI/027 isolates are frequently responsible for major outbreaks of CDI
(McDonald et al., 2005) as well as clinically severe and recurrent cases of the infection
(Marsh et al., 2012; See et al., 2014).
5Sporulation and germination of C. difficile
In particular, the sporulation of NAP1/BI/027 isolates and other C. difficile strains
is thought to be critical for CDI pathogenesis. C. difficile spores are highly resistant to
disinfectants and antibiotics (Lawley et al., 2010; Carroll and Bartlett, 2011; Paredes-
Sabja et al., 2014) and can survive on hospital surfaces for at least five months (Kim et
al., 1981). As with other spore-forming bacteria such as Bacillus subtilis, the
transcriptional regulator Spo0A appears to be vital for sporulation in C. difficile
(Underwood et al., 2009) and is also required for persistence and transmission of the
pathogen (Deakin et al., 2012). However, both the upstream regulation and activation of
Spo0A and its downstream targets are less well understood in C. difficile than in other
organisms. In other species, several orphan histidine kinases phosphorylate Spo0A to
initiation sporulation (Steiner et al., 2011; Higgins and Dworkin, 2012). While several
orphan histidine kinase genes have been discovered in the C. difficile genome
(Underwood et al., 2009), it is currently unclear whether these histidine kinases
participate in sporulation. Following phosphorylation, Spo0A initiates a cascade of
sporulation-specific sigma factors which ultimately direct the process of sporulation (de
Hoon et al., 2010). In C. difficile, four sigma factors have been identified in this cascade,
including two (σE and σK) in the mother cell and two (σF and σG) in the forespore
(Paredes-Sabja et al., 2014). In contrast to B. subtilis, however, there is substantially less,
if any, cross-talk between the mother cell and forespore using these sigma factors
(Fimlaid et al., 2013; Pereira et al., 2013; Saujet et al., 2013). Despite these recent
6insights into C. difficile sporulation, the noticeable differences in sporulation mechanisms
between C. difficile and other organisms suggest there is much left to understand.
Even the relative paucity of knowledge concerning C. difficile sporulation,
however, is much greater than what is currently known about the germination of the
resulting spores. In Bacillus subtilis, germinants such as amino acids, sugars, or
nucleotides bind to the germinant receptor, triggering the release of Ca2+-dipicolinic acid
(DPA) from the specialized spore coat, followed by hydrolysis of the cell cortex, loss of
resistance, loss of dormancy, and ultimately outgrowth (Setlow, 2003). However, recent
work has demonstrated that in C. difficile, cortex hydrolysis precedes and may even
trigger DPA release, suggesting that germination in C. difficile proceeds via a novel
pathway (Francis et al., 2015).
In support of the idea that the process of germination in C. difficile is distinct from
other bacteria, very little is known about the underlying mechanisms. Recent
bioinformatics analyses have unfortunately uncovered very few genes which are
homologous to other known germinant receptors and spore proteins (Sebaihia et al.,
2006; Sebaihia et al., 2007; Lawley et al., 2009). However, it has been recently
demonstrated that CspC, an analog of a subtilisin-family of proteases in which have been
shown to activate the cortex lytic enzyme SleC to induce germination in Clostridium
perfringens, may be a germinant receptor for C. difficile (Francis et al., 2013). In C.
difficile, CspC has lost its catalytic domain, but is necessary for germination and required
for infection in a hamster model of CDI (Francis et al., 2013). Beyond this work,
however, little is known about how C. difficile senses germinants and initiates the process
of germination.
7Despite minimal knowledge of the genetics and regulation of C. difficile
germination, there is a growing body of work focused on the specific germinants which
trigger the process. Most of these germinants are bile acids, molecules produced by the
human liver to aid lipid digestion in the small intestine (Hofmann, 1999). The bile acids
directly produced and secreted by the liver as known as primary bile acids (Hofmann,
1999). Although ~95% of primary bile acids are absorbed by the small intestine and
returned to the liver via enterohepatic circulation (Hofmann and Hagey, 2008), around
5% enter the colon, where they are modified by native intestinal bacteria to form the
secondary bile acids (Ridlon et al., 2006). The two major primary bile acids in humans
are cholate (CA) and chenodeoxycholic acid (CDCA) (Hofmann and Hagey, 2008).
During production in the liver, the majority of these primary bile acids are conjugated to
either glycine or taurine to increase solubility, then stored in the gallbladder until they are
released post-prandially to assist in digestion (Russell and Setchell, 1992; Hofmann,
1999; Hoffman and Hagey, 2008).
Upon reaching the colon, the first transformation these bile acids undergo is the
removal of the conjugated taurine or glycine by bacterial bile salt hydrolases (BSHs)
(Ridlon et al., 2006). BSHs are widespread among colonic microbes, as these genes have
been identified in the Firmicutes, Bacteroidetes, and Actinobacteria phyla, as well as in
the human gut archaeon Methanobrevibacter smithii (Jones et al., 2008). After
deconjugation, CA and CDCA can be metabolized into their respective secondary bile
acids, deoxycholate (DCA) and lithocholic acid (LCA), which comprise most of the bile
acids found in feces (Ridlon et al., 2006). This process is known as 7α-dehydroxylation,
and in contrast to deconjugation, is performed by a very limited number of intestinal
8organisms. It is currently estimated that only approximately 0.0001% of colonic bacteria
can perform 7α-dehydroxylation, all of which are exclusively members of the
Clostridium genus (Wells et al., 2000; Wells et al., 2003; Ridlon et al., 2006). The genes
responsible for 7α-dehydroxylation are encoded by the bile acid inducible (bai) operon,
which has been well-characterized in two species, Clostridium scindens and Clostridium
hylemonae, both of which are members of the Lachnospiraceae family (Ridlon et al.,
2010).
All of these bile acids, primary and secondary, appear to have important effects
on C. difficile physiology. It has been recognized for decades that the addition of
taurocholate (TA), the taurine conjugate of CA, to laboratory media is essential for C.
difficile growth (Wilson et al., 1982; Buggy et al., 1985). Specifically, TA, as well as CA,
has been shown to cause germination of C. difficile (Wilson, 1983; Sorg and Sonenshein,
2008). It has also been suggested that DCA, the secondary bile acid derived from CA, can
induce germination (Sorg and Sonenshein, 2008). In contrast, the primary bile acid
CDCA and its secondary bile acid derivative LCA seem to inhibit TA-mediated
germination (Sorg and Sonenshein, 2009; Sorg and Sonenshein, 2010). Recently,
however, it has been shown that different isolates of C. difficile may respond different to
CDCA: while for the majority of isolates CDCA inhibits germination, on some it has no
effect, and in others CDCA may itself induce germination (Heeg et al., 2012).
In addition to affecting germination, many of these bile acids have important
effects on vegetative growth of C. difficile. While TA appears to have no impact on
growth, growth is significantly inhibited by CDCA and DCA (Sorg and Sonenshein,
2008). Furthermore, colony formation from spores, a function of both germination and
9vegetative growth, is induced by CA, TA, and glycocholate, but not by CDCA (Wilson,
1983; Sorg and Sonenshein, 2008). In addition to understanding how these bile acids
impact growth, and as our knowledge of the mechanisms of germination in C. difficile
increases, it will important to fully assess the effects of the bile acids in the human colon
on C. difficile physiology.
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Treatment of C. difficile infection
An understanding of the physiology of C. difficile is vital for effectively treating
CDI and investigating new, more effective therapies for the infection. Although antibiotic
use is a major risk factor for CDI (Kelly and Lamont, 2008; Borody and Khoruts, 2011;
Louie et al., 2011; Surawicz and Alexander, 2011; Fashner et al., 2011), the current
recommendation for the treatment of this disease is the use of further antibiotics. Oral
metronidazole is the first-line therapy for an initial (mild or moderate) episode, while oral
vancomycin with or without intravenous metronidazole is recommended for severe or
complicated initial episodes of the disease (Cohen et al., 2010). Recurrences of the
disease are also treated with these two antibiotics, and for patients with multiple
recurrences a tapered and/or pulsed regimen of vancomycin may be used (Cohen et al.,
2010).
While vancomycin and metronidazole remain the primary choices for initial
infections, the use of these antibiotics frequently fails to clear the infection, leading to a
recurrence of disease once antibiotics are halted. Infection recurs following vancomycin
treatment in 24% of patients, while the recurrence rate of metronidazole is 27%
(Vardakas et al., 2012). Overall, it is estimated that there are over 83,000 first recurrences
of CDI each year (Lessa et al., 2015). Unfortunately, the rate of recurrence for patients
who have already experienced a recurrence can be as great as 65% or higher (Khoruts
and Sadowsky, 2011), suggesting that patients with recurrent CDI can become refractory
to antibiotic therapy. Indeed, some patients enter vicious cycles characterized by repeated
11
antibiotic use and CDI recurrence, a condition referred to as recurrent CDI syndrome (R-
CDI) (Borody and Khoruts, 2011).
With the observed increase in CDI over the past fifteen years, along with
concomitant increases in R-CDI (Pepin et al., 2005; Kelly and Lamont, 2008), there has
been a push to develop novel therapies for this disease. One recently FDA-approved new
treatment for CDI is fidaxomicin, a macrocyclic antibiotic. In a recent Phase 3 clinical
trial, fidaxomicin was shown to be equally effective to vancomycin, but was associated
with a significantly lower rate of recurrence (Louie et al., 2011). Further work has
indicated that, compared to vancomycin, fidaxomicin has a less dramatic impact on the
fecal microbiota, sparing the Bacteroides/Prevotella groups and Clostridium clusters IV
and XIVa, which may explain the decreased rate of recurrence with the new antibiotic
(Louie et al., 2012).
An older but increasingly popular treatment for CDI, particularly those
individuals with R-CDI who are refractory to antibiotic therapy, is fecal microbiota
transplantation (FMT). First described as an effective treatment for pseudomembranous
colitis in 1958 by Eiseman and colleagues (Eiseman et al., 1958), FMT involves the
delivery of fecal material from a healthy donor into the gastrointestinal tract of a patient,
either by enema (Eiseman et al., 1958; Schwan et al., 1983; Tvede and Rask-Madsen,
1989), nasogastric tube (Aas et al., 2003; MacConnachie et al., 2009; van Nood et al.,
2013), or colonoscopy (Lund-Tonnesen et al., 1998; Yoon and Brandt, 2010; Hamilton et
al., 2012). The overall rate of clinical resolution following an FMT is ~90%, substantially
higher than vancomycin, metronidazole, and even fidaxomicin (Kassam et al., 2013).
FMT via lower gastrointestinal delivery (enema and colonoscopy) is especially
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efficacious at 91%, compared to upper gastrointestinal delivery (nasogastric tube) at 82%
(Kassam et al., 2013). Furthermore, a recent randomized controlled trial comparing FMT
to vancomycin determined that FMT was significantly more effective than the antibiotic
(van Nood et al., 2013); in fact the study was halted early by the data and safety
monitoring board because of the high rate of relapse in control patients. FMT, therefore,
is an extremely promising therapy for individuals with R-CDI.
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A search for mechanisms of fecal microbiota transplantation and novel therapies
Despite the promise of FMT, many issues with standardization of the procedure,
as well as accessibility of the procedure to both patients and physicians, still exist. Many
protocols for FMT involve the use of patient-identified donors (frequently spouses or
family members) (e.g. Aas et al., 2003; Yoon and Brandt, 2010; Shahinas et al., 2012).
While these donations can be successful, recent work indicates both that patients prefer to
use an anonymous, standardized donor and that recovery rates are substantially higher for
patients who receive material from a standardized donor (Hamilton et al., 2012).
Additionally, the protocols for the procedure itself are often poorly-defined, with some
protocols calling for “6 to 8 tablespoons” of fecal material (Kelly et al., 2012) or
suggesting filtration with paper coffee filters (Aas et al., 2003). Again, recent efforts have
been made to standardize and clarify the process as well as define the number of
organisms delivered in each transplant (Hamilton et al., 2012). Finally, the emergence of
frozen (Hamilton et al., 2012), freeze-dried (Khoruts et al., 2015), and encapsulated
(Stollman et al., 2015; Youngster et al., 2015; Hirsch et al., 2015) preparations should
allow the procedure to be done without waiting for a fresh sample from a donor,
increasing the ease with which FMTs are performed. These efforts will improve the
accessibility of FMT and allow more physicians and patients to take advantage of its high
success rate.
In addition to ongoing practical issues with FMT, the mechanisms explaining the
success of the procedure are poorly understood, though it is widely accepted that the
transferred fecal microbiota are responsible, directly or indirectly, for patient recovery.
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Several studies have now demonstrated that following FMT, the fecal microbiota of
patients rapidly shifts to a composition more similar to that of the donor (Khoruts et al.,
2010; Shahinas et al., 2012; Hamilton et al., 2013; van Nood et al., 2013; Song et al.,
2013; Weingarden et al., 2014; Seekatz et al., 2014; Fuentes et al., 2014). Specifically,
fecal bacterial communities prior to FMT in R-CDI patients are typically dominated by
members of the Proteobacteria phylum. Within a few days following transplant,
however, the Bacteroidetes and Firmicutes phyla become dominant. These phyla, along
with the Actinobacteria, are generally thought to dominate the fecal microbiota of healthy
individuals (Zoetendal et al., 2008; Arumugam et al., 2011), and indeed are the most
common phyla in fecal samples from healthy donors used in FMT (Shahinas et al., 2012;
Hamilton et al., 2013; van Nood et al., 2013; Song et al., 2013; Weingarden et al., 2014;
Seekatz et al., 2014; Fuentes et al., 2014). It is thought, therefore, that the fecal
microbiota of the healthy donor engraft in the colon of the transplanted patient and
rapidly replace the dysbiotic, Proteobacteria-dominated population, which prevents
reinfection with Clostridium difficile. However, engraftment of donor microbes, versus
re-growth of a patient’s own native populations, has not been clearly demonstrated.
Furthermore, it has been suggested that the new fecal community remains unstable for
weeks after FMT (Song et al., 2013), implying that further study on how engraftment
may be defined and what happens to patient fecal communities after the transplant is
required.
In addition to investigating differences between donor and patient fecal
populations, some work has attempted to identify specific bacteria responsible for
recovery. Petrof and colleagues demonstrated that inoculation with 33 bacterial isolates
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recovered from healthy human stool prevented recurrence of CDI in two patients (Petrof
et al., 2013). Another group demonstrated that a cocktail of six species cured persistent
infection in mice (Lawley et al., 2012). Meanwhile, recent work by Buffie et al. has
found that a single organism, Clostridium scindens, one of few characterized 7α-
dehydroxylating bacteria in the human gut, can increase survival in mice infected with C.
difficile, although a consortium of four bacteria was more effective (Buffie et al., 2014).
This work in particular emphasizes that the mechanisms behind FMT may not simply be
“colonization resistance,” or the ability of the native colonic microbiota en masse to
outcompete C. difficile for nutrients or space (Hopkins and Macfarlane, 2003; Khoruts
and Sadowsky, 2011; Britton and Young, 2012), but may in fact be related to specific
functions of a healthy microbiota which directly inhibit the pathogen.
To emphasize the idea that specific metabolic functions of the microbiota may
control C. difficile pathogenesis, evidence is emerging that certain commensal bacteria
can in fact promote CDI. The metabolism of host mucin by the symbiont Bacteroides
thetaiotomicron in gnotobiotic mice releases carbohydrates such as succinate which can
be metabolized by C. difficile to promote the pathogen’s expansion (Ng et al., 2013).
These same authors later showed that succinate is increased in antibiotic-treated
conventional mice, and that C. difficile which lacks the ability to metabolize succinate is
at a competitive disadvantage compared to wild-type C. difficile in mice (Ferreyra et al.,
2014). These findings suggest that altered carbohydrate metabolism by intestinal
microbiota following antibiotic treatment permits growth of C. difficile, and implies that
restoration of normal carbohydrate metabolism could be a mechanism behind FMT.
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An accurate understanding of the mechanisms of FMT is critical not only to
improve treatment of CDI, but also to assess whether FMT may be useful in treating
other conditions. Currently, it is known that the fecal microbiota are altered or dysbiotic
compared to healthy individuals in a vast number and variety of diseases, including
inflammatory bowel disease (Tamboli et al., 2004; Swidsinski et al., 2005; Frank et al.,
2007; Knights et al., 2014), atherosclerosis (Karlsson et al., 2012), metabolic syndrome
(Ley et al., 2006; Turnbaugh et al., 2009; Karlsson et al., 2013; Joyce et al., 2014), type 1
diabetes mellitus (Brown et al., 2011; Giongo et al., 2011, de Goffau et al., 2013; Kostic
et al., 2015), and autism (Williams et al., 2011). Because FMT can significantly alter the
fecal microbiota of individuals with CDI, it is possible that the use of FMT in patients
with these other conditions may shift fecal communities towards those of healthy donors,
and therefore may potentially correct or ameliorate the associated disease.
One such disease in which FMT is being investigated is inflammatory bowel
disease (IBD). An early case series of patients with ulcerative colitis, a subset of IBD,
indicated that FMT could completely abrogate symptoms in patients refractory to other
forms of therapy (Borody et al., 2003). A recent randomized controlled trial in ulcerative
colitis patients, however, found no significant difference in remission with FMT
compared to controls, although the patients who did respond to FMT had greater
alteration in their fecal microbial communities, remaining similar to donor communities
for 12 weeks (Rossen et al., 2015). FMT may therefore be promising for patients with
ulcerative colitis, but its efficacy seems to be lower than in patients with CDI, possibly
related to poorer engraftment of donor microbiota. A clearer definition of engraftment
along with an understanding of how engraftment occurs, or knowledge of the
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mechanisms behind FMT leading to the design of novel, non-FMT therapeutics, could
drastically improve our treatment of IBD.
Another promising target for FMT is metabolic syndrome. Metabolic syndrome is
a suite of risk factors including central obesity, elevated blood glucose, hypertension, and
elevated blood triglycerides which can lead to cardiovascular disease, stroke, type 2
diabetes, and other serious conditions (Alberti et al., 2005). As in IBD, substantial work
has revealed differences in fecal microbiota between obese and lean individuals (Ley et
al., 2006; Turnbaugh et al., 2009; Karlsson et al., 2013; Joyce et al., 2014), and some
studies have also demonstrated that transfer of microbes from obese animals or humans is
sufficient to induce obesity in gnotobiotic animals (Turnbaugh et al., 2006; Ridaura et al.,
2013; Duca et al., 2014). A small study found that transplant of fecal microbiota from
lean individuals into patients with metabolic syndrome significantly increased peripheral
insulin sensitivity, while autologous transplant with the patient’s own feces did not
(Vrieze et al., 2012). These findings strongly suggest that FMT may be a useful therapy
for metabolic syndrome, although more work is still needed to demonstrate efficacy in a
larger patient cohort and over longer periods of time.
In summary, Clostridium difficile infection is a widespread and often difficult to
treat disease. Increased understanding of the basic biology of the pathogen, particularly
its survival in the environment as spores and subsequent germination and outgrowth in
the colon of susceptible individuals, is likely to be critical for the development of novel
therapies for this infection. While fecal microbiota transplantation has emerged as a
powerful therapy for CDI, particularly for those individuals who are refractory to
standard antibiotic treatment, the procedure remains poorly understood. As a result, we
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are limited in our ability both to design new treatments for this infection and to expand
the use of FMT into other diseases. In this thesis, we present our findings into the
mechanisms of FMT and subsequent rational design of novel therapeutics for Clostridium
difficile infection.
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Chapter 2
Dynamic Changes in Short- and Long-Term Bacterial Composition Following Fecal
Microbiota Transplantation for Recurrent Clostridium difficile Infection*
* Reprinted from Microbiome. Alexa Weingarden, Antonio Gonzalez, Yoshiki Vazques-
Baeza, Sophie Weiss, Gregory Humphry, Donna Berg-Lyons, Dan Knights, Tatsuya
Unno, Aleh Bobr, Johnthomas Kang, Alexander Khoruts, Rob Knight, and Michael J.
Sadowsky. “Dynamic changes in short- and long-term bacterial composition following
fecal microbiota transplantation for recurrent Clostridium difficile infection.” ©
Weingarden et al.; licensee BioMed Central. Originally published in Microbiome.
2015. 3:10.
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SUMMARY
Fecal microbiota transplantation (FMT) is an effective treatment for recurrent
Clostridium difficile infection (CDI) that often fails standard antibiotic therapy. Despite
its widespread recent use, however, little is known about the stability of the fecal
microbiota following FMT. Here we report on short- and long-term changes, and provide
kinetic visualization of fecal microbiota composition in patients with multiply recurrent
CDI that were refractory to antibiotic therapy and treated using FMT. Fecal samples were
collected from four patients before and up to 151 days after FMT, with daily collections
until 28 days and weekly collections until 84 days post-FMT. The composition of fecal
bacteria was characterized using high throughput 16S rRNA gene sequence analysis, and
compared to microbiota across body sites in the Human Microbiome Project (HMP)
database, and visualized in a movie-like, kinetic format. FMT resulted in rapid
normalization of bacterial fecal sample composition from a markedly dysbiotic state to
one representative of normal fecal microbiota.  While the microbiome appeared most
similar to the donor implant material one day post-FMT, the composition diverged
variably at later time points. The donor microbiota composition also varied over time.
However, both post-FMT and donor samples remained within the larger cloud of fecal
microbiota characterized as healthy by the HMP. Dynamic behavior is an intrinsic
property of normal fecal microbiota, and should be accounted for in comparing microbial
communities among normal individuals and those with disease states.  This also suggests
that more frequent sample analyses are needed in order to properly assess success of
FMT procedures.
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INTRODUCTION
Fecal microbiota transplantation (FMT) has emerged in recent years as a highly
effective treatment for refractory Clostridium difficile infection (CDI) that cannot be
cured with antibiotics alone (Khoruts and Weingarden, 2014). The procedure leads to
prompt engraftment of donor microbiota, attainment of donor-like bacterial diversity, and
normalization of the overall microbial community structure (Khoruts et al., 2010;
Shahinas et al., 2012; Hamilton et al., 2012; van Nood et al., 2013; Weingarden et al.,
2014; Seekatz et al., 2014; Fuentes et al., 2014). However, existing data characterizing
long-term stability of engrafted microbiota are limited. One recent study suggests the
microbiota of patients after FMT may not fully recover until 16 weeks after the procedure
(Song et al., 2013). This type of analysis, however, is complicated by the fact that the
microbial communities are intrinsically dynamic, and affected by daily fluctuations in the
host’s diet, activities, and health (Dethlefsen and Relman, 2011). In addition, multiple
fixed host factors, such as different states of immune competence, genetics, or
gastrointestinal anatomy, likely also affect the composition, stability, or resilience of
colonic microbiota (Bäckhed et al., 2005; Lupp et al., 2007; Koren et al., 2012; Lozupone
et al., 2013; Kawamoto et al., 2014). Therefore, it is unclear whether divergence in post-
FMT microbiota from that of donor implant material represents continued recovery, or
whether these temporal changes are a general characteristic of host-associated gut
microbiota in a changing host environment.
Here we describe both short- and long-term dynamic changes of fecal bacterial
composition in four patients following FMT. All patients received microbiota from the
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same pre-qualified donor according to the standardized FMT protocol we described
previously (Hamilton et al., 2012). Three patients received freshly prepared microbiota
and one patient received microbiota that had previously been frozen. We compared pre-
and post-FMT fecal microbial communities from these patients, as well as pre-FMT
communities from 10 additional patients with multiply recurrent CDI (R-CDI), to the
sequences of normal subjects described in the Human Microbiome Project (Turnbaugh et
al., 2007).  In addition, we compared temporal changes in fecal bacterial composition in
recipients following FMT to temporal changes observed within samples from the donor.
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MATERIALS AND METHODS
Patients and donors
All patients suffered from multiply recurrent CDI refractory to standard antibiotic
therapies. A single standard donor was used in the preparation of all fecal microbiota
material as described previously (Hamilton et al, 2012). The Institutional Review Board
at the University of Minnesota approved prospective collection of fecal specimens and
their analysis. All patients satisfied the inclusion criteria for the FMT within our program,
which included at least two spontaneous recurrences of CDI within a month of
discontinuation of antibiotics and failure of at least one advanced antibiotic regimen such
as a vancomycin pulse/taper protocol or vancomycin treatment followed by
administration of rifaximin or fidaxomicin for 2-3 weeks. The specific clinical
characteristics of patients involved in this study are summarized in Table 2.1.
Fecal microbiota transplantation
FMT was done using a standardized preparation of concentrated fresh or frozen fecal
bacteria via colonoscopy as previously described (Hamilton et al., 2012). All patents
were treated with oral vancomycin, 125 mg four times daily, until two days prior to the
procedure (Hamilton et al., 2012). The day before the procedure, patients received a
polyethylene glycol-based colonoscopy prep (GoLYTELY® or MoviPrep®) to remove
residual antibiotics and fecal material. Donor fecal microbiota was placed into the
terminal ileum and/or cecum via the biopsy channel of the colonoscope. A total of 17
donor samples from the same individual were used in these studies.  The CD1-CD4 donor
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samples were given to patients CD1-CD4, respectively. Patients CD1, CD3, and CD4
received freshly prepared fecal microbiota, while patient CD2 received a previously
frozen preparation of fecal microbiota, all from the same standardized, anonymous donor.
Sample collection
Fecal samples were collected at home by the patients using swabs to sample feces
deposited into a toilet hat immediately after production, and stored frozen at
approximately -20oC. Samples were subsequently transferred to the laboratory and stored
at -80oC until used. Donor samples for DNA extraction were collected during processing
of material for FMT and stored frozen at -80oC until used. Samples from patients CD1- 4
were obtained prior to FMT and between 1 to 151 days post-FMT, with daily collection
until day 28, and weekly collection until day 84. Fecal material prior to FMT was
obtained from patients CD5-CD14.
DNA extraction
DNA was extracted from donor and recipients’ pre- and post-FMT fecal samples using
MOBIO PowerSoil DNA extraction kits (MOBIO, Carlsbad, CA), according to the
manufacturer’s instructions. Fecal DNA concentrations were measured using a QuBit
DNA quantification system (Invitrogen, Carlsbad, CA).
PCR amplification
Extracted DNA was amplified using the EMP standard protocols at
http://www.earthmicrobiome.org/ following the recommendations of Caporaso et al.,
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2012. Briefly, F515/R806 primers were used, with 12-base Golay codes introduced on
the 806 end to provide unique sample indices. Cycling and annealing conditions were as
previously described (Caporaso et al., 2012).
DNA sequencing
DNA sequencing was performed as previously described (Caporaso et al., 2012) on an
Illumina MiSeq platform using 2 x 150 bp paired-end reads and the Illumina v3 reagent
chemistry.
Sequence processing and analysis
Sequence data was processed and analyzed using QIIME (Caporaso et al., 2010)
according to the Illumina demultiplexing and processing protocol (Caporaso et al., 2012)
and current quality-filtering recommendations (Bokulich et al., 2013), using the 1.8.0
pipeline and the default parameters in split_libraries_fastq.py. After quality control and
demultiplexing, we picked close references at 97% similarity against the 97% similarity
Greengenes database (McDonald et al., 2012) version 13_8. All further analyses were
performed at a rarefied depth of 5,000 reads/sample.  EMPeror (Vazquez-Baeza et al.,
2013) was used for data visualization of BIOM-format (McDonald et al., 2012) OTU
tables. OTU analyses were performed by clustering at the 97% level with UCLUST
(Edgar, 2010), and data were integrated with the HMP dataset according to the protocols
used for similar previous meta-analyses (Koren et al., 2012; Lozupone et al., 2013).
Sequences were analyzed by using both weighted and unweighted UniFrac (Lozupone et
al., 2013), followed by principal coordinate analysis (Caporaso et al., 2010). Data were
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visualized using Phinch. The Phinch program provides an easy-to-use, browser-based,
platform to visualize contingency tables along with their sample metadata (Bik et al.,
manuscript in preparation, https://github.com/PitchInteractiveInc/Phinch).
Analysis of microbiome normalization and dynamic range
For each set of post-transplant patient samples we assessed the similarity of that set to the
set of reference samples from the donor (2,000 reads/sample). To reduce noise and
compare patient samples along only relevant dimensions in UniFrac distance space, we
applied principal coordinates analysis (PCoA) to the unweighted UniFrac distance matrix
containing only the post-transplant and donor samples for that donor-patient pair, then
recalculated the distances using only the first n principal coordinates axes required to
explain at least 80% of the variation in the distance matrix. An 80% cutoff was chosen to
balance bias and overfitting. Distances were recalculated using Euclidean distances
between points in PCoA space in order to convert PCoA coordinates to a distance matrix.
The empirical p-values for the ‘normality’ were obtained by comparing the mean distance
between patient and donor samples to the histogram of within-donor distances (generated
using all samples from a given donor by enumerating the pairwise distance between those
samples). The empirical p-values for the ‘dynamic range’ (stability) were obtained by
comparing the mean distance within patient samples to the histogram of within-donor
distances. These analyses were also performed using alternative parameters including,
weighted UniFrac, Jensen-Shannon, root Jensen-Shannon, and Bray-Curtis.
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RESULTS
Bacterial composition of fecal samples from patients with recurrent CDI becomes
healthy and donor-like following FMT
Four patients (CD1-CD4) with recurrent CDI were treated with FMT using
material obtained from a single donor but from different time points, and fecal samples
were collected from these patients before and after the procedure as well as from the
donor at times of donation. Bacterial communities from these fecal samples were
characterized by sequencing the V4 region of the 16S rRNA gene. Following trimming
and quality filtering from a total of 12,536,492 sequences, we randomly subsampled to
5,000 sequences/sample in order to normalize read depth across all samples. All further
analyses were performed using this rarefied read depth.
To better understand changes in bacterial communities following FMT, we
compared the bacterial composition of patient fecal samples to those of microbial
communities from various body sites from the 252 healthy individuals characterized in
the Human Microbiota Project (HMP) (Turnbaugh et al., 2007) (Fig. 2.1) using
unweighted UniFrac (Lozupone et al., 2013) followed by principal coordinates analysis
(PCoA) (Caporaso et al., 2010) (see Movie Supplement). The composition of pre-FMT
fecal samples from patients CD1-CD4 and 10 additional patients with recurrent CDI was
distinct from both fecal samples from healthy individuals and microbial communities at
other body sites, including mouth, vagina, and skin, demonstrating severe alterations in
pre-FMT communities compared to healthy fecal communities as has been previously
shown (Hamilton et al., 2013; van Nood et al., 2013). In contrast, microbial communities
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from the donor fell within the range of healthy fecal samples. Using an animated
visualization of FMT-associated changes in patients’ fecal microbial communities, we
observed rapid and dramatic shifts after FMT towards the communities found in the feces
of healthy individuals and of the original donor (see Movie Supplement).
Fecal microbial communities remain dynamic following FMT
To more closely examine temporal changes in recipient fecal samples following
FMT, we analyzed fecal microbial communities from patients CD1-CD4 and donor, as
well as from 10 additional donor samples, using weighted and unweighted UniFrac
(Lozupone et al., 2005) followed by PCoA (Caporaso et al., 2010). This analysis
demonstrated that fecal bacterial communities continued to undergo compositional
fluctuation following FMT (Fig. 2.2A and Fig. 2.3; individuals OTUs listed in
Supplementary Table).
To determine whether this dynamic range of post-FMT microbial composition fits
within the range seen across healthy individuals, we also compared communities in our
samples to those in the HMP via weighted UniFrac and PCoA (Fig. 2.2B). Again, fecal
microbial communities prior to FMT were highly distinct from healthy fecal microbial
communities, and following the procedure these communities more closely resembled
those of healthy individuals. Similar to the comparison with donor communities above,
fecal microbial communities of recurrent CDI patients following FMT shifted within the
cluster of communities from healthy individuals.
Rapid and substantial changes to Enterobacteriales in feces following FMT
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While overall fecal microbial communities were dramatically altered following
FMT, we also examined the effects of the procedure on the abundance and dynamics of
individual bacterial taxa within the four original CDI patients. As shown previously
(Khoruts et al., 2010; Shahinas et al., 2012; Hamilton et al., 2012; van Nood et al., 2013;
Weingarden et al., 2014; Seekatz et al., 2014; Fuentes et al., 2014), the relative
abundance of bacterial phyla in patient fecal samples shifted substantially following
FMT, with relative decreases in Proteobacteria and relative increases in Bacteroidetes
and Firmicutes (Fig. 2.4). These Proteobacteria are primarily the order
Enterobacteriales, which were also substantially decreased in relative abundance
following FMT (Fig. 2.5A).
We focused on these changes by examining the relative abundance of
Enterobacteriales alone in each patient before and after FMT. The relative abundance of
this taxon ranged from 44 to 82% in all four patient samples prior to FMT, and rapidly
dropped to undetectable levels within one week after the procedure. Moreover,
abundance of this taxon remained low at 26 days after FMT, the latest time point shared
by all four patients (Fig. 2.5A), although other members of the Proteobacteria remain
detectable if decreased in relative abundance (Fig. 2.4). In addition, we generated
individual value control charts based on the average abundance of this taxon in recurrent
CDI patients. Compared to relative abundance, these control charts displayed the
expected variation of the abundance of Enterobacteriales in these fecal samples. In all
patients, the abundance of Enterobacteriales was above the expected variation (i.e. more
than three standard deviations above the mean relative abundance [the standard upper
control limit, or UCL] of this order across all samples) prior to FMT, and rapidly fell
30
below the upper control limit within 1-2 days after the procedure (Fig. 2.5B). These
results suggest that the relative abundance of Enterobacteriales significantly decreased in
all patients soon after FMT to levels similar to donor samples, and remained within a
statistically expected range for the duration of sample collection (up to 151 days post-
FMT).
Post-FMT communities are initially similar to donor samples but can later diverge
Next, we compared fecal microbial communities within each patient over time to
that of the initial donor sample. We generated heat maps based on Pearson correlations
between every sample within a given patient set, including respective donor samples and
samples from 10 additional pre-FMT patients (Fig. 2.6A). This analysis revealed that
while microbiota in samples from patients after FMT quickly became similar to
microbiota in donor samples, the similarity of samples taken at later time points after
FMT fluctuated.
To further investigate how fecal microbial communities in these patients correlate
to donor communities, we examined Pearson and Spearman correlations between donor
and patient samples, which were common to each patient (pre-FMT samples and those up
to 26 days post-FMT; Fig. 2.6B and C and Fig. 2.7). While fecal microbial communities
from patients before FMT were highly distinct from those in the donor, fecal microbial
communities from samples one day after the procedure were highly correlated to donor
communities via both Pearson and Spearman analyses in all patients. After the initial time
point after FMT, the Pearson correlation values of patient to donor samples were highly
variable within and across patients, although Spearman correlations remained high for
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three patients. To examine whether this variation is similar in healthy individuals, we
determined Pearson and Spearman correlations within the four donor samples used in
FMT, as well as eight additional donor samples from the same individual as a control.
Results of this analysis revealed that donor microbiota also changed over time (Fig.
2.6D). These findings suggested that the level of variability seen across patient post-FMT
fecal microbial communities was within the range of normal microbiota behavior in a
healthy individual.
Normalization and dynamic range of post-FMT patient fecal microbial communities
are similar to donor communities
Because of the observed variability in later post-FMT patient fecal communities
relative to single donor communities, we compared the communities of these patient
samples to an expanded set of 17 samples taken from the same donor. We generated two
metrics to evaluate the relationships between these communities: normalization and
dynamic range (stability). Normalization refers to the mean between-sample distance for
each set of patient samples versus the set of donor samples, while dynamic range is the
mean distance between each sample within a single patient set. Effectively, the normality
of a post-FMT patient sample set is a measure of how similar it is to the donor (healthy)
sample set, while dynamic range is a measure of variability within a given patient sample
set. We found that neither the normalization nor the dynamic range of any post-FMT
patient sample set was significantly different than the donor set following analysis using
unweighted UniFrac (Table 2.2). This suggested that although fecal microbial
communities of patients post-FMT do not remain identical to the donor, they nonetheless
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fall within expected parameters relative to the healthy donor. Similar results were
obtained when these analyses were repeated with other parameters, including weighted
UniFrac, Jensen-Shannon and root Jensen-Shannon, and Bray-Curtis (data not shown).
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DISCUSSION
It is now well understood that the fecal microbiota change substantially following
FMT, typically shifting to fecal microbial communities more similar to those of the donor
after transplant (Khoruts et al., 2010; Shahinas et al., 2012; Hamilton et al., 2012; van
Nood et al., 2013; Weingarden et al., 2014; Seekatz et al., 2014; Fuentes et al., 2014).
Here we show that these communities shift away from a dysbiotic state towards a
composition that is representative of fecal microbial communities from hundreds of
healthy individuals, collected in the HMP (Turnbaugh et al., 2007). Similarly to previous
studies (Hamilton et al., 2012; van Nood et al., 2013; Weingarden et al., 2014; Seekatz et
al., 2014; Fuentes et al., 2014), the dysbiotic state in these patients with multiply
recurrent CDI is characterized by a large expansion of Proteobacteria (primarily
members of the order Enterobacteriales, which contains the family Enterobacteriaceae),
and FMT is associated with reemergence of dominance by members of the Bacteroidetes
and Firmicutes phyla.
Analysis of multiple donor and post-FMT samples demonstrates the dynamic
behavior of fecal microbial communities over time. Both donor and recipient samples are
characterized by highly dynamic shifts that nonetheless remain within the compositional
range of normal fecal microbiota. This observation is consistent with known rapid
responsiveness of the fecal microbiome to environmental inputs, such as dietary
variations (David et al., 2014), and drifts in microbiota composition over time in healthy
individuals (Faith et al., 2013).
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The dynamic nature of intestinal microbiota is an intrinsic property, which should
be taken into account when considering how therapeutic interventions, including FMT,
impact its composition over time. In long-term post-FMT follow-up, Song and colleagues
also noted dynamic changes in the fecal microbiome of R-CDI patients up to 16 weeks
post-FMT (Song et al., 2013). These investigators concluded that the fecal microbiome of
post-FMT patients did not fully recover over this time, despite clinical recovery. Indeed,
we observed divergence of microbiome in some of the patients away from the original
implanted material over time. However, analysis of multiple donor samples showed that
this movement is within the same dynamic range observed in the donor’s fecal
microbiome. We therefore conclude that the dynamic behavior of microbiota needs to be
taken into account in making comparisons between individuals, and should become an
integral part of analysis of the success of FMT.
Three of the recipients in this study received freshly prepared microbiota, while
one received frozen/thawed preparation. Use of frozen microbiota preparations is
increasing in clinical practice (Youngster et al., 2014), and its equivalency has not been
rigorously established in randomized clinical trials. The ability to store microbiota allows
the most up-to-date testing of the donor and fecal material for infectious pathogens, as
some of the current tests may take several weeks to complete. Therefore, ability to
preserve donor microbiota long-term is critical for its development as a therapeutic agent
in clinical practice. Our results here, although limited in the number of patients,
demonstrate indistinguishable behavior of fresh and frozen/thawed microbiota
preparation.
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The patients in this study did not have any significant gastrointestinal co-
morbidities. However, a significant proportion of patients with recurrent CDI have
underlying inflammatory bowel disease, take potent immunosuppressive medications, or
have multiple other medical problems (Hamilton et al., 2012; Kelly et al, 2014). The
importance of these host factors in contributing to microbiota behavior is currently
unknown, but is a subject of great interest (Gevers et al., 2014). Understanding these
influences will require analysis of multiple samples. Recently, Fuentes and colleagues
(Fuentes et al., 2014) reported that some specific microbial groups and interactive
networks are likely to be very important for the maintenance of microbiota in healthy
individuals. However, although there is a great deal of effort focused on discovery of
compositional differences in microbiota between normal subjects and individuals with
different gastrointestinal and medical conditions, the dynamic behavior of fecal
microbiota constitutes another dimension that may distinguish these cases. Thus,
predictors of stable or dysbiotic intestinal microflora may also change over time. Further
detailed studies of dynamic behavior of post-FMT microbiota may improve our
understanding of causal connections between microbial communities and different
disease states.
The fecal microbiota of patients with R-CDI continues to undergo change after
FMT is performed, though these changes appear to fall within the range of normal
variation of healthy individuals over time. Dynamic behavior is an intrinsic property of
normal fecal microbiota, and should be accounted for in comparing microbial
communities among normal individuals and those with disease states.
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Table 2.1 - Clinical metadata of patients used in this study.
Pa
tie
nt
Age Gender TriggerEvent
Trigger
Antibiotic
Duration
of RCDI
prior to
FMT
(months)
Co-morbidities;
History of GI
Surgery
History of
Treatment of
CDI with
Metronidazole
History of
Treatment of
CDI with
Vancomycin
History of
Treatment
of CDI
with
Rifaximin
History of
Treatment of
CDI with
Fidaxomicin
History
of
Trreatm
ent with
Nitazox
anide
C
D
1
39 F Antibiotics
with
Caesarian
section
N/A 18 None Yes Yes Yes No Yes
C
D
2
52 M Sinusitis N/A 5 None Yes Yes Yes No No
C
D
3
55 M Antibiotics
with a
dental
procedure
N/A 18 Immunoglobulin
deficiency
secondary to
administration of
rituximab; s/p
cholecystectomy
Yes Yes Yes No No
C
D
4
60 F Diverticular
abcess
Ciprofloxacin
and
Metronidazole
7 None Yes Yes No No No
C
D
5
83 F Sepsis
(Proteus
mirabilis)
N/A 8 None Yes Yes No No No
C
D
6
71 M N/A N/A 7 Diverticulosis Yes Yes No No No
C
D
7
66 F Antibiotics
with spinal
surgery
N/A 3 S/P Billroth II
gastrectomy;
Diverticulosis
Yes Yes No No No
C
D
8
72 M Pneumonia Trimethoprim/su
lfamethoxazole;
vancomycin;
13 S/P heart
transplant; Liver
cirrhosis due to
Yes Yes No No No
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levofloxacin;
meropenem
hepatitis B;
Diverticulosis
C
D
9
65 F Vaginal
infection
Clindamycin 7 S/P
appendectomy
Yes Yes Yes No No
C
D
10
47 F Upper
respiratory
tract
infection
Clindamycin 3 S/P
cholecystectomy;
Lymphocytic
colitis
Yes Yes Yes No No
C
D
11
36 M N/A N/A 8 None Yes Yes No No No
C
D
12
52 F Antibiotics
with
hysterecto
my
N/A 5 Yes Yes Yes Yes No
C
D
13
56 F Antibiotics
with knee
replacemen
t
N/A 3 None Yes Yes No Yes No
C
D
14
53 F Urinary
tract
infection
Ciprofloxacin 8 None Yes Yes No Yes No
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Table 2.2 - P-values of normalization and dynamic range of patient samples sets
versus donor set.
Patient CD1 CD2 CD3 CD4
Normalization 0.154 0.429 0.165 0.484
Dynamic Range 0.484 0.429 0.308 0.473
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Figure 2.1 - Fecal bacterial communities of recurrent CDI patients shift
towards HMP fecal bacterial communities after FMT. Red circles = pre-FMT
patient samples; green circle = post-FMT patient samples; blue line = trajectory of
patient fecal communities after FMT.
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Figure 2.2 - Microbial communities shift following FMT. A) Unweighted (left) and weighted (right) UniFrac analyses followed by
principal component analysis of bacterial communities of recurrent CDI patient fecal samples before (red) and after FMT and donor
samples (blue). B) Weighted UniFrac analysis followed by principal component analysis of bacterial communities of patients before
(red) and after FMT versus HMP fecal communities (purple). PC: principal component. Percentages represent percent variability
explained by each principal component. Se key at right for colors associated with samples before FMT (Pre-FMT), from HMP and
donor, and from patients after FMT (CD1-CD4).
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Figure 2.3 - Microbial communities remain dynamic after FMT. (A) Unweighted  and (B) weighted UniFrac analyses, followed
by principal component analysis of bacterial communities of recurrent CDI patient fecal samples, by time point after FMT and donor
samples (blue). PC: principal component. Percentages represent percent variability explained by each principal component. See key at
right for colors associated with samples from patients after FMT (CD1-CD4).
42
Figure 2.4 - Fecal microbial communities change after FMT. Relative abundance of sequences classified to the level of bacterial
phyla before and after FMT in patient fecal samples. Samples after FMT indicated with dashed line. See key at right.
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Figure 2.5 - Abundance of the order Enterobacteriales changes after FMT. A) Relative abundance of Enterobacteriales in donor
and patient samples before and after FMT in samples common across all patients. B) Control charts of relative abundance of
Enterobacteriales in donor (leftmost sample) and patient samples before and after FMT. Top left: patient CD1, top right: patient CD2,
bottom left: patient CD3, bottom right: patient CD4. LCL: lower control limit; UCL: upper control limit; Center: mean relative
abundance in all samples. LCL and UCL represent three standard deviations in relative abundance below and above the mean,
respectively. Dashed lines indicate samples after FMT.
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Figure 2.6 - Fecal communities of patients undergo shifts relative to donor after FMT. A) Heat map of Pearson correlation values
between each sample within each patient set, corresponding donor, and 10 additional pre-FMT patient samples (far right). B) Pearson
correlation values between donor sample and each patient sample. C) Spearman correlations between donor sample and each patient
sample. D) Heat maps of Pearson (i) and Spearman (ii) correlation values between earliest donor sample and eleven subsequent
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samples; days represent collection time of each sample versus earliest donor sample. CD1-4: patients 1-4. Dashed lines indicate
samples after FMT.
46
Figure 2.7 - Fecal communities of patients undergo shifts relative to donor after
FMT. Heat maps indicating Pearson (left) and Spearman (right) correlation values
between respective donor and pre- or post-FMT fecal microbial communities of patients.
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Chapter 3
Microbiota Transplantation Restores Normal Fecal Bile Acid Composition in
Recurrent Clostridium difficile Infection †
† Reprinted from American Journal of Physiology, Gastrointestinal and Liver Physiology.
Alexa R. Weingarden, Chi Chen, Aleh Bobr, Dan Yao, Yuwei Lu, Valerie M. Nelson,
Michael J. Sadowsky, and Alexander Khoruts. “Microbiota transplantation restores
normal fecal bile acid composition in recurrent Clostridium difficile infection.” © The
American Physiological Society. Originally published in American Journal of
Physiology, Gastrointestinal and Liver Physiology. 2014. 306(4):G310-G319.
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SUMMARY
Fecal microbiota transplantation (FMT) has emerged as a highly effective therapy for
refractory, recurrent Clostridium difficile infection (CDI), which develops following
antibiotic treatments. Intestinal microbiota play a critical role in the metabolism of bile
acids in the colon, which in turn have major effects on the lifecycle of C. difficile
bacteria. We hypothesized that fecal bile acid composition is altered in patients with
recurrent CDI and that FMT results in its normalization. General metabolomics and
targeted bile acid analyses were performed on fecal extracts from patients with recurrent
CDI treated with FMT and their donors. In addition, 16S rRNA gene sequencing was
used to determine the bacterial composition of pre- and post-FMT fecal samples.
Taxonomic bacterial composition of fecal samples from FMT recipients showed rapid
change to become similar to the donor after the procedure. Pre-FMT fecal samples
contained high concentrations of primary bile acids and bile salts, while secondary bile
acids were nearly undetectable. In contrast, post-FMT fecal fecal samples contained
mostly secondary bile acids, as did non-CDI donor feces. Therefore, our analysis showed
that FMT resulted in normalization of fecal bacterial community structure and metabolic
composition. Importantly, metabolism of bile salts and primary bile acids into secondary
bile acids is disrupted in patients with recurrent CDI, and FMT corrects this abnormality.
Since individual bile salts and bile acids have both pro-germinant and inhibitory
activities, the changes observed suggest that correction of bile acid metabolism is likely a
major mechanism by which FMT results in a cure and prevents recurrence of CDI.
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INTRODUCTION
Clostridium difficile infection (CDI) is currently one of the most common
nosocomial infections in the US, affecting over 500,000 people annually in health care
facilities and many more in the community (Ananthakrishnan, 2011; Miller et al., 2011;
Khanna et al., 2012; Lessa et al., 2012; Chitnis et al., 2013). Unfortunately antibiotic
therapy alone commonly fails to achieve a cure for this disease; in fact, the use of
antibiotics is the primary risk factor for CDI and antibiotic treatment of CDI can
perpetuate its recurrence (Borody and Khoruts, 2011; Miller et al., 2011; Surawicz and
Alexander, 2011; Khanna et al., 2012). Approximately 20-30% of patients experience
recurrence of the disease after antibiotic treatment of the initial infection (Kelly and
Lamont, 2008; Louie et al., 2011). The risk of recurrence continues to rise with each
relapse, and some patients ultimately develop a recurrent C. difficile infection syndrome
(R-CDI), where the cycle of infections becomes indefinite (Borody and Khoruts, 2011;
Surawicz and Alexander, 2011). Fecal microbiota transplantation (FMT), which achieves
restoration of the normal composition of fecal bacteria, is a powerful emerging therapy
that successfully treats over 90% of patients with R-CDI (Borody and Khoruts, 2011;
Gough et al., 2011; van Nood et al., 2013). However, the mechanisms by which this
transplanted microbiota prevents recurrence of CDI remain poorly understood.
One known function of the normal human gut microbiota, which may affect C.
difficile physiology, is the metabolism of primary bile acids to secondary bile acids in the
colon. The primary bile acids cholic acid and chenodeoxycholic acid are produced in the
liver and conjugated to taurine or glycine to form bile salts before secretion into bile for
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assisting lipid digestion in the small intestine (Hofmann and Hagey, 2008). While ~95%
of secreted bile salts are reabsorbed from the small intestine via the enterohepatic
circulation pathway, ~5% reach the colon, where by the actions of intestinal bacteria they
are deconjugated and dehydroxylated at the C7 position to form deoxycholic and
lithocholic acids, from cholic acid and chenodeoxycholic acid, respectively (Hofmann
and Hagey, 2008). Considering the cytotoxic effects of antibiotics on microbiota,
including normal gut microflora, it is unsurprising that a variety of antibiotics, including
ciprofloxacin, neomycin, and β-lactams, significantly alter the fecal bile acid pool in both
rodents and in vitro human fecal cultures, reducing the proportion of secondary relative to
primary bile acids (Hashimoto et al., 1996; Carman et al., 2005; Toda et al., 2009; Giel et
al., 2010). These findings suggest that antibiotic treatment is likely to substantially alter
intestinal bacteria-mediated fecal bile acid metabolism in R-CDI patients.
Bile acids substantially affect germination and growth of C. difficile. The primary
bile acid taurocholic acid, the taurine-conjugated form of cholic acid secreted by the
liver, is a potent germinant of the organism, and is even used as a key component of C.
difficile growth media (Wilson, 1983; Sorg and Sonenshein, 2008). Recently, a putative
C. difficile bile acid germinant receptor was identified to be a protease CspC, and a cspC
mutant of C. difficile had decreased pathogenicity in a hamster model (Francis et al.,
2013). Notably, the secondary bile acids lithocholic and ursodeoxycholic acid have been
shown to inhibit C. difficile germination in vitro (Sorg and Sonenshein, 2010). Fecal
samples from mice treated with clindamycin, which have a significantly lower proportion
of secondary bile acids compared to untreated mice, are better able to stimulate colony
formation from C. difficile spores compared to controls, suggesting that secondary bile
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acids may also inhibit germination and/or growth in vivo (Giel et al., 2010). These studies
suggest that secondary bile acids in feces, which decrease following antibiotic treatment,
may inhibit germination and/or growth of C. difficile in the colon.
To examine the influence of FMT on the gut microflora-mediated metabolism in
R-CDI patients, we conducted general metabolomic and targeted bile acid analyses on
fecal extracts from 12 R-CDI patients before and after treatment with FMT. We also
analyzed the composition of fecal microbiota in these patients using high-throughput 16S
rRNA gene sequencing. Here we demonstrate that restoration of normal bacterial
composition of fecal microbiota is accompanied by rapid normalization of fecal bile acid
composition in these patients. These results offer a potential mechanism by which FMT
treats R-CDI and suggest novel pathways of therapeutics development for this frustrating
clinical condition.
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MATERIALS AND METHODS
Patients and donors
All patients recruited into this study had R-CDI syndrome and failed to clear the infection
despite multiple rounds of antibiotic treatments (Table 3.1). Two standard donors were
used in the preparation of fecal microbiota material as described previously (Hamilton et
al., 2012). The Institutional Review Board at the University of Minnesota approved
prospective collection of fecal specimens and their analysis (Protocol 1303M29781).
FMT procedure
The fecal microbiota were infused via colonoscopy as previously described (Hamilton et
al., 2012). All patients took oral vancomycin until 2 days prior to the procedure. The
patients received a polyethylene glycol-based colonoscopy prep the day prior to FMT
(GoLYTELY® or MoviPrep). Fecal microbiota were prepared from one of two standard
donors, selected as described previously using successive filtration to separate the
microbial fraction from the rest of the fecal material (Hamilton et al., 2012). Ten patients
received FMT which were frozen in 10% (v/v) glycerol and stored at -80°C until used as
previously described (Hamilton et al., 2012), while 6 patients received freshly-processed
(non-frozen) material. Recovery from CDI was defined by resolution of clinical diarrhea
(≤ 3 bowel movements per day and normalization of stool consistency) over two months.
All patients continue to be followed clinically since their FMT.
Sample collection
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Fecal samples were collected by patients prior to FMT and at days 7 to 22 following
FMT. All patients were actively taking vancomycin when pre-FMT samples were
collected. Samples were stored at -80°C within 24 h of production until DNA extraction.
An unprocessed portion of each donor sample was also collected at the time of donation
and stored immediately at -80°C.
DNA extraction
DNA was extracted from each patient and donor sample (0.25 to 0.50 g) using the
PowerSoil® DNA Isolation Kit (MO BIO, Carlsbad, CA) according to the manufacturer’s
instructions. Samples with high water content (Bristol stool scale types 5 to 7) were
centrifuged at 12,000 RPM for 3 min to pellet solids, which were used for DNA
extraction. Each sample was extracted in triplicate, and each replicate was eluted in 50 µl
of 10mM Tris-HCl buffer (pH 8.0) and pooled. DNA concentrations of extracted samples
were measured with a QuBit® DNA quantification system (Invitrogen, Carlsbad, CA)
using QuBit high sensitivity assay reagents. All extracted DNA samples were stored at -
20°C until amplification.
PCR amplification
Fecal DNA samples (25 ng) were used as template for PCR amplification of the V6
region of the 16S rRNA gene. Degenerate primer sets (Table 3.2) were designed with 6
bp Illumina index sequences on the 5’ end of the reverse primer which were specific to
each fecal DNA sample and allowed for multiplexed sequencing. Primers also contained
Illumina PCR primer sequences (reverse primer) and Illumina TruSeq Universal Adapter
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sequences (forward primers) for library creation. Triplicate reactions were
electrophoresed on a 2% agarose gel, followed by extraction using the Qiaquick® Gel
Extraction Kit (Qiagen, Valencia, CA), eluted in 30 µl of 10 mM Tris-Cl buffer, pH 8.0,
and pooled. DNA concentrations were measured using the QuBit® DNA quantification
system and high sensitivity assay reagents. Samples were stored at -20o C until pooled for
sequencing.
DNA sequencing
Up to 24 equimolar aliquots of each product were pooled to give 3 samples of ~1 µg of
DNA in 100 µL total volume. DNA concentration in the final pooled solutions was
measured by using the Quant-IT™ PicoGreen quantitation system (Invitrogen, Carlsbad,
CA). Amplicon size analysis was done using an Agilent DNA 1000 chip and a 2100
BioAnalyzer (Agilent, Santa Clara, CA). Sequencing was performed at the University of
Minnesota BioMedical Genomics Center. Paired-end sequences were generated on the
Illumina MiSeq Personal Sequencer (2 x 150 nt read length). Reads in each pair for each
sequencing run overlapped and paired ends were merged. The hamming distance (number
of substitutions) was calculated for sliding overlaps of the two reads in a pair to find the
best overlap (lowest hamming distance with a minimal overlap of 25 nucleotides and
98% identity). Merged sequences were binned according to barcode sequence and both
barcode and amplicon primer sequences were trimmed using custom Perl scripts.
Sequence processing and analysis
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Sequence data was processed and analyzed using the mothur program (Schloss et al.,
2009). To ensure high quality data for analysis, sequence reads containing: ambiguous
bases; homopolymers >7 bp; more than one mismatch in the primer sequence; or an
average per base quality score below 35 within each 50 bp window were removed.
Sequences that only appeared once in the total set were assumed to be a result of
sequencing error and removed from the analysis. Chimeric sequences were removed from
the data set using the UCHIME algorithm within the mothur program (Edgar et al.,
2011). A random subset of 22,353 sequences per sample were used to balance read
numbers and clustered into operational taxonomic units (OTUs). Taxonomy was assigned
at a cutoff value of >90% (Hamilton et al., 2013). Using a 16S rRNA database prepared
from the Ribosomal Database Project (RDP) 9, using the Bayesian method with a
bootstrap algorithm (100 iterations) and a probability cutoff of 0.60 (Cole et al., 2009).
Samples were clustered using the Fast UniFrac algorithm to generate trees and principle
coordinate analysis (PCoA) plots (Hamady et al., 2010). The UniFrac algorithm was run
using the Fast Unifrac program available at www.bmf2.colorado.edu/fastunifrac/.
Reagents
All solvents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless
stated otherwise. LC-MS grade acetonitrile was purchased from Fisher Scientific
(Pittsburgh, PA). Cholic acid, cholesterol, and diethyl phosphorocyanidate (DEPC) were
purchased from Alfa Aesar (Ward Hill, MA). Isodeoxycholic acid was purchased from
Steraloids (Newport, RI).
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Liquid chromatography-mass spectrometry (LC-MS) analysis of fecal extracts
Fecal samples were suspended in 1 ml of 50% acetonitrile (w/v), and extracted by
vortexing and sonication for 10 min. The suspension was centrifuged twice at 18,000  g
for 10 min, and after passing the supernatant through a 2 µm filter, the filtrate was
transferred into a sample vial and subjected to LC-MS analysis. A 5 µl aliquot of fecal
extract was injected into an AcquityTM UPLC system (Waters, Milford, MA) and
separated by a mobile phase gradient ranging from H2O to 95% aqueous acetonitrile
containing 0.1% formic acid over a 10-min run. The LC eluant was introduced into a
SYNAPT QTOF mass spectrometer (Waters) for accurate mass measurement and ion
counting. Capillary and cone voltage for electrospray ionization (ESI) were maintained at
-3 kV and -35 V for negative-mode detection, respectively. Source temperature and
desolvation temperature were 120 °C and 350 °C, respectively. Nitrogen was used as a
cone gas (50 l/h) and desolvation gas (600 l/h), and argon as the collision gas. For
accurate mass measurement, the mass spectrometer was calibrated with sodium formate
solution (range m/z 50-1000) and monitored by the intermittent injection of the lock mass
leucine enkephalin ([M-H]- = 554.2615 m/z) in real time. Mass chromatograms and mass
spectral data were acquired and processed by MassLynxTM software (Waters) in
centroided format. Additional structural information was obtained via tandem MS
(MS/MS) fragmentation with collision energies ranging from 15 to 30 eV. The
concentration of bile acids in fecal samples was determined based on the peak areas of
individual bile acids and external standards.
Chemometric analysis and biomarker identification
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Chromatographic and mass spectral data of fecal samples were deconvoluted using
MarkerLynxTM software (Waters). Each detected ion was represented by its retention
time (RT) in the LC-system and its mass-to-charge ratio (m/z). A multivariate data matrix
comprising sample identity, ion identity (RT and m/z) and relative ion abundance was
generated through centroiding, deisotoping, filtering, peak recognition and integration,
and was further exported into SIMCA-P+TM software (Umetrics, Kinnelon, NJ) (Chen et
al., 2007). Unsupervised principal component analysis (PCA) and supervised orthogonal
partial least squares (OPLS) analysis were used to analyze data from fecal extracts. Major
latent variables in the data matrix were described in a scores scatter plot of established
multivariate model. Fecal metabolites affected by FMT were identified by analyzing ions
contributing to the separation of pre-FMT and post-FMT samples in the multivariate
models (Chen et al., 2007; Bylesjo et al., 2008). The chemical identities of metabolites of
interest were determined by accurate mass measurement, elemental composition analysis,
database search (Lipid Maps: http://www.lipidmaps.org/, Human Metabolome Database:
http://www.hmdb.ca/), MS/MS fragmentation, and comparisons with authentic standards.
Statistics
Experimental values for fecal metabolites are expressed as mean ± standard deviation
(SD). Statistical analysis was performed using ANOVA followed by Tukey’s HSD on
significant groups at α = 0.05. A p-value of <0.05 was considered statistically significant.
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RESULTS
Complete patient recovery following one or two FMT procedures
Eleven of the 12 patients (91.6%) treated with FMT and analyzed in this study
achieved clinical recovery with no recurrence of CDI following a single FMT over at
least a one-year period of follow-up. Interestingly, while the patients were maintained on
vancomycin prior to FMT, they continued to experience mild diarrheal symptoms (4.1 ±
1.3 stools per day; median type 5 on the Bristol stool scale).  After the FMT procedure
the frequency of stools decreased (2.0 ± 1.4 stools per day; median type 4 on the Bristol
stool scale). Following a second FMT, the single patient with an initial recurrence of the
disease also recovered. He was documented to be C. difficile toxin B negative and
remained free of diarrhea for 6 months, at which point he experienced a relapse of CDI.
This relapse was associated with a course of laxatives taken for constipation associated
with his Parkinson’s disease. The infection was successfully treated with a single 10-day
course of fidaxomicin. Two patients were incidentally discovered to have underlying
inflammatory bowel disease at the time of their FMT; one had Crohn’s terminal ileitis
and the second had lymphocytic colitis (Table 3.1). Neither patient required additional
pharmacological therapy.
Composition of fecal communities dramatically changes following FMT
The composition of fecal microbiota in 14 patients before and after FMT, as well
as each donor sample, was examined by sequencing the V6 region of the 16S rRNA gene.
A total of 13,873,260 sequences were generated and 8,175,859 sequences remained after
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quality filtering, removal of chimeras, and preclustering. Sequences were subsampled to
22,535 to obtain the same number of reads for each sample, clustered into operational
taxonomic units (OTUs) at 90% sequence identity as used previously (Hamilton et al.,
2013), and classified using the Ribosomal Database Project (RDP) (Cole et al., 2009).
As we previously showed for a small set of patients (Hamilton et al., 2013), fecal
bacterial communities changed dramatically following FMT. Initially, α-diversity
(diversity within each sample) was examined using the Shannon diversity index, which
indicated that both donor samples and post-FMT samples were significantly more diverse
than pre-FMT samples (Fig. 3.1A). To examine β-diversity (diversity between samples)
principal coordinate analysis (PCoA) was performed based on UniFrac distances (Fig.
3.1B). The PCoA demonstrated that while donor and post-FMT samples clustered
together along principal coordinate 1 (PC1), pre-FMT sample communities were distinct.
These shifts in diversity following FMT were related to changes in the relative
abundance of the bacterial phyla Bacteroidetes, Firmicutes, and Proteobacteria (Fig.
3.1C). Donor samples, representative of a healthy fecal microbiome (Zoetendal et al.,
2008; Arumugam et al., 2011), were dominated by Bacteroidetes and Firmicutes
(together accounting for ~80-90% of OTUs in each sample), with a very low abundance
of Proteobacteria (~2% or fewer OTUs per sample). In contrast, patient samples prior to
FMT tended to be dominated by the Proteobacteria, comprising at least 30% of OTUs in
13 of 14 samples (92.8%), and over 50% in seven samples. Following FMT, microbiota
in patient samples more closely resembled the donors’ composition, with increased
abundance of Firmicutes and Bacteroidetes and decreased abundance of Proteobacteria.
Overall, the number of Actinobacteria, Bacteroidetes, Firmicutes, and unclassified
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bacterial OTUs significantly increased following FMT (p=0.044, p=0.0015, p=0.0016,
and p<0.0001, respectively), while Proteobacteria and Verrucomicrobia significantly
decreased (p<0.0001 and p=0.035, respectively) (Table 3.3).
Dramatic differences in community composition were also seen at the family
level (Fig. 3.1D). Together, the bacterial families Lachnospiraceae, Bacteroidaceae, and
Ruminococcaceae comprised 50% or more of the OTUs in each donor sample. In
contrast, these families were found in much lower abundance in the majority of pre-FMT
patient samples, with the Lachnospiraceae at less than 2% abundance in 11 of 14 samples
(78.6%), the Bacteroidaceae at less than 1% abundance in each sample, and the
Ruminococcaceae at less than 1% abundance in 13 of 14 samples (92.8%). Instead,
Enterobacteriaceae, Veillonellaceae, and Verrucomicrobiaceae, minor constituents of
donor communities, together represented ≥50% of OTUs in 13 of 14 pre-FMT samples
(92.8%). Following FMT, these patterns reversed in most patient samples, with increased
Lachnospiraceae, Bacteroidaceae, and Ruminococcaceae, and decreased
Enterobacteriaceae, Veillonellaceae, and Verrucomicrobiaceae. Bacterial families with
significantly altered OTU abundance after FMT compared to pre-FMT samples are
shown in Table 3.4.
Changes in fecal bile acid composition following FMT
To explore changes in fecal bile acid composition induced by FMT, fecal samples
collected from 14 CDI patients, before and after the FMT procedure, and six fecal
samples from two donors were analyzed via LC-MS, together. Microbial composition in
12 of these patient sets and 4 donor samples (1 from donor 1, 3 from donor 2) were
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analyzed above (Fig. 3.1). The profile of primary and secondary bile acids in fecal
extracts was defined by examining the extracted ion chromatograms of deprotonated bile
acids in the pre-and post-FMT samples. The results showed that FMT induced dramatic
changes in fecal bile acid composition (Fig. 3.2A). Two primary bile acids, cholic acid (I)
and chenodoxycholic acid (II), were present in significant amount in most pre-FMT
samples, but were absent or existed in low abundance in most post-FMT and donor
samples (Fig. 3.2B and C). In contrast, three secondary bile acids, lithocholic acid (III),
deoxycholic acid (IV), and isodeoxycholic acid (V), were only present in the post-FMT
and donor samples but were absent in the pre-FMT samples (Fig. 3.2D-F).
Metabolomic analysis of FMT-induced metabolic changes in the fecal extracts of R-
CDI patients
To examine overall metabolic changes following FMT, the same fecal samples
analyzed for bile acid composition were also analyzed via LC-MS-based metabolomics.
Unsupervised principal component analysis (PCA) of chromatographic and mass spectral
data acquired from LC-MS analysis revealed a clear separation of pre-FMT samples from
the donor and post-FMT samples in a multivariate model (Fig. 3.3A). These findings
suggest that FMT transformed the fecal metabolome of CDI patients to that consistent
with the donors. The fecal metabolites which differed among pre-FMT, post-FMT, and
donor samples were revealed in an S-plot of the supervised OPLS model (Fig. 3.3B and
Table 3.5). Besides confirming the primary and secondary bile acids (I-V) as the fecal
metabolites that distinguish pre-FMT and post-FMT samples, bile salts, including taurine
conjugates (VI and VII, Fig. 3.3C-D) and glycine conjugates of cholic acid and
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chenodeoxycholic acid (VIII and IX, data not shown) were identified as major
contributors to sample separation in the multivariate models. The presence of significant
amount of bile salts in many pre-FMT samples suggested their incomplete hydrolysis in
these patients.
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DISCUSSION
The appearance of hypervirulent strains of C. difficile infection has led to an
increased incidence of recurrent and severe forms of the disease refractory to antibiotic
therapies alone (Merrigan et al., 2010; Surawicz and Alexander, 2011; He et al., 2013).
FMT has emerged as a solution to this unmet clinical need, and its use is becoming
increasingly widespread in clinical practice (Borody and Khoruts, 2011; Surawicz and
Alexander, 2011; Surawicz et al., 2013). However, the mechanisms behind the success of
this therapy still remain largely unknown. Previous work by our group and others has
demonstrated dramatic changes in the fecal microbiota of patients undergoing FMT, with
fecal microbial communities becoming more similar to that of the donor, including an
increased abundance of Bacteroidetes and Firmicutes, a decreased abundance of
Proteobacteria, and an increase in overall microbial diversity (Khoruts et al., 2010;
Shahinas et al., 2012; Hamilton et al., 2013; van Nood et al., 2013). The results presented
in this study indicate that these microbiome changes also hold true for a larger sample
size of patients. Consistent with the previous reports, FMT resulted in an increase in
OTUs corresponding to Bacteroidetes and Firmicutes and a decrease in the abundance of
Proteobacteria. The PCoA analysis also indicated that these changes represent shifts in
the fecal bacterial community towards the composition of the donor and a shift from a
highly altered community dominated by Proteobacteria towards the community typically
found in healthy individuals (Zoetendal et al., 2008; Arumugam et al., 2011). The
dramatic dysbiosis documented in the pre-FMT samples is likely induced and perpetuated
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by continuous antibiotic pressure, mainly vancomycin, that the patients were taking at the
time of collection.
Considering that gut microbiota in the colon have multiple metabolic functions,
targeted metabolite profiling and untargeted metabolomics were adopted to examine the
metabolic events induced by FMT. The results showed that after FMT the overall
metabolic composition of samples shifted to one similar to that of the donors, mimicking
our findings for taxonomic microbial composition. The bile acids and primary bile salts
were by far the dominant metabolites contributing to the separation of pre-FMT samples
from post-FMT and donor samples revealed by the multivariate model on the fecal
metabolomes, suggesting that the changes in bile acid composition account for much of
the overall change in fecal metabolome in R-CDI patients treated with FMT. Strikingly,
secondary bile acids were simply not detectable in any of the pre-FMT fecal samples.
Because of the well-known functions of gut microbiota in the hydrolysis of bile salts
(taurine and glycine conjugates) to bile acids and the biotransformation of primary bile
acids into secondary bile acids in the colon (Mahony et al., 1977; Stellwag and Hylemon,
1978; Hirano et al., 1981; Takamine and Imamura, 1995; Hofmann and Hagey, 2008),
this observation suggests that pre-FMT patients in this study were deficient of microbiota
that were capable of metabolizing secondary bile salts and bile acids, possibly due to the
depletion or decrease of bile acid-metabolizing microbiota after extensive antibiotic
treatment (Hashimoto et al., 1996; Carman et al., 2005; Toda et al., 2009). Therefore,
FMT likely rehabilitated bile acid metabolizing microbiota in these same patients. It is
even plausible that normalization of bile acid metabolism contributed to resolution of
mild diarrheal symptoms experienced by patients while they were being maintained on
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vancomycin prior to FMT. Indeed, increased content of primary bile acids in stool is
correlated with diarrheal symptoms, while increased content of secondary bile acids
correlates with constipation (Shin et al., 2013).
Increased concentrations of primary bile acids and their conjugates in R-CDI
patients are consistent with relentless relapses of the infection each time suppressive
antibiotics are discontinued. Taurocholic acid, which existed in high abundance in many
pre-FMT samples, is a potent germinant for C. difficile, transforming inert spores into
toxin-producing, free-living vegetative cells (Sorg and Sonenshein, 2008). In fact,
taurocholic acid has been used for decades as a key component of laboratory medium
used to germinate C. difficile spores (Wilson, 1983). In contrast, lithocholic acid and
other secondary bile acids, which were deficient in pre-FMT samples but abundant in
post-FMT and donor samples, inhibit C. difficile germination and colony growth (Sorg
and Sonenshein, 2010; Giel et al., 2010). These findings suggest that changes in fecal bile
acid composition observed in FMT patients following the procedure may generate an
environment unsuitable to C. difficile germination or growth. Prompt restoration of
normal fecal bile acid composition following FMT fits this hypothesis, as clinical
recurrence of CDI would otherwise peak during the second and third weeks after
discontinuation of antibiotics.
The changes in fecal bile acid composition of FMT patients may be directly
related to changes in fecal bacterial composition. Many of the bacteria known to have 7α-
dehydroxylation activity, which transforms primary bile acids into secondary bile acids,
are members of the Lachnospiraceae and Ruminococcaceae families (i.e. Clostridium
clusters XIVa and IV), including the best-studied of these species, Clostridium scindens
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(Stellwag and Hylemon, 1978; sHirano et al., 1981; Takamine and Imamura, 1995;
Doerner et al., 1997; Kitahara et al., 2000; Ridlon et al., 2006). By increasing the relative
abundance of members of these bacterial families, it is possible that FMT increases 7α-
dehydroxylation activity, leading to increased secondary bile acids and decreased primary
bile acids. This may directly inhibit germination and thus toxin production by C. difficile.
In conclusion, our results support a mechanistic model where FMT prevents
recurrence of CDI by restoring normal bile acid composition in the colon (Fig. 3.4). In
this model, antibiotics used to treat CDI also inhibit normal members of the microbiota
that hydrolyze bile salts to bile acids and then convert primary bile acids to secondary
bile acids. The lack of bile acid metabolism in antibiotics-treated R-CDI patients
generates a local environment that promotes germination of C. difficile spores and growth
of new vegetative bacteria that actively produce toxins once antibiotic treatment is
completed. Restoration of normal colonic microbial ecology by FMT restores bile acid
metabolism and normal bile acid composition in the colon producing an unfavorable
environment for C. difficile spore germination allowing clinical recovery of R-CDI
patients.  Therefore, microbiological or pharmacological strategies to manipulate the
intestinal bile acid composition may become effective approaches for the treatment of R-
CDI.
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Table 3.1 - Clinical characteristics of the patient cohort.
Patient Number 1 2 3 4 5 6
Age 68 66 60 29 24 59
Gender F F F F F M
Total Number of C.
difficile Episodes Prior
to FMT 6 3 5 7 9 4
Duration of R-CDI
Prior to FMT (months) 6 3 6 8 12 4
Original Trigger Event Sinusitis
Spinal
Surgery Diverticulitis C-section Pelvic Pain Bronchitis
Trigger Antibiotic
Not
documented Cephalosporin
Ciprofloxacin
Metronidazole Cephalosporin Metronidazole
Azithromycin
Ciprofloxacin
Prior hospitalization for
severe or complicated
CDI No Yes Yes No No Yes
Metronidazole Courses 2 1 2 2 2 1
2-week Vancomycin
Courses 1 1 1 3 4 1
Vancomycin
Taper/Pulse 2 1 2 2 1 1
Fidaxomicin 1 0 0 0 2 1
Rifaximin Chaser 0 0 0 1 0 0
Intercurrent Antibiotics None None None None None None
Immunosuppression None None None None None None
Probiotics Florastor None Florastor None Florastor
Lactobacillus
rhamnosus
Findings at
Colonoscopy
Normal
Examination
Diverticulosis,
severe
Diverticulosis,
moderate
Normal
Examination
Normal
Examination
Diverticulosis,
moderate
Type of Fecal
Microbiota Preparation Frozen Frozen Fresh Frozen Fresh Fresh
Donor 1 1 1 1 2 1
Resolution of CDI Yes Yes Yes Yes Yes Yes
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Patient Number 7 8 9 10 11 12
Age 56 87 65 52 47 52
Gender F F F F F F
Total Number of C.
difficile Episodes Prior
to FMT 5 8 5 8 4 9
Duration of R-CDI Prior
to FMT (months) 6 9 7 11 4 7
Original Trigger Event Knee Surgery
Duodenal Ulcer
Perforation
Vaginal
Infection
Urinary
Tract
Infection Sinusitis
Pelvic
Reconstruction
Surgery
Trigger Antibiotic Cephalosporin
Not documented;
multiple
antibiotics Clindamycin Ciprofloxacin
Not
documented Clindamycin
Prior hospitalization for
severe or complicated
CDI No Yes No No Yes No
Metronidazole Courses 1 2 2 2 1 1
2-week Vancomycin
Courses 1 2 1 3 1 2
Vancomycin
Taper/Pulse 1 1 2 2 1 4
Fidaxomicin 1 1 0 2 0 1
Rifaximin Chaser 1 1 0 0 1 1
Intercurrent Antibiotics None None None None None None
Immunosuppression None None None None None None
Probiotics None Florastor None None None
Acidophilus
Probiotic Blend
Findings at
Colonoscopy
Terminal Ileitis
(Crohn's)
Normal
Examination
Normal
Examination
Normal
Examination
Lymphocytic
Colitis
Diverticulosis,
mild
Type of Fecal
Microbiota Preparation Frozen Frozen Fresh Frozen Fresh Frozen
Donor 1 1 1 1 1 1
Resolution of CDI Yes Yes Yes Yes Yes Yes
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Patient Number 13 14 15 16
Age 71 72 79 83
Gender M M F F
Total Number of C. difficile
Episodes Prior to FMT 5 6 4 3
Duration of R-CDI Prior to FMT
(months) 11 7 5 5
Original Trigger Event
Multiple Infections,
including pneumonia
Diarrheal Illness of
Unclear Cause Bladder Infection Urinary Sepsis
Trigger Antibiotic Multiple antibiotics
No identified
antibiotic trigger Not documented
Not documented; multiple
antibiotics
Prior hospitalization for severe
or complicated CDI Yes Yes Yes No
Metronidazole Courses 2 2 0 1
2-week Vancomycin Courses 1 2 2 1
Vancomycin Taper/Pulse 3 2 2 1
Fidaxomicin 0 0 0 0
Rifaximin Chaser 0 0 0 0
Intercurrent Antibiotics Ciprofloxacin None None None
Immunosuppression
Tacrolimus;
Mycophenolate Mofetil None None None
Probiotics Lactobacillus rhamnosus None None None
Findings at Colonoscopy Diverticulosis, mild
Diverticulosis,
severe
Adenomatous
polyps; moderate
diverticulosis
Non-diagnostic inflammation in
the lamina propria
Type of Fecal Microbiota
Preparation Fresh Fresh Frozen Frozen
Donor 1 1 1 2
Resolution of CDI Yes No Yes Yes
R-CDI = Recurrent C. difficile infection; severe CDI = WBC ≥ 15,000 cells/mm3, albumin < 3, abdominal tenderness or documentation of colitis on CT scan; complicated CDI =
one of the following: ICU admission, WBC ≥ 35,000 cells/mm3, albumin < 2.5, hypotension, fever > 38.5°C, mental status changes, evidence of end-organ failure; intercurrent
antibiotics = antibiotics used to treat non-C. difficile infection after CDI diagnosis.
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Table 3.2 - Primers for V6 16S PCR.
Primer Name Sequence (5’ - 3’)
Forward Primer 1 [*]NCNACGCGAAGAACCTTANC
Forward Primer 2 [*]NNCAACGCGAAAAACCTTACC
Forward Primer 3 [*]NNNCAACGCGCAGAACCTTACC
Forward Primer 4 [*]NNNNATACGCGARGAACCTTACC
Forward Primer 5 [*]NNNNNCTAACCGANGAACCTYACC
Reverse Primer [**][6 bp Index sequence][†][4-7 N]
CGACRRCCATGCANCACCT
* = Illumina TruSeq Universal Adapter sequence
** = Illumina PCR primer
† = Illumina multiplexing PCR primer 2.0
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Table 3.3 - Abundance of major bacterial phyla in patient and donor samples.
Average no. OTUs (of 22,535
total)
Phylum Donor Pre-FMT Post-FMT p-value (pre vs.
post-FMT)
Actinobacteria 275 24 219 0.044
Bacteroidetes 8316 36 4402 0.0015
Firmicutes 10,223 5412 12,443 0.0016
Fusobacteria 0 480 2 0.177
Proteobacteria 207 12,689 1234 <0.0001
Verrucomicrobia 189 3469 449 0.035
Bacteria-unclassified 3302 424 3785 <0.0001
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Table 3.4 - Significantly changed bacterial families in patient and donor samples.
Average no. OTUs (of 22,535
total)
Family Donor Pre-FMT Post-FMT p-value (pre vs. post-
FMT)
Bacteroidaceae 6451 25 4348 0.0009
Coriobacteriaceae 150 12 150 0.034
Enterobacteriaceae 13 11,572 1083 <0.0001
Lachnospiraceae 4002 286 4737 <0.0001
Lactobacillaceae 2 255 12 0.0019
Rikenellaceae 388 2 455 0.0014
Ruminococcaceae 1749 112 3797 0.0002
Veillonellaceae 117 1261 81 0.0006
Verrucomicrobiaceae 189 3469 449 0.035
Bacteroidetes-
unclassified
2185 501 1809 0.0064
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Table 3.5 - Fecal metabolite markers of FMT.
Major primary and secondary bile acids and the conjugates of primary bile acids (I-IX)
were identified as the metabolite markers contributing to the separation of the pre-FMT
samples from the post-FMT and donor samples in the metabolomic analysis. [M-H]- =
mass-to-charge ratio of deprotonated metabolite; ↑ = increased after FMT; ↓ = decreased
after FMT.
ID [M-H]- Formula Identity Effect of FMT
I 407.279
8
C24H40O5 cholic acid (CA) ↓
II 391.284
8
C24H40O4 chenodeoxycholic acid (CDCA) ↓
III 391.284
8
C24H40O4 deoxycholic acid (DCA) ↑
IV 375.289
9
C24H40O3 lithocholic acid (LCA) ↑
V 391.284
8
C24H40O4 isodeoxycholic acid (isoDCA) ↑
VI 514.283
9
C26H45NO7S4 taurocholic acid (TCA) ↓
VI
I
498.288
9
C26H45NO6S taurochenodeoxycholic acid (TCDCA) ↓
VI
II
464.281
7
C26H43NO6 glycocholic acid (GCA) ↓
IX 448.306
3
C26H43NO5 glycoochenodeoxycholic acid (GCDCA) ↓
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Figure 3.1 - Fecal bacterial communities change following FMT. A) Shannon
diversity indices of fecal samples. Legend:  * = p <0.05. B) Principal coordinate analysis
of UniFrac distances between bacterial communities. PC1 = Principal coordinate 1, PC2
= Principal coordinate 2. C) Relative abundance of OTUs from bacterial phyla in fecal
samples. Colors correspond to phyla (see key below figure). D) Relative abundance of
OTUs from bacterial families in fecal samples. Colors correspond to families (see key to
right of figure). Legend: † = patient who failed initial FMT.
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Figure 3.2 - Bile acid concentrations are significantly altered after FMT. Conditions
for LC-MS analysis are described in the Methods. A) The overlay of representative
chromatograms of bile acid metabolites in pre-FMT and post-FMT fecal extracts. The
chromatograms were generated by extracting MS signals within 20 ppm of calculated
exact masses (407.2797, 391.2848, and 375.2899 m/z in negative mode) of primary and
secondary bile acids of sterol metabolites (I - V).  The signal intensity of deoxycholic
acid (III) in the post-FMT sample was arbitrarily set as 100%. B-F) Concentration of bile
acids (I - V) in the pre-FMT, post-FMT, and donor samples. Legend: * = p <0.05.
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Figure 3.3 - Identification and characterization of FMT-responsive sterol
metabolites in fecal extracts of CDI patients. Multivariate analysis of LC-MS data
from fecal extracts is described in the Methods. A) The scores plot of a PCA model on
pre-FMT (▲), post-FMT (∆), and donor (*) samples. The t[1] and t[2] values represent
the scores of each sample in the principal component 1 and 2, respectively. B) The
loadings plot of PCA model. Sterol metabolites contributing to the separation of pre-FMT
and post-FMT samples (I - IX) were labeled and their chemical identities are listed in
Table 3. C-D) Relative abundances of taurine conjugates of primary bile acids (VI and
VII) in the pre-FMT, post-FMT, and donor samples. Legend: * = p < 0.05.
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Figure 3.4 - Antibiotics promote recurrence of C. difficile infection by decreasing
hydrolysis of bile salts and conversion of primary bile acids into secondary bile acids
(the model). A) Normal bile acid composition in the colon (shown in brown color)
prevents germination of C. difficile spores. B) Antibiotics allow increased levels of bile
salts and primary bile acids in the colon (shown in green color), which promote
germination of C. difficile spores and growth of vegetative forms of bacteria.
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Chapter 4
Fecal Bile Acid Composition is a Mechanism of Fecal Microbiota Transplantation
Which Controls Clostridium difficile Germination and Growth
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SUMMARY
Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent
Clostridium difficile infection (R-CDI), but its mechanisms remain poorly understood.
Emerging evidence suggests that bile acids in the gut have significant effects on C.
difficile physiology, and therefore on patient susceptibility to recurrent infection. We
analyzed germination of spores from 10 clinical C. difficile isolates exposed to
combinations of bile acids present in patient feces before and after FMT. Bile acids
present in feces prior to FMT induced germination of C. difficile, while those present
after FMT did not. Furthermore, post-FMT bile acids inhibited vegetative growth of C.
difficile. Ursodeoxycholic acid (UDCA), a minor human secondary bile acid clinically
available as a therapeutic, also inhibited C. difficile germination and growth. Finally, we
sequenced the newly-identified germinant receptor in C. difficile, CspC, and found that
variations in germination response across isolates corresponded to mutations in this
receptor. These results indicate that changes to fecal bile acids are in fact a key
mechanism of FMT, that differences in the germinant receptor correspond to differences
in response to these bile acids, and that bile acids can be developed into effective non-
antibiotic pharmacologic agents which may treat R-CDI.
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INTRODUCTION
Clostridium difficile infection (CDI) has become one of the most common
nosocomial infections in developed countries in the last 20 years, and more recently has
become an important cause of community-acquired infectious colitis (Kelly and Lamont,
2008; Miller et al., 2011; Ananthrakishnan, 2011; Lessa et al., 2012; Khanna et al., 2012;
Chitnis et al., 2013). Unfortunately, antibiotic therapy alone commonly fails to cure this
disease. In fact, the use of antibiotics is the primary risk factor for CDI and perpetuates its
recurrence (Kelly and Lamont, 2008; Miller et al., 2011; Ananthrakishnan, 2011; Lessa et
al., 2012; Khanna et al., 2012; Chitnis et al., 2013; Borody and Khoruts, 2011; Hu et al.,
2009). Approximately 20-30% of patients experience recurrence of CDI after the initial
infection, and the risk of recurrence increases with each subsequent antibiotic treatment
(Kelly and Lamont, 2008; Borody and Khoruts, 2011; Louie et al., 2011; Surawicz and
Alexander, 2011). After three or more relapses, patients typically develop recurrent CDI
syndrome (R-CDI), a state of persistent infection that is resistant to existing antibiotic
regimens (Borody and Khoruts, 2011; Surawicz and Alexander, 2011). However, fecal
microbiota transplantation (FMT), in which fecal material from a healthy donor is
delivered into the gastrointestinal tract of a patient, is increasingly employed in clinical
practice as a highly effective method to break the cycle of R-CDI (Gough et al., 2011;
Hamilton et al., 2012; van Nood et al., 2013; Youngster et al., 2014; Youngster et al.,
2015).
Despite the high clinical efficacy of FMT, its mechanisms are poorly understood.
It is known that the fecal microbiota of R-CDI patients undergoes compositional
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normalization following the procedure (Khoruts et al., 2010; Shahinas et al., 2012;
Hamilton et al., 2013; van Nood et al., 2013; Seekatz et al., 2014; Fuentes et al., 2014;
Shankar et al., 2014). This normalization is associated with functional restoration of fecal
bacterial bile acid metabolism in these patients, including restoration of bacterially-
mediated conversion of primary to secondary bile acids (Weingarden et al., 2014). Some
primary bile acids, such as taurocholate (TA), are potent germinants for C. difficile
spores, while certain secondary bile acids act as inhibitors of both germination and
vegetative growth of the bacterium (Sorg and Sonenshein, 2008; Sorg and Sonenshein,
2009; Sorg and Sonenshein, 2010; Giel et al., 2010; Heeg et al., 2012), though no work
has yet examined the effects of a combination of bile acids which reflects the colonic
environment in humans with or without CDI. Based on these observations, we
hypothesized that antibiotics used to treat CDI patients alter bacterially-mediated bile
acid metabolism towards a composition that favors C. difficile germination, and that FMT
prevents C. difficile expansion via restoration of gut microbial ecology and normalization
of colonic bile acid composition.
In this report, we demonstrate that the combination of bile acids present in the
feces of R-CDI patients prior to FMT induced germination of multiple clinical isolates of
C. difficile, while the combination of bile acids present after FMT did not. We also report
that ursodeoxycholic acid (UDCA), a minor secondary bile acid in humans that is
currently approved for certain cholestatic conditions (Poupon, 2010; Lindor et al., 2009),
inhibits C. difficile germination and growth in vitro. Finally, we show that variations in
germination response across different strains may be related to variation in the C. difficile
germinant receptor. These findings support the hypothesis that restoration of secondary
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bile acid metabolism is an important mechanism of FMT, and that novel pharmacological
interventions based on this insight can be developed to treat R-CDI.
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MATERIALS AND METHODS
Isolation and characterization of C. difficile isolates
Isolation of C. difficile from environmental samples was done using a protocol developed
by the CDC and modified for the present study. Sterile phosphate buffered saline, pH 7,
with 0.1% Tween 80 (50 mL) was added to sterile bags containing environmental sample
sponges. Bags were placed into a Stomacher 400 circulator (Seward Laboratory Systems,
Davie, FL) and macerated at 260 RPM for 1 min. The liquid was removed and
centrifuged at 3500xg for 15 min. The pellet was resuspended in the remaining buffer and
a 0.2 mL aliquot of the resulting suspension was plated, in duplicate, onto pre-reduced
cycloserine-cefoxitin-fructose agar with horse blood and taurocholate (CCFA-HT,
Anaerobic systems, USA). 1 mL of suspension was inoculated into cycloserine-cefoxitin-
fructose broth (CCFB) (Arroyo et al., 2005). CCFA-HT plates and CCFB tubes were
incubated for 48-72 hr at 37oC under anaerobic conditions. C. difficile colonies from
CCFA-HT plates were identified using McLung Toabe agar (lecithinase and lipase-
negative), blood agar (no hemolysis), PRO kit (Remel, USA), and Gram staining (Gram-
positive spore forming bacilli). Presumptive C. difficile colonies were further
characterized by PCR detection of the pathogenicity locus (PaLoc), binary toxin (cdtB),
and C. difficile toxin regulator tcdC genes; toxinotyping; and sequence analysis of the
tcdC gene for specific base pair deletions (Braun et al., 1996; Rupnik et al., 1998; Stubbs
et al., 2000; Spigaglia and Mastrantonio, 2002). Confirmed C. difficile isolates also
underwent pulsed-field gel electrophoresis (PFGE) analysis, allowing assignment to an
established or novel North American pulsotype (NAP) based on an 80% similarity
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threshold in comparison with CDC reference profiles (Killgore et al., 2008). Confirmed
isolates were stored in 25% glycerol at -80°C.
C. difficile spore isolation
C. difficile cells from frozen stocks were inoculated into CCFB medium and grown
anaerobically at 37°C for 48 hr. Cultures were plated onto brain heart infusion with 5 g/L
yeast extract and 0.1% L-cysteine (BHIS) and grown for 7 d at 37°C under anaerobic
conditions. Following Sorg and Sonenshein, 2010, colonies from each plate were scraped
into 1 mL of ice-cold water and incubated at 4°C overnight to release spores. A 3 mL
suspension was loaded onto 10 mL of 50% (w/v) sucrose in a 15 mL conical tube and
centrifuged in a swinging bucket rotor at 3200 x g for 20 min at 4°C. Sucrose and
vegetative cells above the spore pellet were removed, and the pellet was washed 5 times
in ice-cold water to remove remaining sucrose. Spores were examined under phase-
contrast microscopy to determine purity; spore samples with >99% purity (<1%
vegetative cells) were stored at 4°C.
C. difficile spore germination
Germination assays were done as previously described by Sorg and Sonenshein, 2010.
Spores were heated to 65°C for 30 min and inoculated into BHIS, with or without bile
acids, within an anaerobic bag flushed and filled with N2 gas. OD600 was measured
initially (OD600(t0)) and every minute for 20 min (OD600(t)) using an EL808 Microplate
Reader (Biotek Instruments, Inc., Winooski, VT). Relative OD600 for each time point was
calculated as OD600(t)/OD600(t0). Experiments were performed in triplicate.
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Growth of C. difficile vegetative cells
Cells from frozen stocks were inoculated into BHIS broth with 0.1% (w/v) taurocholate
and incubated overnight at 37°C under anaerobic conditions. Vegetative cells were
inoculated into tubes containing BHIS, with or without bile acids, normalized to an OD600
of 0.005, and grown anaerobically at 37°C. Measurements of OD600 were collected each
hour for 12 hr following inoculation, and a final OD600 was measured after 24 hr growth.
Experiments were performed in triplicate.
Sequencing of C. difficile germinant receptor
Two sets of PCR primers were designed based on a published DNA sequence of the C.
difficile germinant receptor CspC (Francis et al., 2013) (Table 4.4). For each primer set,
three PCR reactions were run in order to generate ~700 bp overlapping fragments for
Sanger sequencing. Samples were amplified in 50 μL reactions containing 1x PCR buffer
with 1.5 mM magnesium chloride, 0.2 μM nucleotides, 0.4 μM one forward and reverse
primer, 2.5 U Choice Taq (Denville Scientific, South Plainfield, NJ), and 25 ng of
template. Reactions were heated to 95°C for 3 min, then subjected to 25 cycles of 95°C
for 30 sec, 51°C (forward primers 1A, 1B, and 1C), 57°C (primer 2B), or 58°C (primers
2A and 2C) for 30 sec, and 72°C for 150 (primers 1A and 2A), 90 (primers 1B and 2B),
or 60 (primers 1C and 2C) sec, before a final elongation step at 72°C for 15 min.
Amplicons were purified with the QIAquick PCR purification kit (Qiagen, Germantown,
MD) and sequenced via Sanger sequencing. Sequences were manually edited using
Chromas Lite (Technelysium Pty Ltd, Australia) and assembled into full-length cspC
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sequences, then translated into protein sequences using the ExPASy protein translate tool
(Gasteiger et al., 2003). Protein sequences were aligned and UPGMA tree (with boot-
strapping) was generated using Clustal X (Larkin et al., 2007).
Reagents
Sodium taurocholate, sodium cholate, sodium deoxycholate, chenodeoxycholic acid
(CDCA), lithocholic acid (LCA), and ursodeoxycholic acid (UDCA) were obtained from
Fisher Scientific (Waltham, MA). The CDCA, LCA, and UDCA were dissolved in 100%
ethanol prior to use.
Statistical analysis
Analysis of variance (ANOVA) followed by Tukey’s honest significant difference (HSD)
test was used to determine statistical significance of germination and growth assay
results.
Study approval
The study was approved by the University of Minnesota Institutional Review Board
(IRB). Collection of household C. difficile isolates was performed under IRB
1112M07323. The study of fecal specimens was performed under IRB 0901M56962. All
human subjects provided informed consent for participation in the study.
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RESULTS
Fecal bile acids present before FMT induce germination of C. difficile spores
An established spectrophotometric assay that relies on the refractive nature of
bacterial spore coats was used to examine germination of C. difficile (Sorg and
Sonenshein, 2008; Sorg and Sonenshein, 2009; Sorg and Sonenshein, 2010; Heeg et al.,
2012). Spore coats are refractive towards light and appear phase-bright under phase-
contrast microscopy, but are rapidly degraded during the initial step of germination and
become phase-dark (Moir and Smith, 1990) (Fig. 4.1A). This degradation can be
measured as a decrease in light absorption at 600nm (OD600), allowing for the
measurement of germination of C. difficile spores independent of subsequent growth of
the resulting vegetative cells. This decrease in OD600 is measured as a relative OD600, or
OD600 at a given time normalized to initial OD600. We validated this assay by correlating
relative OD600 to the appearance of phase-dark spores and vegetative cells via phase-
contrast microscopy and to the percent of colony-forming units (CFUs) which resulted
from plating these cells on BHIS (Fig. 4.1A). A decrease of 16.5% of initial OD600
(0.165) after 20 min exposure to 2 mM of the germinant TA in BHIS corresponded to an
increase of 69.1% phase-dark and vegetative cells compared to spores exposed to BHIS
alone. In addition, exposure to 2 mM TA resulted in colony formation by 0.1% of total
cells, compared to no detectable growth from cells exposed to BHIS alone. Having
demonstrated that a decrease in OD600 corresponds to spore coat loss and colony
outgrowth, we used this germination assay to determine whether bile acids present in
patient feces before or after FMT induce germination of C. difficile spores.
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We previously demonstrated that treatment of R-CDI patients with FMT results in
conversion of fecal bile acid composition from domination by primary bile acids to
domination by secondary bile acids (Weingarden et al., 2014). Here we exposed C.
difficile spores from a North American Pulsed-field gel electrophoresis type 1 (NAP1)
strain, which is typically considered hypervirulent (McDonald et al., 2005), to
combinations of bile acids at concentrations present in patient feces before FMT (pre-
FMT bile acids) and after FMT (post-FMT bile acids) (Table 4.1 and Fig. 4.1B). The
relative OD600 of spores exposed to pre-FMT bile acids significantly decreased (p<0.05)
compared to spores exposed to post-FMT bile acids, which suggests that the combination
of intracolonic bile acids prior to FMT induce germination of C. difficile spores, while the
combination of bile acids present after FMT do not.
Although these findings indicated that a single isolate of C. difficile germinates in
response to pre-FMT bile acids combinations, previous work has shown that the
germination response to bile acids can vary among different strains of C. difficile (Heeg
et al., 2012). To test whether the germination response to fecal bile acid combinations
varied across C. difficile strains, we tested spores from nine additional C. difficile
isolates, along with the NAP1 strain above for a total of 10 isolates, which were collected
from the household environment of R-CDI patients treated with FMT in our program.
These 10 isolates included representatives from four different NAP types and three
distinct toxinotypes (Table 4.2). When spores from all 10 isolates were exposed to pre-
FMT or post-FMT bile acid combinations, there was a significant (p<0.05) decrease in
the relative OD600 of spores exposed to pre-FMT bile acids versus post-FMT (Fig. 4.1C,
Table 4.3). These results indicate that the typical fecal bile acid composition before FMT
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can induce germination in multiple strains of C. difficile, whereas bile acids present after
FMT do not.
To investigate how much each bile acid in the pre-FMT combination individually
contributed to C. difficile germination, we examined the effects of a range of
concentrations of primary bile acids on the relative OD600 of spores. Taurocholate, which
has long been known as a germinant for C. difficile spores (Wilson, 1983; Sorg and
Sonenshein, 2008) caused a significant (p<0.001) decrease in relative OD600 of NAP1
spores alone and of spores from all 10 isolates (Fig. 4.2A, Table 4.3). Cholate has also
been considered a germinant for C. difficile (Wilson, 1983; Sorg and Sonenshein, 2008).
While we found no significant decrease in relative OD600 after cholate exposure for
spores from the NAP1 isolate alone, the relative OD600 of spores from all 10 isolates
decreased significantly following exposure to 1 and 2 mM cholate (p<0.05 and p<0.01,
respectively) (Fig. 4.2B). These findings suggest that both taurocholate and cholate
induce germination in spores from these clinical isolates of C. difficile.
In contrast to taurocholate and cholate, chenodeoxycholic acid (CDCA), another
major primary bile acid in our pre-FMT combination, is typically found to inhibit C.
difficile germination (Sorg and Sonenshein, 2009; Sorg and Sonenshein, 2010).
Consistent with this, we found that exposure to CDCA significantly (p<0.01) inhibited
the decrease in relative OD600 seen with taurocholate alone for spores from both the
NAP1 isolate alone and spores from all 10 isolates (Fig. 4.3). This result indicates that
CDCA inhibits germination of spores from our C. difficile isolates. While exposure to
CDCA without taurocholate did not decrease the relative OD600 of NAP1 spores alone, 2
mM CDCA caused a significant (p<0.05) decrease in relative OD600 for all 10 isolates
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(Fig. 4.2C, Table 4.3). This suggests that higher concentrations of CDCA can induce
germination in some isolates of C. difficile. Overall, these findings indicate that all three
primary bile acids that predominate in pre-FMT feces (taurocholate, cholate, and CDCA)
can induce germination of C. difficile at sufficiently high concentrations. Furthermore,
although CDCA can also inhibit taurocholate-mediated germination, the effects of
cholate and taurocholate outweigh the effects of CDCA at the concentrations present in
pre-FMT patient feces (Table 4.1).
We next investigated the individual effects of bile acids in the post-FMT
combination on C. difficile germination. Deoxycholate, the most abundant bile acid in the
post-FMT combination, has been shown to cause germination of C. difficile (Sorg and
Sonenshein, 2008). We tested whether physiological concentrations of deoxycholate led
to germination of our isolates by exposing spores to a range of concentrations inclusive of
the average concentration of this bile acid in post-FMT patient feces. There was no
decrease in relative OD600 of spores from the NAP1 isolate alone or of spores from all 10
isolates after exposure to any tested concentration of deoxycholate (Fig. 4.4A, Table 4.3).
Similarly, no decrease in relative OD600 was observed when spores were exposed to any
tested concentration of lithocholic acid, the other secondary bile acid present in the post-
FMT bile acid combination (Fig. 4.4B, Table 4.3). These results indicate that the
secondary bile acids deoxycholate and lithocholic acid, which are elevated in post-FMT
patient feces, do not induce germination of C. difficile spores.
Overall, our findings demonstrate that primary bile acids at the concentrations
observed in patient feces prior to FMT can induce C. difficile spores to germinate, likely
due to the dominant effects of cholate and taurocholate. Furthermore, the secondary bile
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acids deoxycholate and lithocholic acid do not induce germination of C. difficile at the
concentrations found in patient feces after FMT.
Fecal bile acids present after FMT strongly inhibit vegetative growth of C. difficile
We also investigated whether pre- and post-FMT bile acid combinations affect
vegetative growth of C. difficile. Overnight cultures of all 10 isolates were grown with
taurocholate to induce germination, and resulting vegetative cells were inoculated (to
OD600 = 0.005) into BHIS medium or BHIS containing pre-FMT or post-FMT bile acid
combinations. The growth of cells in BHIS containing either pre-FMT bile acids or post-
FMT bile acids was delayed relative to cells grown in BHIS alone (Fig. 4.5A, Fig. 4.6).
However, in 9 out of 10 isolates, the OD600 of cells after 24 h in medium with post-FMT
bile acids was significantly (p<0.05) lower than cells grown with pre-FMT bile acids.
This suggests that secondary bile acids present in post-FMT patient feces also inhibit
vegetative growth of C. difficile compared to bile acids found in patient feces before
FMT (Fig. 4.5B, Fig. 4.6). This effect was not likely due to a decrease in pH from the
addition of bile acids, since the pH of BHIS alone was not significantly different from the
pH of BHIS containing either combination of bile acids (data not shown).
UDCA inhibits germination and vegetative growth of C. difficile
Our findings confirmed that secondary bile acids present in patient feces
following FMT do not induce germination and significantly inhibit growth of vegetative
C. difficile. We therefore hypothesized that the one secondary bile acid currently
92
approved for use in human patients, UDCA, could also inhibit C. difficile germination
and growth, and that UDCA might therefore be a novel treatment for CDI.
To explore UDCA as a therapeutic agent against C. difficile, we tested whether
UDCA could inhibit taurocholate-mediated germination of our 10 isolates (Table 4.2).
Compared to spores exposed to taurocholate alone, addition of any concentration of
UDCA significantly (p<0.01) blunted the decrease in relative OD600 of spores from these
10 isolates (Fig. 4.7, Table 4.3). These findings indicate that UDCA can prevent
taurocholate-induced germination of multiple C. difficile isolates.
Having demonstrated that UDCA can significantly inhibit germination of C.
difficile, we examined whether the drug could also affect vegetative growth. As above,
overnight cultures of vegetative cells from each isolate were inoculated into tubes
containing BHIS or BHIS with 2 mM UDCA. Isolates grown with UDCA showed
substantially delayed growth compared to control cultures, and after 24 h the OD600 of
cultures grown with UDCA was significantly (p<0.001) lower than controls (Fig. 4.8,
Fig. 4.9). These findings suggest that UDCA inhibits growth of vegetative C. difficile in
addition to inhibiting spore germination.
Variation in germination response to UDCA may be explained by variations in the C.
difficile germinant receptor
Although our findings suggested that pre-FMT bile acids induce C. difficile spore
germination across a range of strains, previous work has indicated that the response of
spores from different isolates and strains of C. difficile to bile acids may vary (Heeg et
al., 2012). We therefore investigated whether there was variation in the response to our
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pre-FMT bile acid combination across the five strains represented by our 10 isolates, and
found that while all strains germinated in response to pre-FMT compared to post-FMT
bile acids, this response did vary across strains, and in particular was more profound in
NAP7 isolates (Fig. 4.10).
While little is known about the genetics and mechanisms of C. difficile
germination, recent work has revealed that CspC, an analog of a serine protease involved
in germination in Clostridium perfringens, may be the germinant receptor which senses
bile acids in C. difficile (Francis et al., 2013). We therefore hypothesized that some of the
variation in germination response to bile acids by our isolates might be due to variations
in this receptor.
To test this hypothesis, we generated two sets of polymerase chain reaction (PCR)
primers which targeted the published cspC gene sequence in C. difficile (Francis et al.,
2013) and successfully sequenced the cspC gene from nine of our isolates (Table 4.4).
Alignment of the protein sequences translated from the sequenced cspC genes revealed
that while all sequences are highly similar, CspC sequences do tend to cluster by strain
(Fig. 4.11A, Fig. 4.12). In particular, while sequences from the two successfully
sequenced NAP7 isolates were identical, all other sequences were more similar to each
other (99.1% or greater similarity), regardless of strain, than they were to NAP7
sequences (96.6 to 97.5% similarity) (Fig. 4.11B). We identified a total of 14 amino acid
substitutions unique to the NAP7 isolates compared to all other isolates (Table 4.5), of
which 7 were conservative, 3 were semi-conservative, and 4 were non-conservative.
These findings suggest that there are identifiable mutations in the C. difficile germinant
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receptor which may correspond to differences in germination in response to bile acids
present in the feces of R-CDI patients.
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DISCUSSION
Although fecal microbiota transplantation (FMT) is a highly effective treatment
for R-CDI (Gough et al., 2011; Hamilton et al., 2012; van Nood et al., 2013; Youngster et
al., 2014; Youngster et al., 2015), its acceptance into mainstream medicine requires
further development and regulatory approval (Khoruts et al., 2014). Furthermore, some
patients may not benefit from FMT, including those who require frequent courses of
antibiotics for other infections. Therefore, there remains a need to develop non-antibiotic
approaches to therapy for R-CDI. A mechanistic understanding of FMT has the potential
to enable more rational development of such therapeutics.
Microbial metabolism of intracolonic bile acids provides a link between the
transplantation of a healthy microbiome and durable recovery from CDI. The impact of
bile acids on the C. difficile lifecycle has long been recognized. For example,
taurocholate is routinely used in C. difficile culture media (Wilson, 1983; Arroyo et al.,
2005), and both taurocholate and cholate are known to induce germination of the
bacterium (Sorg and Sonenshein, 2008). In contrast, lithocholic acid, one of the dominant
colonic secondary bile acids produced from primary bile acids via bacterial metabolism,
is a known inhibitor of C. difficile germination (Sorg and Sonenshein, 2009; Sorg and
Sonenshein, 2010).
The impact of bile acids on pathogenicity of C. difficile is further supported by
animal models of the infection. The abundance of intracolonic secondary bile acids is
markedly decreased in mice treated with antibiotics and susceptible to CDI and is
significantly greater in mice resistant to CDI (Giel et al., 2010; Theriot et al., 2014;
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Buffie et al., 2014; Koenigsknecht et al., 2014). These findings suggest that the types of
bile acids present in the colon and the ability of C. difficile to respond to those bile acids
might play an important role in this infection.
We previously showed that secondary bile acids are absent in the feces of patients
with R-CDI syndrome, whereas primary bile acids are abundant (Weingarden et al.,
2014). FMT promptly normalizes the fecal bile acid composition, decreasing primary bile
acid concentrations and increasing secondary bile acids to levels found in healthy
individuals. Therefore, we hypothesized that suppression of secondary bile acid
metabolism in the colon by antibiotics creates an environment that is favorable for C.
difficile germination and growth, and that restoration of normal secondary bile acid
metabolism contributes to the clinical success of FMT in the treatment of R-CDI.
We tested these hypotheses here by measuring C. difficile spore germination and
vegetative growth in the presence of mixtures of bile acids at concentrations found in pre-
FMT and post-FMT feces of patients treated for R-CDI. Our results indicated that both
germination and growth were inhibited in all tested, clinical isolates of C. difficile in the
presence of post-FMT fecal bile acids (secondary bile acids) compared to pre-FMT bile
acids (primary bile acids). However, recent work suggests that a model wherein primary
bile acids promote C. difficile germination and secondary bile acids are inhibitory might
be overly simplistic. One of the major primary bile acids in humans, chenodeoxycholic
acid (CDCA), can prevent taurocholate-mediated spore germination (Sorg and
Sonenshein, 2008; Sorg and Sonenshein, 2009). We confirmed these findings, although
as previously reported we also found that high (non-physiological) concentrations of
CDCA (2 mM) cause some strains of C. difficile to germinate (Heeg et al., 2012).
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Importantly, however, CDCA is absorbed in the colon with far greater efficiency than
cholate (Mekhjian et al., 1979), which diminishes its intraluminal impact relative to
cholate derivatives. As we have shown, the resulting low CDCA concentration in pre-
FMT feces cannot fully inhibit taurocholate- and cholate-induced C. difficile germination.
Furthermore, it is not clear that secondary bile acids cannot promote C. difficile
germination. Deoxycholate, which is abundant in healthy donor and post-FMT feces, has
been shown to be a germinant for C. difficile (Sorg and Sonenshein, 2008; Sorg and
Sonenshein, 2009). Our results, however, suggest that many C. difficile strains do not
germinate in response to physiologically relevant concentrations of deoxycholate (0.5 – 2
mM) as measured in post-FMT feces. Furthermore, compared to taurocholate, even
greater concentrations of deoxycholate induce only modest germination (Sorg and
Sonenshein, 2008; Theriot et al., 2014). Lithocholic acid, which is also elevated in post-
FMT and donor feces, is not known to cause germination (Sorg and Sonenshein, 2010),
in agreement with our present findings. Overall, our results suggest the combination of
these two bile acids does not induce C. difficile germination, and emphasizes the
importance of assessing the impact of combinations of bile acids which reflect the
colonic environment in human patients, rather than individual bile acids.
One limitation of our study was the use of fecal measurements of bile acids, rather
than intracolonic concentrations. The process of transforming primary to secondary bile
acids by bacteria, 7α-dehydroxylation, is thought to be exclusively performed in the
colon (Ridlon et al., 2006). It is likely that bile acid concentrations measured in the feces
may underestimate the levels of primarily bile acids in the proximal colon. Furthermore,
our results also demonstrated that post-FMT bile acids inhibit vegetative growth of C.
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difficile, suggesting that even if some germination can occur in healthy or post-FMT
individuals, proliferation of the bacteria would be limited.
Importantly, our findings were consistent across all 10 tested C. difficile isolates,
including a representative of the NAP1 strain, which is considered hypervirulent and
responsible for several epidemic outbreaks of CDI (McDonald et al., 2005). Since the
germination response to CDCA varies among C. difficile strains (Heeg et al., 2012), it is
necessary to investigate the response of a range of isolates to these bile acids. All of our
tested C. difficile came from households of patients suffering from R-CDI who were
treated with FMT, likely representing the strains responsible for disease in these patients.
Therefore, our findings are likely to be directly applicable to future R-CDI patients.
Understanding the impact of intracolonic bile acids on the lifecycle of C. difficile
allows investigators to rationally design novel and effective therapeutics. Recently,
Buffie and colleagues demonstrated that inoculation with commensal bacteria that
transform primary to secondary bile acids (7α-dehydroxylation) can prevent CDI in mice
(Buffie et al., 2014). Additionally, a bile acid analog, a meta-benzene sulfonate derivative
of cholate (CamSA), was found to prevent germination of C. difficile spores in a mouse
colon assay and prevent symptoms in the infection model (Howerton et al., 2013a;
Howerton et al., 2013b). Here, we explored the bile acid hypothesis based on data from a
human system, including testing of a clinically-available secondary bile acid, UDCA. We
demonstrated that UDCA prevents taurocholate-induced germination of spores from 10
clinical isolates of C. difficile across a range of concentrations, suggesting its potential as
a therapeutic agent. Additionally, we demonstrated that UDCA can prevent vegetative
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growth of C. difficile, suggesting that there is a second mechanism whereby this drug
may help prevent recurrence of CDI.
Although these findings were overall consistent across our C. difficile isolates, we
also found that the magnitude of response varied by PFGE type. In particular, isolates
from the NAP7 PFGE type demonstrated a notably stronger response to the pre-FMT bile
acid combination. This finding is not unexpected, given that other investigators have also
demonstrated variation in C. difficile germination response to bile acids across a variety
of ribotypes and isolates (Heeg et al., 2012). To explain the variation we found here, we
sequenced the recently identified bile acid receptor, the serine protease CspC, from nine
of our isolates (Francis et al., 2013). Our results indicated that although CspC sequence is
highly similar across isolates, the CspC sequence of NAP7 isolates is somewhat more
distinct, matching well with our germination results. Although the catalytic domain of C.
difficile CspC is absent (Francis et al., 2013), limiting our ability to interpret the
significance of mutations in NAP7 CspC compared to our other isolates, the presence of
several non-conservative mutations suggests potential sites of interest which could be
investigated further. Notably, NAP7 (ribotype 078), like NAP1, is known to be a
hypervirulent strain of C. difficile and is associated with an increased mortality rate
(Walker et al., 2013). It is therefore possible that this increased sensitivity to bile acid
germinants, related to mutations in the germinant receptor, is a mechanism of increased
virulence in this strain. In addition to fully exploring these mutations, sequencing of the
CspC protein from additional isolates, both NAP7 and other PFGE types, will be
necessary to fully understand the significance of these results.
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Our understanding of the mechanisms behind FMT has been limited, which has
reduced our ability to design novel therapeutics for individuals with R-CDI who do not
meet inclusion criteria for or have failed FMT. Our results provide strong evidence that
the observed shift in bile acid composition following FMT is an important mechanism
underlying the therapeutic efficacy of the procedure. Furthermore, we have shown that
UDCA inhibits C. difficile germination and growth and has potential as a novel
therapeutic for R-CDI.
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Table 4.1 - Average concentration of bile acids measured in patient feces before and
after FMT and concentration used in bile acid combinations.
Bile acid
Concentration (mM)a
Pre-FMT Post-FMT
Taurocholate (10)b 0.55 -c
Cholate (10) 1.45 -
Chenodeoxycholic acid (10) 0.37 -
Deoxycholate (20)b - 1.24
Lithocholic acid (20) - 0.95
aMean fecal concentration, n=12 patients (Weingarden et
al., 2014) and standard concentration used in this work.
b10 = primary bile acid, 20 = secondary bile acid.
cBile acid undetected or below 1% of total bile acids; not
used in experimental combination.
102
Table 4.2 - Characteristics of Clostridium difficile isolates used in this study.
aPFGE = Pulsed field gel electrophoresis.
btcdC deletion = length of deletion in tcdC gene.
PFGE type (isolate no.)a tcdC deletionb
(bp)
Binary toxin Toxinotype (48)
NAP1 18 + III
NAP2 (i) 0 - 0
NAP2 (ii) 0 - 0
NAP6 (i) 0 - 0
NAP6 (ii) 0 - 0
NAP6 (iii) 0 - 0
NAP7 (i) 39 + V
NAP7 (ii) 39 - V
NAP7 (iii) 39 - V
NAP10 0 - 0
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Table 4.3 - Mean relative OD600 of spores from 10 isolates after 20 min exposure to bile acids.
Bile
Acid
(mM) PFGE type (isolate no.)a
Bile acid NAP1
NAP2
(i)
NAP2
(ii)
NAP6
(i)
NAP6
(ii)
NAP6
(iii)
NAP7
(i)
NAP7
(ii)
NAP7
(iii) NAP10
Pre-FMT Bile Acids 0.90 0.93 0.88 0.90 0.88 0.86 0.60 0.65 0.62 0.88
SEM i 0.02 0.08 0.02 0.03 0.01 0.01 0.01 0.01 0.02 0.01
Post-FMT Bile Acids 1.01 1.00 1.02 1.09 1.07 1.02 0.96 1.04 1.05 1.11
SEM 0.02 0.06 0.03 0.03 0.02 0.01 0.02 0.03 0.01 0.03
BHISb 0.97 1.03 1.10 1.01 1.10 1.07 1.10 0.97 1.08 0.94
SEM 0.03 0.03 0.05 0.06 0.07 0.04 0.07 0.02 0.05 0.06
TAc 0.5 0.66 0.73 0.76 0.90 0.84 0.89 0.70 0.69 0.62 0.67
SEM 0.02 0.02 0.03 0.02 0.03 0.05 0.01 0.02 0.00 0.03
2 0.52 0.47 0.48 0.62 0.69 0.60 0.56 0.43 0.43 0.55
SEM 0.01 0.03 0.01 0.02 0.01 0.01 0.02 0.03 0.01 0.01
CAd 0.5 0.98 1.05 1.02 0.94 0.94 1.03 0.73 0.83 0.90 1.00
SEM 0.01 0.08 0.04 0.01 0.03 0.03 0.10 0.04 0.06 0.04
1 0.89 1.01 0.97 1.03 0.94 0.93 0.7 0.66 0.79 0.90
SEM 0.03 0.05 0.03 0.03 0.03 0.04 0.00 0.05 0.02 0.04
2 0.94 0.96 0.93 0.93 0.91 0.92 0.60 0.71 0.71 0.95
SEM 0.02 0.04 0.01 0.04 0.04 0.03 0.01 0.04 0.02 0.04
CDCAe 0.25 1.02 1.00 1.01 0.93 1.03 0.93 0.99 0.92 0.97 0.99
SEM 0.06 0.06 0.06 0.09 0.04 0.02 0.03 0.02 0.03 0.03
0.5 1.00 1.08 1.00 0.95 0.94 0.97 1.09 0.98 0.91 1.05
SEM 0.01 0.07 0.02 0.03 0.02 0.03 0.01 0.02 0.05 0.07
1 1.01 1.04 1.09 1.06 0.96 1.03 1.11 1.13 1.00 1.06
SEM 0.02 0.03 0.01 0.04 0.03 0.01 0.04 0.04 0.07 0.07
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2 0.91 0.90 1.07 0.98 0.96 0.98 0.83 0.97 0.94 0.77
SEM 0.03 0.02 0.05 0.01 0.01 0.05 0.04 0.04 0.01 0.01
CDCA+2 mM TA 0.25 0.57 0.61 0.56 0.64 0.64 0.70 0.57 0.59 0.62 0.57
SEM 0.01 0.04 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01
0.5 0.84 0.71 0.86 0.79 0.74 0.73 0.76 0.67 0.72 1.11
SEM 0.07 0.05 0.03 0.07 0.01 0.01 0.01 0.03 0.02 0.11
1 1.05 0.86 1.02 1.01 0.85 0.91 0.87 0.87 0.83 1.10
SEM 0.02 0.10 0.12 0.01 0.01 0.03 0.00 0.02 0.04 0.04
2 1.08 0.87 1.03 1.10 0.96 1.04 0.85 0.95 0.87 0.96
SEM 0.04 0.06 0.04 0.01 0.04 0.01 0.03 0.03 0.01 0.05
DCAf 0.5 1.04 1.06 1.02 0.93 0.89 0.93 0.72 0.77 0.92 1.03
SEM 0.01 0.02 0.02 0.01 0.01 0.04 0.01 0.01 0.01 0.05
1 1.00 1.05 0.99 1.03 0.90 0.95 0.78 0.76 0.89 1.11
SEM 0.01 0.04 0.05 0.02 0.05 0.04 0.08 0.07 0.03 0.06
2 1.12 1.00 0.83 0.97 0.86 0.80 0.98 0.71 0.85 1.05
SEM 0.07 0.01 0.05 0.01 0.02 0.04 0.02 0.03 0.05 0.03
LCAg 0.5 1.08 1.01 1.05 1.04 0.99 1.05 0.97 1.00 1.00 0.98
SEM 0.02 0.01 0.02 0.03 0.02 0.04 0.03 0.02 0.02 0.04
1 1.05 1.06 1.03 1.02 1.00 1.00 1.04 1.03 0.94 0.96
SEM 0.04 0.07 0.02 0.02 0.03 0.02 0.03 0.00 0.04 0.01
2 1.05 1.03 0.88 1.00 1.03 1.10 0.96 1.01 0.94 1.02
SEM 0.06 0.11 0.11 0.04 0.03 0.05 0.04 0.02 0.03 0.03
UDCAh+2 mM TA 0.5 1.05 1.02 0.98 0.84 0.76 0.78 0.63 0.55 0.60 0.96
SEM 0.02 0.04 0.05 0.02 0.01 0.04 0.02 0.06 0.01 0.04
1 0.97 1.02 1.02 0.98 0.93 0.96 0.74 0.77 0.74 0.97
SEM 0.05 0.04 0.02 0.01 0.03 0.05 0.03 0.04 0.02 0.06
2 1.04 1.16 1.05 1.05 1.06 0.96 1.00 0.91 0.99 1.03
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SEM 0.05 0.05 0.04 0.04 0.03 0.04 0.01 0.04 0.03 0.04
aPFGE = Pulsed-field gel electrophoresis, bBHIS = BHI broth with yeast extract and 0.1% L-cysteine, cTA = taurocholate, dCA =
cholate, eCDCA = chenodeoxycholic acid, fDCA = deoxycholate, gLCA = lithocholic acid, hUDCA = ursodeoxycholic acid.
iBottom row of each group displays the standard error of the mean (SEM) for the mean listed in the cell above.
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Table 4.4 – C. difficile cspC PCR primers used in this study.
Primer Position on
cspC gene
(5’ end)
Sequence
(5’ to 3’)
Forward primer 1A 4 AACACGTATGCAACTATAACTG
Forward primer 1B 650 CAAATCCACCTCCAGAAGGT
Forward primer 1C 1300 GAAAATACTACTTATGCAATGAG
Reverse primer 1 2146 AAAATTCATAAGTCTAAATTATAATG
Forward primer 2A 22 ACTGGTACAGCAGCAGCA
Forward primer 2B 628 TTATGGGACCAAGAAGCAA
Forward primer 2C 1250 ATATAAGGTATTCTCCAGAC
Reverse primer 2 2167 ACTTTTAGCAATTTTACAAATAAA
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Table 4.5 – Amino acid substitutions in CspC protein sequences of NAP7 isolates.
Position Amino acid in
most isolates
Amino acid in
NAP7 isolates
Type of substitution
47 Leu Ile Conservative
59 Glu Ala Non-conservative
73 Asn Asp Conservative
83 Glu Gly Non-conservative
85 Asp Glu Conservative
179 Val Ala Semi-conservative
184 Ile Val Conservative
187 Gln Lys Conservative
206 Thr Ile Non-conservative
207 Asp Gly Semi-conservative
237 Lys Arg Conservative
250 Ser Gly Semi-conservative
338 Ser Ala Conservative
384 Ile Thr Non-conservative
108
Figure 4.1 - C. difficile spores germinate in response to pre-FMT fecal bile acids. A)
Decrease in relative OD600 after 20 min exposure to germinant (TA) corresponds to
decrease in non-germinated spores (top) and appearance of germinated spores (bottom)
and vegetative cells under phase-contrast microscopy, which in turn corresponds to
outgrowth of spores and colony formation. BHIS: BHI with yeast extract and L-cysteine;
2 mM TA: BHIS with 2 mM taurocholate; CFUs: colony-forming units.
OD600(t)/OD600(t0) = OD600 normalized to initial OD600 (relative OD600); % CFUs = % of
colonies formed from total number of cells. B) Relative OD600 of NAP1 spores following
exposure to bile acids present before (▲) or after (●) FMT. C) Mean relative OD600 of
spores from 10 isolates after 20 min of exposure to bile acids present before or after
FMT. * = p <0.05. Data represent mean ± SEM.
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Figure 4.2 - C. difficile spores germinate in response to primary bile acids. A) (Left)
Relative OD600 of NAP1 spores exposed to 0.5 mM (■) or 2 mM (▲) TA versus BHIS
alone (●). (Right) Mean relative OD600 of spores from 10 isolates after 20 min exposure
to 0.5 or 2 mM TA vs. BHIS alone. B) (Left) Relative OD600 of NAP1 spores exposed to
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0.5 mM (■), 1 mM (♦), or 2 mM (▲) CA versus BHIS alone (●). (Right) Mean relative
OD600 of spores from 10 isolates after 20 min exposure to 0.5, 1, or 2 mM CA vs. BHIS
alone. C) (Left) Relative OD600 of NAP1 spores exposed to 0.25 mM (dashed line), 0.5
mM (■), 1 mM (♦), or 2 mM (▲) CDCA versus BHIS alone (●). (Right) Mean relative
OD600 of spores from 10 isolates after 20 min exposure to 0.25, 0.5, 1, or 2 mM CDCA
vs. BHIS alone. OD600(t)/OD600(t0) = OD600 normalized to initial OD600 (relative OD600);
*** = p <0.001, ** = p <0.01; * = p <0.05, n.s. = non-significant. BHIS: BHI with yeast
extract and L-cysteine; TA: taurocholate; CA: cholate; CDCA: chenodeoxycholic acid.
Data represent mean ± SEM.
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Figure 4.3 - CDCA inhibits taurocholate-mediated germination of C. difficile. A)
Relative OD600 of NAP1 spores exposed to 0.25 mM (dashed line; ●), 0.5 mM (■), 1 mM
(♦), or 2 mM (▲) CDCA and 2 mM TA versus TA alone (●). B) Mean relative OD600 of
spores from 10 isolates after 20 min exposure to 0.25, 0.5, 1, or 2 mM CDCA and 2 mM
TA vs. TA alone. OD600(t)/OD600(t0) = OD600 normalized to initial OD600 (relative
OD600); * = p <0.01. BHIS: BHI with yeast extract and L-cysteine; TA: taurocholate;
CDCA: chenodeoxycholic acid. Experiments performed in triplicate. Data represent
mean ± SEM.
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Figure 4.4 - C. difficile spores do not germinate in response to secondary bile acids.
A) (Left) Relative OD600 of NAP1 spores exposed to 0.5 mM (■), 1 mM (♦), or 2 mM
(▲) DCA versus BHIS alone (●). (Right) Mean relative OD600 of spores from 10 isolates
after 20 min exposure to 0.5, 1, or 2 mM DCA vs. BHIS alone. B) (Left) Relative OD600
of NAP1 spores exposed to 0.5 mM (■), 1 mM (♦), or 2 mM (▲) LCA versus BHIS
alone (●). (Right) Mean relative OD600 of spores from 10 isolates after 20 min exposure
to 0.5, 1, or 2 mM LCA vs. BHIS alone. OD600(t)/OD600(t0) = OD600 normalized to initial
OD600 (relative OD600); n.s. = non-significant. BHIS: BHI with yeast extract and L-
cysteine; DCA: deoxycholate; LCA: lithocholic acid. Data represent mean ± SEM.
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Figure 4.5 - Growth of vegetative C. difficile is inhibited by post-FMT bile acids. A)
Hourly OD600 measurements for NAP1 cells in BHIS alone (●), BHIS with pre-FMT bile
acids (▲), and BHIS with post-FMT bile acids (■). B) Mean OD600 at 24 hr across 10
isolates. BA: bile acids. * = p<0.01. Data represent mean ± SEM.
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Figure 4.6 - Growth of vegetative C. difficile from all 10 isolates is inhibited by post-
FMT bile acids. Hourly OD600 measurements for cells in BHIS alone (●), BHIS with
PreFMT bile acids (▲), and BHIS with PostFMT bile acids (■). A-B) NAP2 isolates. C)
NAP10 isolate. D-F) NAP6 isolates. G-I) NAP7 isolates. * = p<0.01; n.s. = non-
significant. Experiments performed in triplicate. Data represent mean ± SEM.
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Figure 4.7 – UDCA inhibits C. difficile spore germination. A) Relative OD600 of NAP1
spores exposed to 0.5 mM (■), 1 mM (♦), or 2 mM (▲) UDCA in the presence of 2 mM
TA vs. 2 mM TA alone (●). B) Mean relative OD600 of spores from 10 isolates after 20
min exposure to 0.5, 1, or 2 mM UDCA in the presence of 2 mM TA vs. 2 mM TA alone.
OD600(t)/OD600(t0) = OD600 normalized to initial OD600 (relative OD600); * = p<0.01. TA:
taurocholate; UDCA: ursodeoxycholic acid. Data represent mean ± SEM.
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Figure 4.8 – UDCA inhibits vegetative growth of C. difficile. A) Hourly OD600
measurements for NAP1 cells in BHIS alone (●) or BHIS with 2 mM UDCA (▲). B)
Mean OD600 at 24 hr across 10 isolates. UDCA: ursodeoxycholic acid. * = p<0.0001.
Data represent mean ± SEM.
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Figure 4.9 – Growth of all C. difficile isolates is inhibited by UDCA. Hourly OD600
measurements for cells in BHIS alone (●) or BHIS with 2 mM UDCA (▲) A-B) NAP2
isolates. C) NAP10 isolate. D-F) NAP6 isolates. G-I) NAP7 isolates. * = p<0.001; ** =
p<0.0001 Experiments performed in triplicate. Data represent mean ± SEM.
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Figure 4.10 – Germination of C. difficile spores varies by strain. Mean relative OD600
of spores from the five PFGE types used in this study when exposed to pre-FMT bile
acids (black bars) or of spores from all isolates when exposed to post-FMT bile acids
(grey bar) for 20 min. OD600(t)/OD600(t0) = OD600 normalized to initial OD600 (relative
OD600). Data represent mean ± SEM across isolates within PFGE type.
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Figure 4.11 – CspC sequences primarily cluster by PFGE type. A) Boot-strapped
phylogenetic tree of CspC sequences generated by UPGMA method. Boot-strap values
are indicated at each node. B) Percent identity matrix of CspC sequences from different
isolates. Roman numerals indicate isotype number within each PFGE type. NAP: North
American pulsed-field gel electrophoresis (PFGE) type.
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Figure 4.12 – Alignment of C. difficile CspC protein sequences. Protein sequences
from 9 isolates. Roman numerals represent isolate number within PFGE type. * =
conserved residue; : = conservative mutation; . = semi-conservative mutation; blank =
non-conservative mutation. NAP: North American pulsed-field gel electrophoresis
(PFGE) type.
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Chapter 5
C7-Sulfated Ursodeoxycholic Acid as a Novel Therapy to Prevent Clostridium
difficile Infection
122
SUMMARY
Clostridium difficile infection (CDI) is the most common nosocomial infection in the US,
but unfortunately standard antibiotic therapy is not effective in a number of patients,
creating a need for novel, non-antibiotic treatments. We recently demonstrated that a
potential mechanism behind a powerful emerging treatment for CDI, fecal microbiota
transplantation (FMT), is a shift in fecal bile acid composition. Specifically, restoration
of bacterial secondary bile acid metabolism in the feces following FMT prevents
germination and growth of C. difficile. Furthermore, we demonstrated that a clinically
available secondary bile acid, ursodeoxycholic acid (UDCA), can inhibit C. difficile
germination and growth. Because UDCA may be of limited therapeutic utility due to its
absorption into enterohepatic circulation, here we examined whether synthetic C7-
sulfated UDCA (7-SUDCA), which is not significantly absorbed and achieves a high
concentration in the colon, could inhibit C. difficile germination. Using an in vitro assay
for germination and a mouse model of CDI, we determined that 7-SUDCA can inhibit C.
difficile germination in vitro and both reduce pathology and delay the appearance of C.
difficile in the feces in vivo. These findings suggest that 7-SUDCA is a promising non-
antibiotic therapy for the prevention of CDI.
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INTRODUCTION
Clostridium difficile infection (CDI) is an extremely common nosocomial
infection, responsible for nearly half a million cases of diarrhea, and nearly 30,000
deaths, in the United States each year (Lessa et al., 2015). Unfortunately, standard
antibiotic therapy often fails to cure CDI, as symptoms return in 20-30% of patients
following the cessation of antibiotics (Kelly and Lamont, 2008; Vardakas et al., 2012;
Lessa et al., 2015). Once an individual has experienced a single such recurrence of the
infection, the chances for further recurrence can be as high as 65% or greater (Khoruts
and Sadowsky, 2011). Often, these patients eventually fall into vicious cycles
characterized by repeated antibiotic treatment and recurrence of disease, a state known as
recurrent CDI syndrome (R-CDI) (Borody and Khoruts, 2011).
For patients with R-CDI, therapy options are limited. Although these patients are
typically refractory to further antibiotic treatment, fecal microbiota transplantation (FMT)
is emerging as a highly effective therapy for R-CDI (Yoon and Brandt, 2010; Hamilton et
al., 2012; van Nood et al., 2013). However, FMT may not be the best treatment option for
all patients with R-CDI; for example, patients who require frequent antibiotic use for
other conditions often do not meet the criteria for FMT. We have recently demonstrated
that a shift in fecal bile acid composition as a result of the procedure may be a
mechanism behind FMT (Weingarden et al., 2014; Chapter 4). Specifically, the bile acids
present in the feces before FMT, typically primary bile acids produced by the liver,
induce C. difficile germination and allow growth of vegetative cells, while the bile acids
present after FMT, typically secondary bile acids which are transformed from primary
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bile acids by native colonic bacteria (Ridlon et al., 2006), do not induce germination and
inhibit growth. Furthermore, recent work has indicated that treatment with bile acid-
transforming bacteria can limit C. difficile infection in mice (Buffie et al., 2014). These
findings suggest that manipulation of fecal bile acid composition is a viable strategy for
uncovering novel treatments for R-CDI.
In particular, recent work suggests that pharmacological manipulation of fecal
bile acids is a promising avenue of CDI treatment. A bile acid analog, a meta-benzene
sulfonate derivative of cholate (CamSA), was found to prevent germination of C. difficile
spores in a mouse colon assay and prevent symptoms in a model of infection (Howerton
et al., 2013a; Howerton et al., 2013b). Furthermore, our work and the work of others has
indicated that ursodeoxycholic acid (UDCA), a minor human secondary bile acid
clinically available as a therapeutic, can also inhibit C. difficile germination and growth
(Chapter 4, Sorg and Sonenshein, 2010). However, despite the promise of UDCA, it is
well-absorbed in the small intestine, limiting its intracolonic concentration (Rodrigues et
al., 1995; Hofmann and Hagey, 2008), and therefore it may have limited in vivo potential.
In contrast, a derivative of UDCA, C7-sulfated UDCA (7-SUDCA), is poorly absorbed in
the small intestine and may have potential as a new treatment for CDI (Rodrigues et al.,
1995).
Here we demonstrate that 7-SUDCA may be a novel therapeutic for CDI. We
show that 7-SUDCA inhibits C. difficile germination in vitro, and developed a mouse
model of CDI to investigate whether 7-SUDCA can prevent C. difficile infection in vivo.
Our results indicate that in this model, 7-SUDCA can prevent weight loss associated with
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CDI and delays the appearance of C. difficile colony-forming units (CFUs) in the feces.
These preliminary findings suggest that 7-SUDCA is a potential novel therapy for CDI.
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MATERIALS AND METHODS
Synthesis of C7-sulfated UDCA
C7-sulfated UDCA (7-UDCA) was synthesized as described by Setchell, 1996. Imidazole
(3.84 g, 56.4 mmol) and tert-butyldimethylsilyl chloride (1.86 g, 12.3 mmol) were added
to a solution of UDCA (1.98 g, 5.04 mmol) in DMF (1.5 mL) and pyridine (0.75 mL) at 0
°C. The solution was stirred for 30 min at RT, diluted with ice water, and extracted with
ethyl acetate. The organic layer was dried under Na2SO4 and concentrated under reduced
pressure. The resulting residue was purified by silica gel column (25% EtOAc/hexanes)
and recrystallized from ethanol to furnish a white solid (1.315 g). 627 mg of this material
was dissolved in 9 mL pyridine and placed in an ice bath. Chlorosulfonic acid (0.6 mL)
was added dropwise and then the mixture was heated to 50°C for 30 min. After cooling to
RT, water (300 mL) was added and the resulting precipitate collected by filtration (597
mg). 60.5 mg of this solid was suspended in acetone (2 mL) and concentrated HCl added
(150 L). After 30 min., the mixture was concentrated under reduced pressure, run
through a C18 cartridge (1 gram) washing with methanol, and concentrated under reduced
pressure. The residue was dissolved in methanol (0.5 mL) and NaOMe (0.5 mL of 0.5 M
solution in methanol) was added. Cold ether (10 mL) was added and the resulting fine
precipitate collected by filtration. The solid was redissolved in methanol (1.0 mL) and
reprecipitated with cold ether (10 mL) to furnish 14 mg of C7-sulfated UDCA as a
disodium salt.
C. difficile spore isolation
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C. difficile cells from frozen stocks were inoculated into CCFB medium and grown
anaerobically at 37°C for 48 hr. Cultures were plated onto brain heart infusion with 5 g/L
yeast extract and 0.1% L-cysteine (BHIS) and grown for 7 d at 37°C under anaerobic
conditions. Following Sorg and Sonenshein, 2010, colonies from each plate were scraped
into 1 mL of ice-cold water and incubated at 4°C overnight to release spores. A 3 mL
suspension was loaded onto 10 mL of 50% (w/v) sucrose in a 15 mL conical tube and
centrifuged in a swinging bucket rotor at 3200 x g for 20 min at 4°C. Sucrose and
vegetative cells above the spore pellet were removed, and the pellet was washed 5 times
in ice-cold water to remove remaining sucrose. Spores were examined under phase-
contrast microscopy to determine purity; spore samples with >99% purity (<1%
vegetative cells) were stored at 4°C.
C. difficile spore germination
Germination assays were done as previously described by Sorg and Sonenshein, 2010.
Spores were heated to 65°C for 30 min and inoculated into BHIS, with or without bile
acids, within an anaerobic bag flushed and filled with N2 gas. OD600 was measured
initially (OD600(t0)) and every minute for 20 min (OD600(t)) using an EL808 Microplate
Reader (Biotek Instruments, Inc., Winooski, VT). Relative OD600 for each time point was
calculated as OD600(t)/OD600(t0). Experiments were performed in triplicate.
Infection of mice with C. difficile
Following the protocol of Theriot et al., 2011, 8 week old female C57BL/6 mice were
given 0.5 mg/mL cefoperazone in drinking water for 10 days, changing the water every
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2-3 days to keep the antibiotic fresh. After 10 days, cefoperazone was removed, and mice
were allowed to recover for 2 days prior to infection. Mice were infected with 2 x 105
spores of a NAP1 isolate (Chapter 4) via oral gavage, while controls were given PBS.
Fecal pellets were collected prior to antibiotic treatment, at the conclusion of antibiotic
treatment, and daily following infection for 3 or 5 days. After 3 or 5 days, mice were
sacrificed and cecal contents were collected. Mice were weighed prior to infection and
each day following infection until sacrifice.
Administration of 7-SUDCA
In the first experiment, 7-SUDCA (15 mg/mL) was originally administered via drinking
water, for 2 days prior to infection. Additionally, 37.5 mg of 7-SUDCA in 100 μL sterile
water was administered to mice the day prior to infection, 4 hours prior to infection, and
on days 2-4 following infection, via oral gavage. In the second experiment, mice were
given two gavages per day of 18.75 mg of 7-SUDCA per gavage one day prior to
infection and the day of infection, then given one gavage per day on days 1-2 following
infection.
Assessment of C. difficile growth from pellets
Fecal pellets from each mouse were divided into two portions, weighed, and suspended in
200 μL sterile water. One set of fecal pellets was heated at 65°C for 30 min to isolate
spores. Suspended fecal material was diluted by 103, 104, and 105, and plated on
taurocholate-cycloserine-cefoxitin-fructose agar (TCCFA) (Bliss et al., 1997). Plates
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were incubated overnight at 37°C under anaerobic conditions before calculating the
number of colony-forming units (CFUs). CFUs were normalized to g feces.
Approval for mouse studies
This study was approved by the University of Minnesota Institutional Animal Care and
Use Committee (IACUC 1309-30905A) and the Institutional Biosafety Committee (IBC
1310-30990H).
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RESULTS
7-SUDCA prevents C. difficile germination in vitro
Although we have shown that UDCA can inhibit C. difficile germination in vitro
(Chapter 4), it is unlikely to be useful for R-CDI in the majority of patients due to poor
colonic delivery (Rodrigues et al., 1995, Hofmann and Hagey, 2008). To overcome this
limitation, we synthesized a C7-sulfated derivative of UDCA (7-SUDCA), which is
poorly absorbed in the small intestine (Rodrigues et al., 1995), and tested whether it
could also inhibit germination of C. difficile. To investigate the potential of 7-SUDCA as
an inhibitor of C. difficile germination, we used an established spectrophotometric assay
which relies on the refractive nature of bacterial spore coats (Sorg and Sonenshein, 2008;
Sorg and Sonenshein, 2009; Sorg and Sonenshein, 2010; Heeg et al., 2012). A decrease
in OD600 over time indicates loss of this spore coat and therefore initiation of germination
(Moir and Smith, 1990). We have previously used and validated this assay to confirm that
this decrease in OD600 corresponds both to spore coat loss and ability of the spores to
subsequently form colonies (Chapter 4).
To investigate the effectiveness of 7-SUDCA, we tested its ability to inhibit
germination of spores from a NAP1 hypervirulent strain of C. difficile which we had
previously isolated and described (Chapter 4). These spores were exposed to a known
germinant, taurocholate, with or without different concentrations of 7-SUDCA. When
spores were exposed to ≥2 mM concentrations of 7-SUDCA in the presence of
taurocholate, germination was significantly (p<0.01) inhibited compared to spores
exposed to taurocholate alone (Fig. 5.1A, Table 5.1). Furthermore, when spores from a
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set of 10 isolates including the NAP1 strain, all previously described (Chapter 4), were
exposed to taurocholate with or without 7-SUDCA, 2 mM or greater concentrations of
the drug significantly (p<0.01) inhibited germination (Fig. 5.1B, Table 5.1). These results
indicate that 7-SUDCA can inhibit germination of a variety of C. difficile strains, and that
it may have potential as a novel therapeutic to prevent recurrence of CDI.
Establishing a mouse model of CDI
With these promising in vitro results, we next moved towards testing 7-SUDCA
in an in vivo model. We used a mouse model of C. difficile infection based on the model
described by Theriot and colleagues (Theriot et al., 2011). In this model, mice are given
the antibiotic cefoperazone (0.5 mg/mL) for 10 days, followed by two days recovery off
the antibiotic before infection with 2 x 105 C. difficile spores via oral gavage. Theriot et
al., 2011, have demonstrated that in this model mice maintain the bacterium in their stool
and lose weight across 2-5 days post-infection with a variety of C. difficile strains,
although the severity of disease varies across these strains. One such strain was a clinical
isolate of the NAP1 pulsed-field gel electrophoresis/027 ribotype, similar to the NAP1
isolate used in our in vitro work above and elsewhere (Chapter 4). We therefore used our
NAP1 isolate for infection when developing our model (Fig. 5.2).
Following infection with this NAP1 isolate, mice were weighed daily, and daily
fecal pellets were collected and plated on selective taurine-cycloserine-cefoxitin-fructose
agar (TCCFA) to enumerate C. difficile colony-forming units (CFUs) in the feces. At 2
and 3 days post-infection, mice infected with the NAP1 isolate weighed significantly less
than control uninfected mice (Fig. 5.3). Furthermore, mice maintained between 106 and
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108 C. difficile CFUs per gram feces up to 5 days following infection (Fig. 5.4). These
findings suggest that this model is capable of replicating CDI in human patients and
therefore represents a useful model for testing novel therapies for this disease.
7-SUDCA prevents weight loss associated with CDI and delays appearance of CFUs in
stool
Using our established model of CDI, we sought to investigate whether 7-SUDCA
could prevent infection. Initially, mice were given 7-SUDCA in drinking water (15
mg/mL), but the drug was found to be unpalatable. Instead, after 1 day of recovery
following antibiotic treatment, mice were given 37.5 mg of 7-SUDCA via oral gavage.
This gavage was repeated the day of infection and 2-4 days post-infection. Both weight
and CFU counts were tracked daily in these mice following infection (Fig. 5.2).
Unlike control mice infected with C. difficile, mice given 7-SUDCA before and
after infection weighed significantly (p<0.05) more at 2, 3, and 5 days post-infection
(Fig. 5.3). Furthermore, on the first day following infection, there were substantially
fewer colonies formed by C. difficile spores (Fig. 5.4A) and total cells (Fig. 5.4B) in mice
treated with 7-SUDCA compared to controls; in fact, the number of CFUs from one
mouse was at or below the limit of detection. However, perhaps because mice were not
treated with drug on the first day following infection, the number of CFUs on subsequent
days was comparable to the number of CFUs from control mice. Despite this, however,
these are promising preliminary results which suggest that 7-SUDCA can both decrease
severity of disease and delay the appearance of C. difficile in the feces following
infection.
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Improving delivery of 7-SUDCA increases stress due to gavage but decreases C.
difficile appearance in stool
Although our results above indicated that 7-SUDCA could partially inhibit
infection with C. difficile spores, we next investigated whether improving drug delivery
could further ameliorate disease. Because the gavage to rectum transit time of mice is
typically 6-7 hours (Padmanabhan et al., 2013), a single gavage per day may not insure
that colonic levels of 7-SUDCA remain at a high enough concentration to prevent C.
difficile germination. Therefore, we repeated the previous experiment, giving two
gavages with half the amount of drug (18.75 mg per gavage, vs. 37.5 mg) per day (Fig.
5.5).
Unfortunately, we found here that the stress of additional gavage masked the
effects of treatment on mouse weight. Mice given both the drug and C. difficile spores did
not weigh significantly more than control infected mice up to 3 days post-infection (Fig.
5.6). However, mice given drug but not infected also did not weigh significantly more
than control infected mice, suggesting that the beneficial effects on weight seen in the
previous experiment were masked here by the stress of additional gavage.
Although the effects on weight were less clear, treatment with 7-SUDCA still
delayed the appearance of C. diffiicile in the stool. Mice treated with 7-SUDCA
continued to have fewer CFUs of C. difficile in feces on day 1 post-infection compared to
untreated mice, particularly fewer total cells (vegetative cells and spores) (Fig. 5.7).
Notably, of the four animals tested on 1 d.p.i., the numbers of C. difficile CFUs in feces
(total cells and spores) were below the limit of detected in three animals. Once again,
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these results suggest that 7-SUDCA can ameliorate the effects of C. difficile infection and
may therefore be a novel therapy for R-CDI.
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DISCUSSION
Clostridium difficile infection (CDI) is the most common nosocomial infection in
the US (Zilberberg et al., 2008; Miller et al., 2011; Dubberke and Olsen, 2012; Magill et
al., 2014), but unfortunately standard antibiotic therapy frequently fails to clear the
infection, resulting in a recurrence of disease in 20-30% of patients (Kelly and Lamont,
2008; Borody and Khoruts, 2011; Louie et al., 2011; Surawicz and Alexander, 2011).
Although fecal microbiota transplantation (FMT) is becoming widely accepted as a
therapy for patients with recurrent CDI (R-CDI) (Yoon and Brandt, 2010; Hamilton et al.,
2012; Kassam et al., 2013), there remains a need to develop non-antibiotic therapeutic
options for patients who cannot have an FMT or who fail to recover following the
procedure.
Recently we demonstrated that ursodeoxycholic acid (UDCA) is a potential novel
therapy for CDI which inhibits both germination and vegetative growth of C. difficile
(Chapter 4). Unfortunately, clinical efficacy of UDCA in R-CDI is hindered by its
efficient absorption into the enterohepatic circulation, preventing delivery to the colon,
the site of infection (Rodrigues et al., 1995; Hofmann and Hagey, 2008). Therefore, here
we tested inhibition of C. difficile germination by a minimally absorbed UDCA
derivative, C7-sulfated UDCA (7-SUDCA). Taurocholate-induced C. difficile spore
germination was inhibited by 7-SUDCA at a range of concentrations below that measured
in the colon in an animal model (Rodrigues et al., 1995). These results suggest that 7-
SUDCA may be a potential non-antibiotic therapeutic for R-CDI.
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To explore the potential of 7-SUDCA as a therapy for R-CDI, we developed a
mouse model based on the model of Theriot et al., 2011. Our work with this model
demonstrated that mice infected with C. difficile spores following 10 days of
cefoperazone treatment resulted in significant weight loss relative to uninfected animals
as well as growth of over 106 colony-forming units (CFUs) of C. difficile per g feces in
these animals from the day after infection until sacrifice (5 d post-infection). This model,
therefore, represents a model of productive infection useful for testing whether 7-SUDCA
can prevent or limit C. difficile infection in vivo.
Treatment with 7-SUDCA using this model indicated that the drug has potential
as a novel therapy for CDI. Specifically, 7-SUDCA prevented weight loss associated with
infection and delayed the appearance of C. difficile in the stool. These findings indicate
that unlike UDCA, 7-SUDCA may be useful for preventing recurrence of CDI in patients
with normal gastrointestinal anatomy. Unfortunately, 7-SUDCA was found to be poorly
palatable to mice, resulting in decreased delivery of drug (and the loss of two animals).
Mice were not treated 1 day post-infection, possibly leading to increased appearance of
C. difficile in the stool after this point. Additionally, once-daily delivery of 7-SUDCA
may not be sufficient to provide continuous protection against C. difficile, as the
gastrointestinal transit time of mice is only ~6 hours following gavage (Padmanabhan et
al., 2013). However, multiple gavages per day to insure higher concentrations of drug in
the colon may substantially increase stress and therefore mask beneficial effects on
weight.
Additional work is therefore necessary to fully test whether 7-SUDCA is an
effective therapy to prevent CDI. Further improvements to drug delivery will be
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necessary to assess the effects of the drug on CDI without causing additional stress to the
animals, which obscures the effects of the drug. Furthermore, additional analysis of this
current experiment is in progress, including histopathology of animal colons following
sacrifice, 16S rRNA gene analysis of the feces and cecal contents to track bacterial
communities of this model, and bile acid analysis of feces and cecal contents to track
other germinants and germination inhibitors as well as to ensure that 7-SUDCA is
reaching the site of infection.
7-SUDCA is not the first bile acid analog tested as a treatment for CDI in a mouse
model. Recent work by Howerton and colleagues (2013) has demonstrated that an analog
of cholic acid, CamSA, is capable of decreasing symptoms of CDI and decreasing the
number of vegetative cells in animal feces. This work tested efficacy when drug was
given 24 hr prior to infection, 1 hr after infection, and 24 hr after infection. In contrast,
we saw similar results when drug was delivered 24 and 4 hours prior to infection,
suggesting that we may see even more promising results if 7-SUDCA is given
immediately following infection and on the first day following infection. Importantly,
CamSA is not water soluble and was given dissolved in dimethyl sulfoxide (DMSO),
while 7-SUDCA is water soluble and was delivered to mice in water. The use of DMSO
may limit the ability of CamSA to be translated effectively into human patients, while 7-
SUDCA has no such limitation.
Although the results presented here are limited, they indicate that 7-SUDCA may
be a novel therapy to prevent recurrence of CDI. In vitro, 7-SUDCA prevents
germination of C. difficile, while in vivo 7-SUDCA abrogates weight loss of animals and
delays the appearance of C. difficile in the stool. Overall, these are promising findings
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that suggest with additional work 7-SUDCA may be a useful and translatable treatment
for Clostridium difficile infection.
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Table 5.1 - Mean relative OD600 of spores from 10 isolates after 20 min exposure to 7-SUDCA and 2 mM taurocholate.
7-SUDCAa
concentration (mM)
PFGE type (isolate no.)b
NAP1
NAP2
(i)
NAP2
(ii)
NAP6
(i)
NAP6
(ii)
NAP6
(iii)
NAP7
(i)
NAP7
(ii)
NAP7
(iii) NAP10
0.5 0.55 0.46 0.51 0.58 0.60 0.58 0.59 0.60 0.42 0.56
SEMc 0.02 0.00 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01
1 0.54 0.48 0.58 0.65 0.71 0.59 0.57 0.62 0.38 0.67
SEM 0.01 0.03 0.01 0.02 0.01 0.03 0.02 0.02 0.03 0.02
2 0.72 0.77 0.96 0.79 0.74 0.80 0.62 0.68 0.55 0.85
SEM 0.01 0.09 0.04 0.02 0.01 0.03 0.00 0.03 0.02 0.02
3 1.02 1.03 0.91 0.82 0.83 0.90 0.66 0.76 0.88 0.94
SEM 0.03 0.01 0.02 0.02 0.04 0.05 0.04 0.04 0.01 0.05
4 1.05 1.04 0.99 0.93 0.93 1.01 0.65 0.73 0.97 0.95
SEM 0.03 0.02 0.04 0.01 0.01 0.02 0.00 0.06 0.03 0.04
5 1.05 0.99 0.95 0.94 0.90 0.98 0.70 0.85 1.03 0.92
SEM 0.02 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01
a7-UDCA = C7-sulfated UDCA, bPFGE = Pulsed-field gel electrophoresis
cBottom row of each group displays the standard error of the mean (SEM) for the mean listed in the cell above.
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Figure 5.1 – 7-SUDCA inhibits C. difficile germination. A) Relative OD600 of NAP1
spores exposed to 0.5 mM (■), 1 mM (♦), 2 mM (▲), 3 mM (dashed line; ●), 4 mM
(dashed line; ■), or 5 mM (dashed line; ♦) C7-sulfated UDCA in the presence of 2 mM
TA vs. 2 mM TA alone (●). B) Mean relative OD600 of spores from 10 isolates after 20
min exposure to 0.5, 1, 2, 3, 4, or 5 mM C7-sulfated UDCA in the presence of 2 mM TA
vs. 2 mM TA alone. OD600(t)/OD600(t0) = OD600 normalized to initial OD600 (relative
OD600); * = p<0.01. TA: taurocholate; 7-UDCA: C7-sulfated UDCA. Data represent
mean ± SEM.
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Figure 5.2 – Experimental design of mouse model. Mice were given cefoperazone (0.5
mg/mL) in drinking water for 10 days, then allowed to recover for 2 days prior to
infection. One group of mice (n=2) was given 37.5 mg 7-SUDCA via oral gavage one
day prior to infection and day of infection. This group and a control group (n=4) then
received 2 x 105 C. difficile spores via gavage; an additional control group (n=4) received
PBS alone via gavage. Following infection, fecal pellets were collected daily for C.
difficile counts and all mice were weighed. The first group continued to receive 37.5 mg
7-SUDCA via oral gavage at 2, 3, and 4 days post-infection. After 5 days, mice were
sacrificed and colons preserved for histopathology. 7-SUDCA: C7-sulfated
ursodeoxycholic acid; PBS: phosphate buffered saline; d.p.i.: days post-infection.
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Figure 5.3 – C. difficile-infected mice lose more weight than control or 7-SUDCA-
treated mice. Weight of control, uninfected mice (●, n=4), C. difficile-infected mice (▲,
n=4), and C. difficile-infected mice treated with 7-SUDCA (■, n=2) following infection,
normalized to pre-infection weight. * = p<0.05; ** = p<0.01. Error bars represent SEM.
CDI: Clostridium difficile-infected; 7-SUDCA: C7-sulfated ursodeoxycholic acid; d.p.i.:
days post-infection.
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Figure 5.4 – 7-SUDCA delays appearance of C. difficile in feces. A) C. difficile CFUs
from spores present in feces from control infected mice (▲, n=4) and in each infected
mouse treated with 7-SUDCA (■). B) C. difficile CFUs from total cells (spores and
vegetative cells) present in feces from control infected mice (▲, n=4) and in each
infected mouse treated with 7-SUDCA (■). Arrows indicate days on which 7-SUDCA
was administered. Solid line indicates limit of detection. Error bars represent SEM. CFU:
colony-forming unit; d.p.i.: days post-infection; CDI: Clostridium difficile-infected; 7-
SUDCA: C7-sulfated ursodeoxycholic acid.
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Figure 5.5 – Experimental design of second mouse experiment. Mice were given
cefoperazone (0.5 mg/mL) in drinking water for 10 days, then allowed to recover for 2
days prior to infection. Both group of mice were given two gavages of 18.75 mg 7-
SUDCA one day prior to infection and day of infection. One group (n=4) received 2 x
105 C. difficile spores via gavage; an additional control group (n=2) received PBS alone
via gavage. Following infection, fecal pellets were collected daily for C. difficile counts
and all mice were weighed. All mice continued to receive one gavage of 18.75 mg 7-
SUDCA on 1 and 2 days following infection. After 3 days, mice were sacrificed and
colons preserved for histopathology. 7-SUDCA: C7-sulfated ursodeoxycholic acid; PBS:
phosphate buffered saline; d.p.i.: days post-infection.
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Figure 5.6 – Multiple gavages with 7-SUDCA do not inhibit weight loss associated
with CDI, likely related to stress of gavage. Weight of control, uninfected mice (●,
solid line, n=4), C. difficile-infected mice (▲, solid line, n=4), mice gavaged with 7-
SUDCA but not infected (●, dashed line, n=2), and C. difficile-infected mice treated with
7-SUDCA (▲, dashed line, n=4 [1 d.p.i.], n=3 [2-3 d.p.i.]) following infection,
normalized to pre-infection weight. Error bars represent SEM. CDI: Clostridium difficile-
infected; 7-SUDCA: C7-sulfated ursodeoxycholic acid; d.p.i.: days post-infection.
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Figure 5.7 – 7-SUDCA delays appearance of C. difficile in feces. A) C. difficile CFUs
from spores present in feces from control infected mice (▲, n=4) and in infected mice
treated with 7-SUDCA (■, n=4 [1 d.p.i.], n=3 [2-3 d.p.i.]). B) C. difficile CFUs from total
cells (spores and vegetative cells) present in feces from control infected mice (▲, n=4)
and in each infected mouse treated with 7-SUDCA (■, n=4 [1 d.p.i.], n=3 [2-3 d.p.i.]).
Error bars represent SEM. CFU: colony-forming unit; d.p.i.: days post-infection; CDI:
Clostridium difficile-infected; 7-SUDCA: C7-sulfated ursodeoxycholic acid.
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Chapter 6
Ursodeoxycholic Acid Prevents Recurrence of Clostridium difficile Infection-
Associated Pouchitis
148
SUMMARY
Clostridium difficile infection (CDI) is an extremely common nosocomial
infection which is often refractory to antibiotic treatment. Although fecal microbiota
transplantation (FMT) is emerging as a successful therapy for the majority of patients
with recurrent CDI (R-CDI), there remains a need to develop novel therapies for this
disease for patients who fail the criteria for FMT or who fail to recover following the
procedure. Recent work has indicated that fecal bile acid composition plays a significant
role in recovery following FMT, and that ursodeoxycholic acid (UDCA), a minor human
secondary bile acid clinically available as a therapeutic, can inhibit C. difficile
germination and growth. While UDCA may be of limited therapeutic utility due to its
absorption into enterohepatic circulation in the small intestine, we successfully used
UDCA to control antibiotic- and FMT-refractory R-CDI pouchitis in a status post-
colectomy patient. Fecal microbial community structure was tracked in this patient before
and after initiation of UDCA by 16S rRNA gene sequencing and indicated that the fecal
bacterial community did not recover after more than three months of UDCA therapy.
These results indicate that UDCA may be an effective non-antibiotic pharmacologic
agent to treat R-CDI pouchitis.
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INTRODUCTION
Clostridium difficile infection (CDI) is an antibiotic-associated diarrheal disease
that is currently estimated to be the most common nosocomial infection in the US
(Zilberberg et al., 2008; Miller et al., 2011; Dubberke and Olsen, 2012; Magill et al.,
2014). Although prior antibiotic use is considered the primary risk factor for CDI (Kelly
and Lamont, 2008; Miller et al., 2011; Ananthrakishnan, 2011; Lessa et al., 2012;
Khanna et al., 2012; Chitnis et al., 2013; Borody and Khoruts, 2011; Hu et al., 2009;
Fashner et al., 2011), current standard therapy for this disease is additional antibiotics
(Cohen et al., 2010). Unfortunately, 20-30% of CDI patients treated with antibiotics
experience a recurrence of the infection once antibiotics are halted (Kelly and Lamont,
2008; Borody and Khoruts, 2011; Louie et al., 2011; Surawicz and Alexander, 2011).
Once a patient has experienced a single recurrence, the chances of further recurrence may
be as high as 65% or greater, and some of these patients go on to develop repeated,
vicious cycles of antibiotic use and recurrence of disease (Khoruts and Sadowsky, 2011).
This condition is known as recurrent CDI syndrome (R-CDI) (Borody and Khoruts,
2011).
Fortunately for patients with R-CDI, fecal microbiota transplantation (FMT) is
emerging as an accepted and highly effective therapy for C. difficile infection. Unlike
antibiotics, FMT is over 90% effective in patients with R-CDI (Hamilton et al., 2012;
Kassam et al., 2013). Although the mechanisms of FMT remained obscure for more than
50 years following its first cited use in the literature (Eiseman et al., 1958), recent work
has indicated that bile acid metabolism by the transplanted microbiota is a likely means
of preventing further infection (Weingarden et al., 2014; Chapter 4). Notably, patients
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treated with FMT undergo significant shifts in the composition of fecal bile acids after
the procedure, from a bile acid pool dominated by the primary bile acids (those produced
by the liver) to a pool that is predominantly secondary bile acids (produced from primary
bile acids exclusively by colonic bacteria) (Weingarden et al., 2014). Many primary bile
acids are known to induce C. difficile germination, activating previously inert spores
(Wilson, 1983; Sorg and Sonenshein, 2008), while many secondary acids can prevent
germination and inhibit growth of the resulting vegetative cells (Sorg and Sonenshein,
2009; Sorg and Sonenshein, 2010).
Previously, we demonstrated that the combination of bile acids present in patient
feces prior to FMT induces germination and allows growth of C. difficile, in contrast to
the combination of bile acids present after the procedure (Chapter 4). We further
demonstrated that ursodeoxycholic acid (UDCA), another secondary bile acid which is
not commonly found in human bile (Hofmann and Hagey, 2008) but is clinically
approved for use in bile acid disorders (Lindor et al., 2009; Poupon, 2010), can also
prevent both germination and growth of C. difficile (Chapter 4). We therefore
hypothesized that UDCA could be used to prevent recurrence of CDI in human patients.
Although UDCA has been shown to be potentially inhibitory to C. difficile spore
germination in vitro (Chapter 4; Sorg and Sonenshein, 2010), its efficient uptake into the
enterohepatic circulation in the distal small bowel limits its intracolonic concentration
and therefore its usefulness in treating R-CDI (Rodrigues et al., 1995; Hofmann and
Hagey, 2008). Nonetheless, we considered UDCA as a non-antibiotic option to treat C.
difficile infection associated with ileal pouchitis. Although C. difficile small bowel
enteritis is rare, it is commonly associated with post-colectomy pouch dysfunction (Seril
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and Shen, 2014). Similar to CDI in the colon, infection in the post-colectomy pouch can
become refractory to antibiotics, and unfortunately FMT may be less effective in these
patients compared to patients with normal intestinal anatomy (Hamilton et al., 2012;
Borody et al., 2014; Patel et al., 2014). Therefore, there is a need for alternative
treatments for patients with R-CDI pouchitis.
In this report we demonstrate the use of UDCA to control refractory C. difficile
pouchitis in a status post-colectomy patient. The patient’s isolate of C. difficile was found
to be susceptible to UDCA, and fecal concentrations of the drug were tracked to ensure
delivery to the site of infection. To assess recovery of the fecal microbiota in this patient,
we also performed 16S rRNA sequencing on fecal samples before and up to three months
after initiating UDCA therapy. Overall, these results support the hypothesis that UDCA
can be used to prevent CDI recurrence in status post-colectomy patients.
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MATERIALS AND METHODS
Isolation of C. difficile from patient feces
C. difficile from patient feces was isolated by serial dilution onto taurocholate-
cycloserine-cefoxitin-fructose agar (TCCFA) followed by 48 hr anaerobic growth at 37°C
(Bliss et al., 1997). Colonies were identified by PRO kit test (Remel, USA) and
confirmed by sequencing the 16S rRNA gene using the primer set 515F-806R (Caporaso
et al., 2012). Confirmed isolates were grown in CCFB anaerobically for 48 hr and stored
in 25% glycerol at -80°C.
C. difficile spore preparation
C. difficile cells from frozen stocks were inoculated into CCFB medium and grown
anaerobically at 37°C for 48 hr. Cultures were plated onto brain heart infusion with 5 g/L
yeast extract and 0.1% L-cysteine (BHIS) and grown for 7 d at 37°C under anaerobic
conditions. Following Sorg and Sonenshein, 2010, colonies from each plate were scraped
into 1 mL of ice-cold water and incubated at 4°C overnight to release spores. A 3 mL
suspension was loaded onto 10 mL of 50% (w/v) sucrose in a 15 mL conical tube and
centrifuged in a swinging bucket rotor at 3200 x g for 20 min at 4°C. Sucrose and
vegetative cells above the spore pellet were removed, and the pellet was washed 5 times
in ice-cold water to remove remaining sucrose. Spores were examined under phase-
contrast microscopy to determine purity; spore samples with >99% purity (<1%
vegetative cells) were stored at 4°C.
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C. difficile spore germination
Germination assays were done as previously described by Sorg and Sonenshein, 2010.
Spores were heated to 65°C for 30 min and inoculated into BHIS, with or without UDCA
and/or TA, within an anaerobic bag flushed and filled with N2 gas. OD600 was measured
initially (OD600(t0)) and every minute for 20 min (OD600(t)) using an EL808 Microplate
Reader (Biotek Instruments, Inc., Winooski, VT). Relative OD600 for each time point was
calculated as OD600(t)/OD600(t0). Experiments were performed in triplicate.
Growth of C. difficile vegetative cells
Cells from frozen stocks were inoculated into BHIS broth with 0.1% (w/v) taurocholate
and incubated overnight at 37°C under anaerobic conditions. Vegetative cells were then
inoculated into tubes containing BHIS, with or without UDCA, normalized to an OD600
of 0.005, and grown anaerobically at 37°C. Measurements of OD600 were collected each
hour for 12 hr following inoculation, and a final OD600 was measured after 24 hr growth.
Experiments were performed in triplicate.
Measurement of UDCA and TA in feces
Fecal samples were spiked with oleanolic acid (internal standard), suspended in 10
volumes of 50% aqueous acetonitrile, and extracted by vortexing and sonication for 10
min. The suspension was centrifuged twice at 18,000  g for 10 min. The supernatant was
passed through a 2 µm filter and subjected to LC-MS analysis. A 5 µl aliquot was
injected into an AcquityTM UPLC system (Waters, Milford, MA) and separated by a
mobile phase gradient ranging from water to 95% aqueous acetonitrile containing 0.1%
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formic acid over a 10-min run. LC eluant was introduced into a Xevo-G2-S QTOF mass
spectrometer (Waters) for metabolite identification and quantification. Capillary and cone
voltage for electrospray ionization (ESI) were maintained at -1.5 kV and -35 V for
negative-mode detection, respectively. Source temperature and desolvation temperature
were 120 °C and 350 °C, respectively. Nitrogen was used as a cone (50 l/h) and
desolvation gas (800 l/h), and argon was included as the collision gas. The mass
spectrometer was calibrated with sodium formate solution (range m/z 50-1000) and
monitored by the intermittent injection of the lock mass leucine enkephalin ([M-H]- =
554.2615 m/z) in real-time. Mass chromatograms and mass spectral data were acquired
and processed by MassLynxTM software (Waters) in centroided format. UDCA and TA
were identified by comparing their accurate masses, tandem MS (MS/MS) fragments, and
retention times with authentic standards. Concentrations in fecal samples were
determined using corresponding standard curves and QuanLynxTM software (Waters).
DNA extraction
DNA was extracted from each sample (0.25 to 0.50 g) using the PowerSoil® DNA
Isolation Kit (MO BIO, Carlsbad, CA) according to the manufacturer’s instructions.
Samples with high water content (Bristol stool scale types 5 to 7) were centrifuged at
12,000 RPM for 3 min to pellet solids, which were used for DNA extraction. Each
sample was extracted in triplicate, and each replicate was eluted in 50 µl of 10mM Tris-
HCl buffer (pH 8.0) and pooled. DNA concentrations of extracted samples were
measured with a QuBit® DNA quantification system (Invitrogen, Carlsbad, CA) using
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QuBit high sensitivity assay reagents. All extracted DNA samples were stored at -20°C
until amplification.
PCR amplification and sequencing
Fecal DNA samples were used as template for PCR amplification of the V5-V6 region of
the 16S rRNA gene using a V5F/V6R Nextera primer pair (Table 6.1). Following
amplification with these primers, PCR products were diluted 1:100 and amplified using
Illumina indexing primers, which include flowcell adapters (Table 6.1). Pooled, size-
selected PCR products from the second reaction were denatured with NaOH, diluted to 8
pM in the Illumina HT1 buffer (Illumina, San Diego, CA), spiked with 15% PhiX, and
heat denatured at 96°C for 2 min immediately prior to loading onto the sequencer. A
MiSeq 600 cycle v3 kit was used to sequence the samples.
Sequence processing and analysis
Reads in each pair for each sequencing run overlapped and paired ends were merged. The
hamming distance (number of substitutions) was calculated for sliding overlaps of the
two reads in a pair to find the best overlap (lowest hamming distance with a minimal
overlap of 25 nucleotides and 98% identity). Merged sequences were binned according to
barcode sequence and both barcode and amplicon primer sequences were trimmed using
custom Perl scripts. Sequence data was processed and analyzed using the mothur
program (Schloss et al., 2009). To ensure high quality data for analysis, sequence reads
containing: ambiguous bases; homopolymers >8 bp; more than one mismatch in the
primer sequence; or an average per base quality score below 35 within each 50 bp
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window were removed. Sequences that only appeared once in the total set were assumed
to be a result of sequencing error and removed from the analysis. Chimeric sequences
were removed from the data set using the UCHIME algorithm within the mothur program
(Edgar et al., 2011). A random subset of 25,189 sequences per sample were used to
balance read numbers and clustered into operational taxonomic units (OTUs). Taxonomy
was assigned at a cutoff value of ≥97%, using a 16S rRNA database prepared from the
Ribosomal Database Project (RDP) 9, using the Bayesian method with a bootstrap
algorithm (100 iterations) and a probability cutoff of 0.60 (Cole et al., 2009). Principal
coordinate analysis was performed using a tree generated via Bray-Curtis method, and
Shannon diversity indices were calculated using mothur.
Study approval
The study was approved by the University of Minnesota Institutional Review Board (IRB
0901M56962). The patient provided informed consent for participation in the study.
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RESULTS
Clinical history of recurrent CDI pouchitis
The patient was first seen in our clinic as a 53-year old woman, 6 years status post
total colectomy performed for refractory ulcerative colitis. Following her surgery, she
suffered from chronic, incessant diarrhea averaging approximately 10-15 liquid bowel
movements over 24 hr despite use of antidiarrheal agents, resulting in extreme fatigue
and inability to sleep sufficiently. Laboratory evaluation demonstrated iron deficiency
anemia and protein-losing enteropathy with serum albumin of 2.3 g/dL and moderately
decreased levels of immunoglobulins G, A, and M. Endoscopic evaluation demonstrated
moderate inflammation in the ileal-anal pouch, but also proximal small bowel ulcers and
a stricture in the distal small bowel, which prompted a retained video capsule that was
retrieved endoscopically. These findings were most consistent with Crohn’s disease, and
the patient was started on anti-tumor necrosis factor therapy. Although there was modest
overall clinical improvement attributed primarily to intravenous iron replacement, her
diarrhea was unchanged. Her stool tested positive for C. difficile toxin B despite absence
of any recent antibiotic exposure. The patient was started on oral vancomycin and she
reported marked improvement in her diarrhea, including firmer consistency of her stool
unseen since her colectomy.
Unfortunately, response to vancomycin was not sustained and symptoms recurred
within a week of stopping vancomycin. Additional attempts to clear the infection
included two more courses of vancomycin, including a 2-month tapered regimen, and a
course of fidaxomicin. Antibiotics were discontinued and FMT was performed by
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endoscopic infusion of standardized fecal microbiota directly into the pouch as well as
proximal small bowel. Subsequently the patient tested negative for C. difficile at 2 and 3
weeks post-FMT, but did not experience improvement in diarrhea. Relapse of the
infection was documented at one month after FMT. Vancomycin was restarted at 125 mg
four times daily, tapered down to 125 mg once daily, and maintained at that dosage for 6
months. Despite clinical improvement in the initial months, her diarrhea progressively
became worse and ultimately returned to the original state despite control of C. difficile
infection by vancomycin. Vancomycin was at this time discontinued, and the patient’s
stool again tested positive for C. difficile toxin B.
Germination and growth of C. difficile isolated from CDI pouchitis patient is inhibited
by UDCA
The lack of success with antibiotic or FMT therapy in this patient prompted a trial
of an alternative therapy to prevent CDI recurrence. We previously demonstrated that
ursodeoxycholic acid (UDCA), a secondary bile acid available clinically, could inhibit
germination and growth of C. difficile spores in vitro, suggesting it might prevent
germination and growth in vivo and therefore prevent recurrent disease (Chapter 4).
However, the utility of UDCA in patients with normal gastrointestinal anatomy is limited
due to its effective absorption into enterohepatic circulation (Rodrigues et al., 1995;
Hofmann and Hagey, 2008). But in this patient, who was status post-colectomy, we
hypothesized that oral UDCA would reach the site of infection and prevent recurrence of
CDI.
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To assess whether UDCA might be used to treat this patient, we isolated C.
difficile from a sample of the patient’s feces collected during active infection and
examined whether UDCA could inhibit germination of spores generated from this isolate.
An established spectrophotometric assay that relies on the refractive nature of bacterial
spore coats (Sorg and Sonenshein, 2008; Sorg and Sonenshein, 2009; Sorg and
Sonenshein, 2010; Heeg et al., 2012) was used to examine germination of this isolate
when spores were exposed to a known germinant, taurocholate (TA), versus TA in the
presence of a range of concentrations of UDCA. The relative OD600 of spores exposed to
any concentration of UDCA (0.5, 1, or 2 mM) was significantly (p<0.01) higher
compared to spores exposed to TA alone (Fig. 6.1A), suggesting that concentrations of
UDCA as low as 0.5 mM could prevent germination of spores from this patient’s isolate
of C. difficile.
To assess growth in the presence of UDCA, overnight cultures were grown with
TA to induce germination, and resulting vegetative cells were inoculated (to OD600 =
0.005) into BHIS medium or BHIS containing 2 mM UDCA. After 24 hours, the growth
of cells exposed to UDCA was significantly (p<0.0001) lower than cell grown in BHIS
alone (Fig. 6.1B), indicating that UDCA inhibited vegetative growth of this isolate of C.
difficile. Overall, these findings implied that UDCA could be an effective therapy to
prevent CDI recurrence in this patient.
Successful treatment of recurrent CDI pouchitis with oral UDCA
Based on our in vitro results, the patient was prescribed oral UDCA (300 mg
twice daily), which was well tolerated. After two weeks, the UDCA dose was increased
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to 300 mg four times daily (20 mg/kg/day) and oral vancomycin (125 mg/day) was
discontinued. The frequency of diarrhea decreased and firm bowel movements were
reported. Furthermore, the stool remained negative for C. difficile by PCR tests for toxin
B over nine months following termination of vancomycin.
The concentrations of UDCA and TA were measured in patient feces before and
up to 94 d after initiation of therapy. There was a marked increase in UDCA and decrease
in TA following UDCA dose increase (Fig. 6.2). Together with our in vitro findings,
these results indicate that an oral UDCA dose of 300 mg four times daily is sufficient to
suppress taurocholate-induced C. difficile germination at concentrations measured in the
feces.
Fecal bacterial communities do not normalize following UDCA therapy
Although we successfully prevent recurrence of CDI in this patient, likely due to
ongoing inhibition of C. difficile germination with UDCA, we wanted to assess whether
oral UDCA therapy could be halted. Because R-CDI patients whose fecal microbiota is
normalized via FMT rarely experience further CDI recurrences (Khoruts et al., 2010;
Shahinas et al., 2012; Hamilton et al., 2013; van Nood et al., 2013; Song et al., 2013;
Weingarden et al., 2014; Seekatz et al., 2014; Fuentes et al., 2014), we hypothesized that
after halting vancomycin, this patient’s fecal microbiota could normalize and UDCA
might be stopped.
To test this hypothesis, we sequenced the bacterial 16S rRNA gene from the
patient’s fecal samples before and up to 94 days after initiating UDCA therapy. From a
total of 1,408,244 sequences, each sample was subsampled to 25,189 sequences before
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clustering into operational taxonomic units (OTUs) at a cutoff of 97% sequence
similarity. OTUs were classified by bacterial phylum and family (Fig. 6.3). Although the
fecal microbiome of healthy individuals is dominated by the Bacteroidetes, Firmicutes,
and Actinobacteria phyla (Zoetendal et al., 2008; Arumugam et al., 2011), prior to
beginning UDCA, this patient’s fecal microbiome was predominantly Firmicutes and
Proteobacteria (Fig. 6.3A), similar to what has been observed with other patients who
experience recurrent CDI (Khoruts et al., 2010; Shahinas et al., 2012; Hamilton et al.,
2013; van Nood et al., 2013; Song et al., 2013; Weingarden et al., 2014; Seekatz et al.,
2014; Fuentes et al., 2014). Early after initiating oral UDCA, the Fusobacteria also
became a dominant phylum, representing between 10% and 45% of OTUs up to 35 days
after starting UDCA. The relative abundance of Proteobacteria decreased from 75% of
OTUs at 7 days after therapy initiation to 25% of OTUs 80 days after starting UDCA;
however, at 94 days post-initiation the relative abundance of Proteobacteria returned to
70% of OTUs. The Bacteroidetes phylum remained undetectable until the last time point,
94 days after starting UDCA, and represented only 2% of OTUs at that point. These
findings suggest that the bacterial phyla present in this patient’s feces remain altered
compared to healthy individuals even nearly three months after stopping antibiotic
therapy.
Similar to the phyla, the bacterial families present in this patient’s feces also
remained altered after beginning UDCA therapy (Fig. 6.3B). The majority of
Proteobacteria in this patient’s fecal communities appeared to be Enterobacteriaceae, as
this family represented between 10 and 75% of fecal OTUs in all samples. Similarly, an
increase in the Fusobacteriaceae family was likely responsible for the increase in the
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Fusobacteria phylum following initiation of UDCA. The Lachnospiraceae family, within
Firmicutes, was present during active C. difficile infection at a fairly high relative
abundance of 35% of OTUs, but quickly became undetectable during vancomycin
therapy. Although this family recovered at 35 days following initiation of UDCA (21
days after halting vancomycin), it became undetectable once more at 94 days after
starting UDCA. Although Bacteroidaceae and Prevotellaceae, within Bacteroides, are
thought to be major constituents of the human microbial flora (Arumugam et al., 2011),
neither family was detectable in any sample. Similar to findings at the phylum level,
these results suggest that the fecal microbiome of this patient had not recovered by 94
days after initiating UDCA.
To analyze overall fecal bacterial community structure and diversity of this
patient, we compared these samples to samples collected from nine healthy individuals
who participated our microbial therapeutics program (Khoruts et al., 2015). Shannon
diversity indices, which represent diversity within samples (α-diversity), indicated that
the α-diversity of fecal samples from this patient was lower at all time-points compared
to healthy individuals (Fig. 6.4A). Principal coordinate analysis (PCoA), which is a
reflection of diversity between samples (β-diversity), indicated that while fecal bacterial
communities from healthy individuals were similar, communities in this patient were
distinct from healthy samples, although initiation of UDCA therapy did cause a
noticeable shift in community structure (Fig. 6.4B). These findings indicate that initiation
of UDCA therapy did not result in normalization of either α- or β-diversity, even up to 94
days after the start of treatment.
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Overall, although shifts in bacterial communities were detectable in the patient’s
feces after initiation of UDCA and after halting vancomycin, these changes did not reflect
full recovery of the fecal microbiota even after three months on the drug. This suggests
that the patient could still be at risk for CDI recurrence, were she to stop oral UDCA.
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DISCUSSION
Clostridium difficile infection (CDI) is now considered the most common
hospital-acquired infection in the US (Zilberberg et al., 2008; Miller et al., 2011;
Dubberke and Olsen, 2012; Magill et al., 2014) and community-acquired cases are also
increasingly found (Khanna et al., 2012; Lessa et al., 2014; Lessa et al., 2015).
Unfortunately, many patients with CDI go on to develop recurrent CDI syndrome (R-
CDI), characterized by repeated cycles of antibiotic therapy and reoccurring symptoms
(Borody and Khoruts, 2011). For these patients, fecal microbiota transplantation (FMT)
may be the most promising therapy, offering a far higher rate of cure than standard
antibiotic treatments (Kassam et al., 2013). Despite the efficacy of FMT, however, there
remains a need to develop novel therapies for this disease for individuals who fail the
criteria for FMT or fail to remain infection-free following the procedure.
Although CDI is primarily a colonic disease for individuals with normal intestinal
anatomy, C. difficile infection is also associated with 10% of diarrheal symptoms in
patients with an ileal pouch reservoir that is surgically created after a total colectomy
(Seril and Shen, 2014). Similar to colonic CDI, ileal pouch CDI can become recurrent
and difficult to eradicate with antibiotics. Thus, there is a need for alternative approaches.
FMT has been suggested for R-CDI pouchitis, but its efficacy in this situation is currently
unknown. Patel and colleagues reported the use of FMT in one case (Patel et al., 2014),
but the patient did not respond symptomatically and was continued on anti-CDI
antibiotics for a month after the procedure, ultimately eradicating CDI. In our experience,
large segment partial colectomy has been associated with initial FMT failure (Hamilton et
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al., 2012) and other investigators have noted difficulty curing R-CDI with FMT following
subtotal colectomy (Borody et al., 2014). Bacterial production of secondary bile acids,
thought to be a critical mechanism of FMT which prevents recurrence of CDI
(Weingarden et al., 2014; Chapter 4), may be intrinsically limited in these patients,
although this deserves systematic study. However, the absence of the colon also allows
for greater delivery of UDCA to the site of infection, enhancing its usefulness in the
treatment of CDI-associated pouchitis. This idea is supported by the case report presented
here of a patient who failed to clear CDI in the ileal pouch following multiple courses of
antibiotics and FMT, but was successfully treated with oral UDCA.
In addition to tracking clinical outcomes, we also tracked the fecal microbiota of
this patient, in part to determine whether normalization of the fecal microbiota occurred
during treatment with UDCA. Patients with R-CDI, including the patient presented here,
frequently have fecal microbiota that are highly altered from healthy individuals,
including predominance of the Proteobacteria phylum and Enterobacteriaceae family
(Khoruts et al., 2010; Shahinas et al., 2012; Hamilton et al., 2013; van Nood et al., 2013;
Song et al., 2013; Weingarden et al., 2014; Seekatz et al., 2014; Fuentes et al., 2014),
compared to dominance by the Bacteroidetes, Firmicutes, and Actinobacteria phyla in
normal feces (Zoetendal et al., 2008; Arumugam et al., 2011). Although the relative
abundance of Proteobacteria in the feces of this patient decreased after vancomycin was
halted, it remained a common phylum in her fecal communities, and in fact increased in
relative abundance at our latest time point (94 d post-initiation of UDCA). Furthermore,
while Firmicutes were abundant in every fecal sample, the Bacteroidetes only became
detectable at 94 d after starting UDCA, where they remained a relatively minor
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component of the fecal microbiota. Finally, the α-diversity of the patient’s fecal
communities remained low compared to the healthy individuals, and β-diversity analyses
indicate that community composition remained distinct from that of healthy individuals
even nearly three months after cessation of vancomycin. Overall, these findings indicate
that the patient’s fecal bacterial community did not normalize over the time points we
monitored.
It is likely that the fecal microbiota of this patient remained distinct from that of
healthy individuals either due to a lingering effect of antibiotic therapy or due to the
patient’s altered intestinal anatomy. Even in individuals without underlying pathology,
one or two antibiotic courses can drastically alter fecal microbial communities for 4-10
weeks, and can cause lasting changes in overall composition as well as to individual taxa
for up to 10 months (Dethlefsen et al., 2008; Dethlefsen and Relman, 2011). The
microbiota of the ileal pouch is also often distinct from normal colon. One study in a
small cohort found that three of four patients had mucosal microbial communities in the
ileal pouch which were distinct from healthy colonic mucosal communities (Young et al.,
2013). Interestingly, the patient whose communities were most similar to colonic
communities remained pouchitis-free for the duration of the study, unlike the other three
patients. Another study found that patients with underlying ulcerative colitis (UC) have
distinct pouch microbiota even compared to the microbiota of patients who are status
post-colectomy for familial adenomatous polyposis (FAP): compared to FAP patients,
UC patients have increased Proteobacteria (up to 90% of the microbiota) and decreased
Bacteroidetes in the ileal pouch (Zella et al., 2011), similar to the findings in our patient.
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Overall, our findings suggest that UDCA is a promising therapeutic for patients
with R-CDI of the ileal pouch. However, our findings as well as previous findings
indicate that the microbiota of the pouch may not normalize compared to the microbiota
of the healthy colon. As a result, patients may need to remain on UDCA chronically.
However, because our results represent the findings in one individual, further systematic
trials are now needed to evaluate UDCA as a potential non-antibiotic treatment of CDI-
associated pouchitis, especially in cases of recurrent disease. Furthermore, tracking of the
microbiota in these patients, as well as additional sampling points in the patient presented
here, may be indicated in order to determine whether the microbiota ultimately
normalize.
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Table 6.1 – Primers used in 16S sequencing.
Primer Sequence
V5F
Nextera
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGRGGATTAGATAC
CC
V6R
Nextera
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCGACRRCCATG
CANCACCT
Forwar
d Index
Primer
AATGATACGGCGACCACCGAGATCTACAC[i5]aTCGTCGGCAGCGT
C
Revers
e Index
Primer
CAAGCAGAAGACGGCATACGAGA[i7]aGTCTCGTGGGCTCGG
a[i5] and [i7] refer to index sequence codes for barcoding used by Illumina.
169
Figure 6.1 – UDCA inhibits germination and growth of C. difficile isolated from
patient stool. A) Relative OD600 of spores isolated from patient exposed to 0.5 mM (■), 1
mM (♦), or 2 mM (▲) UDCA in the presence of 2 mM TA vs. 2 mM TA alone (●).
OD600(t)/OD600(t0) = OD600 normalized to initial OD600 (relative OD600). B) Growth of
vegetative cells from C. difficile isolate in BHIS alone (●) or BHIS with 2 mM UDCA
(▲). * = p<0.01, ** = p<0.0001. TA: taurocholate; UDCA: ursodeoxycholic acid. Data
represent mean ± SEM.
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Figure 6.2 – UDCA is detectable in patient feces. Concentration of UDCA (●) and
taurocholate (▲) in patient feces before and after initiation of UDCA therapy. Timing of
significant clinical events is noted. TA: taurocholate; UDCA: ursodeoxycholic acid.
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Figure 6.3 – Fecal bacterial communities are altered after initiating UDCA. A)
Relative abundance of sequences from bacterial phyla in patient feces before and after
start of UDCA therapy. See legend below for list of phyla. B) Relative abundance of
sequences from bacterial families in patient feces before and after start of UDCA therapy.
See legend below for list of families. Significant clinical events are noted above.
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Figure 6.4 – α- and β-diversity of patient fecal samples do not normalize following
UDCA therapy. A) Shannon diversity indices of healthy (●) and patient (♦) fecal
samples before and after initiating UDCA therapy. Significant clinical events are noted
above. Healthy data represent mean ± SEM. B) Principal coordinate analysis of healthy
(●) and patient fecal communities before (▲) and after (♦) initiating UDCA therapy.
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Chapter 7
Stabilization of Distal Gut Bacterial Composition Following Sequential Fecal
Microbiota Transplantation to Treat Severe Clostridium difficile Infection‡
‡ Partially reprinted from Journal of Clinical Gastroenterology. Alexa R. Weingarden,
Matthew J. Hamilton, Michael J. Sadowsky, and Alexander Khoruts. “Resolution of
severe Clostridium difficile infection following sequential fecal microbiota
transplantation.” © Wolters Kluwer Health Lippincott Williams & Wilkins.
Originally published in Journal of Clinical Gastroenterology. 2013. 47(8):735-737.
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SUMMARY
Severe Clostridium difficile infection (CDI) is associated with high mortality even with
surgical intervention. Fecal microbiota transplantation (FMT) is a potential alternative
treatment approach, but one that has not yet been mechanistically investigated. The
primary aim of this study was to measure changes in the bacterial composition of fecal
microbiota following FMT in treatment of severe CDI that is refractory to standard
antibiotic therapy. This is a clinical case series of four patients treated by FMT, using
frozen fecal microbiota, for severe CDI. Bacterial composition of distal gut microbiota
was characterized before and after FMT using high-throughput 16S rRNA gene
sequencing of fecal samples in three of four patients. FMT resulted in initial clinical
improvement in all cases. However, the subsequent course was characterized by
recurrence of CDI. This was associated with instability of the bacterial composition of
fecal microbiota, specifically increasing abundance of Enterobacteriaceae and decreasing
abundance of Lachnospiraceae and Bacteroidaceae family members. Optimal donor
engraftment with stabilization of the fecal microbiota composition and clearing of CDI
was achieved by a second FMT following an intervening course of antibiotics. FMT is a
promising alternative to surgical treatment of severe CDI. However, a single FMT may
not achieve sustained protection against recurrence of CDI in this clinical situation. Our
experience suggests that the double FMT protocol described here achieves sustained
recovery from severe CDI.
175
INTRODUCTION
Over the past two decades Clostridium difficile infection (CDI) has steadily risen
in both incidence and severity in North America and Europe, and is currently the most
common infection associated with healthcare (Miller et al., 2011). This epidemic
correlates with emergence of new, hypervirulent strains of C. difficile, characterized by
greater potential for exotoxin production and sporulation efficiency, which likely
contribute to greater disease severity and recurrence rates (Merrigan et al., 2010). About
3-10% of patients with CDI progress to a severe, complicated, or fulminant state, which
can be highly lethal. Severe CDI can progress rapidly to multisystem organ failure, and
early surgical intervention, typically subtotal colectomy, can be lifesaving (Markelov et
al., 2011). However, even surgical treatment of CDI in practice is associated with
postoperative mortality rates of 35-80% (Dallal et al., 2002; Koss et al., 2006; Wysowski,
2006; Lamontagne et al., 2007).
Fecal microbiota transplantation (FMT) is an alternative to standard antibiotic and
surgical therapy, which is used mainly for multiply recurrent CDI (Bakken et al., 2011;
Gough et al., 2011; Borody and Khoruts, 2011). This procedure aims to repair the
fundamental defect that allows the establishment of CDI: suppression and disruption of
the microbial communities normally inhabiting the distal gut by antibiotics. However,
only a handful of case reports exist on the use of FMT in severe or fulminant CDI (You et
al., 2008; Brandt et al., 2011; Gallegos-Orozco et al., 2012; Trubiano et al., 2012). The
earliest published experience on successful clinical use of FMT by Eiseman and
colleagues in 1958 focused on severe disease associated with pseudomembranous colitis
176
(Eiseman et al., 1958). The approach has not gained traction in medical practice, likely
due to a number of practical constraints which includes a very narrow window of
intervention in addition to other concerns such as aesthetic challenges, no
standardization, and lack of reimbursement (Hamilton et al., 2012). Extremely limited
clinical experience and lack of investigations into the mechanism of microbiota
restoration undoubtedly also contribute to hesitation in using this approach to treat severe
CDI.
In the course of the past several years we have established a clinical program of
FMT for multiply recurrent CDI at the University of Minnesota. Most serious barriers
associated with use of FMT have been overcome by developing a standardized protocol
of preparation of fecal microbiota material that is nearly odorless and can be stored in a
frozen state until needed for the procedure (Hamilton et al., 2012). In the course of this
experience we were called to perform FMT on four patients with severe CDI, who were
poorly responsive to antibiotic therapy and had prohibitive surgical risk. Each case was
associated with a unique clinical narrative, united by the overall degree of complexity
associated with a critical illness in the context of multiple medical co-morbidities. We
measured the clinical response to FMT and characterized the composition of the fecal
microbiota in these patients before and after the procedure.
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MATERIALS AND METHODS
Patients
The four patient cases represent a consecutive experience in treating severe C. difficile
infection with FMT at the University of Minnesota from March 2011 to February 2012.
Surgical teams were involved in all cases, and the decision to perform FMT was done
following establishment of consensus among all the participating medical and surgical
services. The procedures were done after obtaining informed consent and the patients or
their families also consented to participate in the study of bacterial composition of their
feces before and after FMT. The Institutional Review Board at the University of
Minnesota approved prospective collection of clinical and fecal microbial composition
data (project approval date: October 2, 2009), while recognizing this experience does not
constitute a formal clinical trial testing efficacy of FMT in comparison to any other
therapeutic options.
Case Histories
Patient 1. 66 year old woman was admitted to the University Hospital with six day
history of progressive diarrhea following recent treatment of sinusitis with two courses of
amoxicillin. Her past medical history was most notable for metastatic ovarian carcinoma
diagnosed and surgically debulked seven years earlier. She had received multiple courses
of different chemotherapy in the intervening years. Her fourth cycle of paclitaxel was
administered four weeks prior to admission. The patient reported severe diarrhea,
continuous through day and night, along with chills, fatigue, and anorexia. Notable
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findings on physical examinations included tender lower abdomen, which was otherwise
soft and flat. Computerized tomography (CT) scan of her abdomen demonstrated diffuse
colonic wall thickening without pneumatosis, pericolonic fat stranding, and small amout
of ascites. She had slightly increased white blood cell (WBC) count of 12.6 x 109/L and
albumin of 3.4 g/dL. Her stool studies were positive for C. difficile toxin B by PCR. The
patient was initially started on oral metronidazole, but changed to oral vancomycin in the
next two days as she failed to show any clinical improvement. On day 2 of hospitalization
her abdomen was noted to be markedly distended, tympanitic, and diffusely tender. She
developed fevers of 39.5°C, fluid bolus refractory hypotension with blood pressure of
70/40 mmHg and metabolic acidosis with bicarbonate level of 12. Antibiotic
management at this time included oral rectal vancomycin and intravenous metronidazole.
The patient received an infusion of intravenous immunoglobulin. On day 3 of
hospitalization she was transferred to the medical intensive care unit where she was
placed on ventilator and vasopressor support. Surgical consultant concluded that subtotal
colectomy was the surgical procedure of choice, but would carry high risk of mortality,
and cited metastatic ovarian carcinoma and extremely low albumin of 1.3 to be
complicating factors. The consultant recommended to consider FMT prior to committing
to subtotal colectomy.
Antibiotics were discontinued at mid-day of hospitalization day 3 and two liters of
polyethylene glycol electrolyte solution (GoLYTELY) were administered via nasogastric
tube. FMT was performed via colonoscopy in the late evening of hospitalization day 3
using freshly prepared fecal material from a pre-screened volunteer donor. The
colonoscope was gently advanced to the hepatic flexure and severe pseudomembranous
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colitis was noted (Fig. 7.1A). Within several hours of the procedure there was
hemodynamic improvement with lessening vasopressor support and defervescence. WBC
count decreased from peak of 24.3 x 109/L to 10.8 x 109/L within 24 hours (Fig. 7.1B).
Over the next several days her clinical recovery was described as “remarkable.”
However, on day 6 after the procedure clear signs of clinical deterioration were noted
with increasing diarrhea, abdominal pain, and distended abdomen. Unfortunately, the
option to perform a second FMT was not available due to out of town absence of the
performing endoscopist. The patient was taken to surgical subtotal colectomy. She was
able to recover over the next six weeks and continues to be clinically stable.
Patient 2. 74 year old man was admitted to an outside hospital with abdominal pain,
watery diarrhea, nausea, and vomiting, about two and a half weeks following treatment of
foot cellulitis with clindamycin. He had numerous medical problems, including severe
emphysema with oxygen dependence, atherosclerotic heart disease, history of aortic
aneurism repair, recurrent aspiration pneumonias, including an episode a year ago
requiring mechanical ventilation, narcotic dependent back pain, and legal blindness due
to glaucoma. He was afebrile and hemodynamically stable, although his WBC count was
20.4 x 109/L and albumin was 3.2 g/dL. He was admitted and started empirically on oral
metronidazole. His stool studies were positive for C. difficile toxin B by PCR, and also
grew out vancomycin resistant enterococcus. Over the next three days he showed little
clinical improvement and started having fevers up to 39.5°C. Intravenous ertapenem was
administered for suspected systemic infection and metronidazole was changed to
intravenous route of administration. The patient was reported increasing abdominal pains
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and required fluid resuscitation for hypotensive episodes. CT scan of the abdomen
showed thickening of the colon wall from cecum to sigmoid colon. There was a moderate
amount of ascites. The patient was transferred to the medical intensive care unit, started
on oral vancomycin, and surgical consultation was obtained for consideration of
colectomy. The surgeon determined that his multiple medical co-morbidities greatly
increased the likely mortality of subtotal colectomy and recommended stopping
intravenous antibiotics and transferring the patient to the University hospital for
consideration of FMT.
On re-evaluation at the University the patient appeared very tired. His systolic
blood pressure was in the 90s mmHg. Abdomen was distended, mildly tender diffusely,
and bowel sounds were absent. WBC count was 40.0 x 109/L, albumin was 2.0 g/dL, and
C-reactive protein (CRP) was 208 mg/L; these laboratory indicators were monitored daily
through the remainder of his hospital course (Fig. 7.2A). Vancomycin was held for 24
hours during which the patient received several liters of GoLYTELY via nasogastric
tube. FMT was done the next day via colonoscopy, during which pseudomembranous
colitis was seen to involve the entire colon (Fig. 7.2A). The patient appeared clinically
improved the following day and reported complete resolution of abdominal pain. On the
second day following the procedure he had a solid bowel movement. However, his bowel
movement was loose on day 3 after the procedure and he noted return of fatigue. He had
several more loose bowel movements on day 4, and the worsened symptoms correlated
with increased CRP and WBC counts (Fig. 7.2A). On day 5 his stool was positive for C.
difficile toxin B by PCR. The patient was restarted on oral vancomycin and was
discharged to a rehabilitation facility. A second FMT was performed two weeks
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following discharge at which time signs of pseudomembranous colitis were absent (Fig.
2B). The patient had no relapse of C. difficile infection in the subsequent one year despite
two episodes of aspiration pneumonia.
Patient 3. 68 year old woman was admitted to the University hospital with hematochezia,
abdominal pain, and increasing nausea five weeks following Nissen fundoplication
surgery. She had a complex past medical history complicated by a cognitive disorder and
a narcotic dependent chronic pain syndrome related to a motor vehicle accident five years
previously, heavy tobacco dependence, hypertension, and polyneuropathy, among a
number of other medical and surgical items. She was tachycardic on admission with heart
rate of 131 beats per minute and blood pressure of 182/92 mmHg. She was febrile with a
temperature of 38.1°C. Abdomen was diffusely tender, but not distended. WBC count
was 24.1 x 109/L and albumin was 4.1 g/dL. CT of the abdomen demonstrated marked
colonic wall thickening extending from rectosigmoid to the mid-transverse colon with
mild surrounding fat stranding and small amount of ascites. Extensive atherosclerosis was
noted in the abdominal aorta and iliac arteries, although the proximal celiac axis and the
superior mesenteric artery were noted to be patent. Despite these findings, the primary
suspected diagnosis was ischemic colitis. The patient was started on intravenous
piperacillin/tazobactam and metronidazole. There was little clinical improvement over
the next three days as the patient required increasing amounts of narcotics for pain
control and continued to have tachycardia and low grade fevers. C. difficile infection was
considered, but fecal samples failed to be collected during this time. CT angiogram was
performed demonstrating patent inferior mesenteric artery proximally and in its major
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branches. A flexible sigmoidoscopy performed on day 4 of hospitalization due to
persistent rectal bleeding described dark, edematous mucosa with confluent large
pseudomembranes. C. difficile toxin B was found to be positive on day 5 of
hospitalization by PCR. The primary diagnosis was changed to that of severe C. difficile
colitis, and non-CDI antibiotics were discontinued. Oral vancomycin was added to the
intravenous metronidazole. Nevertheless, the patient continued to have diarrhea and
complain of severe abdominal pain, concordant with diffuse abdominal tenderness seen
on physical examination. This CDI antibiotic therapy continued for another five days
without significant change in the clinical status. However, on day 11 she developed
worsening abdominal distension with cessation of stools. Abdominal X-ray showed
dilatation of the transverse colon to 6 cm. Antibiotics were discontinued, and the patient
received GoLYTELY in preparation for FMT; the primary service also opted to
simultaneously administer intravenous immunoglobulin at 1 g/kg. On hospitalization day
12 the patient was noted to be more lethargic than the previous day.
The FMT was performed via colonoscopy on hospitalization day 12, noting
pseudomembranous colitis most severe in the transverse colon as well as a 6 mm polyp in
the rectum. There was little clinical improvement seen on day 13 as the patient became
increasingly somnolent and spiked a fever of 38.6°C. Fidaxomicin was initiated despite
resolution of clinical dilatation on hospitalization day 14, followed by abdominal CT scan
that demonstrated decreased thickening of the colon and decreased amounts of ascites.
On hospitalization day 15 her abdominal exam was markedly improved compared to all
preceding days. However, her mental status worsened further. She was extremely
lethargic, and was no longer able to follow simple commands or identify her husband.
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Analysis of cerebrospinal fluid obtained by lumbar puncture showed moderate
pleocytosis with 11 WBC/μL, protein 48 mg/dL, and glucose of 54 mg/dL. Stool testing
for C. difficile was negative. Neurological assessment was that the patient experienced
aseptic meningitis caused by intravenous immunoglobulin administered to the patient
shortly before the FMT. She was also discovered to have cystitis with >100,000 Gram
negative rods cultured from the urine and received a three day course of
trimethoprim/sulfamethoxazole starting on hospitalization day 19. The neurological
status gradually improved over five days following the lumbar puncture. Dificid was
continued until day 24 and a repeat FMT was performed via colonoscopy on day 25.
There were no signs of pseudomembranous colitis during this examination although some
regenerative changes were still present in the transverse colon mucosa. The adenomatous
polyp noted previously was resected and the patient was transferred to a rehabilitation
unit on day 27. The patient continued to undergo rehabilitation for the next six months
and her bowel function remained normal.
Patient 4. 83 year old woman was admitted with diarrhea and abdominal pain four days
after completion of a 10 day course of amoxicillin/clavulanate, following hospitalization
for gallstone induced pancreatitis and ascending cholangitis. The patient had refused
cholecystectomy and was not interested in ever having surgery for any reason. Her past
medical history was notable for type II diabetes, major depression, and at least mild
dementia. She was tachycardic but afebrile. Abdomen was non-distended. CT scan of the
abdomen demonstrated marked mural thickening with surrounding fat stranding
involving the rectum, sigmoid colon, and descending colon. WBC count on admission
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was 17.2 x 109/L and albumin was 3.2 g/dL. In addition, she was found to have a urinary
tract infection for which she was started on intravenous levofloxacin along with oral
vancomycin. Stool studies were positive for C. difficile toxin B by PCR, and the patient
was started on intravenous metronidazole. Over the next three days the patient developed
increasing abdominal pain and distension, and increasing mental confusion. Abdominal
X-ray demonstrated dilatation of the sigmoid colon to 6 cm. Levofloxacin was
discontinued on day 3 of the hospitalization and the CDI antibiotics were stopped on day
4. WBC count at this time was 19.7 x 109/L and CRP level was 71.3 mg/L. The patient
was administered GoLYTELY prep and underwent FMT on day 5 by colonoscopy,
during which she was noted to have pseudomembranous colitis greatest on the left side
along with diverticulosis. Clinical improvement was noted the day after the procedure
with lesser abdominal pain and distension. WBC count came down to 8.9 x 109/L over
two days, at which time CRP level was 24.8 mg/L. The patient remained off antibiotics
for three days after FMT, after which she was started on fidaxomicin with plans to repeat
her FMT after completion of the 10 day course of this antibiotic. The patient was
discharged to a nursing home. However, she refused to have the second FMT and
returned to the hospital approximately six weeks after finishing fidaxomicin with
abdominal pain and diarrhea. Abdominal CT scan showed massive dilatation of the
colon. Stool studies were positive for C. difficile toxin B. The patient refused further care,
including antibiotics, and elected hospice care for comfort.
Transplantation of fecal microbiota
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All patients were on antibiotics prior to FMT.  Systemic antibiotics, including
metronidazole, were discontinued for at least 48 h prior to the procedure. Vancomycin,
which is poorly absorbed, was discontinued 12-24 h prior to the procedure, and the
patients were administered 2-3 liters of polyethylene glycol electrolyte solution
(GoLYTELY®) via NG tube or orally. FMT was performed using a standardized
preparation of concentrated fecal microbiota as previously described (Hamilton et al.,
2012). Patient 1 received the preparation the day it was processed. For Patients 2-4, the
bacterial preparation was frozen in 10% (v/v) glycerol and stored frozen at -80oC until
used. The same donor was used for all FMT procedures (Hamilton et al., 2012).
FMT was performed via colonoscopy by an experienced endoscopist with the
assumption of higher perforation risk in the setting of severe CDI. The colonoscope was
advanced gently to the farthest point possible, while maintaining minimal loop formation.
Carbon dioxide was used for insufflation during the colonoscopy procedures. The donor
fecal microbiota material was injected into the proximal colon via the biopsy channel of
the colonoscope.
Sample collection
Fecal samples were collected by hospital staff from patients prior to FMT and for several
days following FMT, and stored at -80°C within 24 h of production until DNA
extraction. An unprocessed portion of each donor sample was also collected at the time of
donation and stored immediately at -80°C.
DNA extraction
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DNA was extracted from each patient and donor sample (0.25 to 0.50 g) with the
PowerSoil® DNA Isolation Kit (MO BIO, Carlsbad, CA) according to the manufacturer’s
instructions. Samples with high water content (Bristol stool scale types 5-7) were
centrifuged at 12,000 RPM for 3 min to pellet solids, which were used for DNA
extraction. Each sample was extracted in triplicate, and each replicate was eluted in 50 µl
of 10mM Tris-HCl buffer (pH 8.0) and pooled. DNA concentrations of extracted samples
were measured with a QuBit® DNA quantification system (Invitrogen, Carlsbad, CA)
using QuBit high sensitivity assay reagents. All extracted DNA samples were stored at -
20°C until amplification.
PCR amplification
Fecal DNA samples (25 ng) were used as template for PCR amplification of the V6
region of the 16S rDNA gene. Primer sets (Table 7.1) were designed with a 6 bp ID tag
on the 5’ end of either the forward or reverse primer, which was specific to each fecal
DNA sample and allowed for multiplexed sequencing. Triplicate reactions were purified
using the Qiaquick® PCR Purification Kit (Qiagen, Valencia, CA), eluted in 50 µl of 10
mM Tris-Cl buffer, pH 8.0, and pooled. DNA concentrations were measured using the
QuBit® DNA quantification system and high sensitivity assay reagents. Samples were
stored frozen at -20o C until pooled for sequencing.
DNA sequencing
Equimolar aliquots of each product from Patient 2 and donor (10 samples) were pooled
and equimolar aliquots of each product from Patients 3 and 4 and donors (15 samples)
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were pooled to give two samples of ~1 µg of DNA in 100 µL total volume. Final pooled
DNA concentration was measured by using the Quant-IT™ PicoGreen quantitation
system (Invitrogen, Carlsbad, CA). Amplicon size analysis was done using an Agilent
DNA 1000 chip and a 2100 BioAnalyzer (Agilent, Santa Clara, CA). Library preparation
and sequencing, done using Illumina technology, was performed at the University of
Minnesota BioMedical Genomics Center. Paired-end sequences from Patient 2 and donor
samples were generated on the HiSeq 2000 sequencer (100 nt read length), with 1-3
pooled samples per lane following Illumina multiplexing protocols. Paired-end sequences
from Patients 3 and 4 and donor samples were generated on the MiSeq Personal
Sequencer (150 nt read length). Reads in each pair for both sequencing runs overlapped
and paired ends were merged. The hamming distance (number of substitutions) was
calculated for sliding overlaps of the two reads in a pair to find the best overlap (lowest
hamming distance with a minimal overlap of 25 nucleotides and 98% identity). Merged
sequences were binned according to barcode sequence and barcode and amplicon primer
sequences were trimmed using custom Perl scripts.
Sequence processing and analysis
Sequence data was processed and analyzed using the mothur program (Schloss et al.,
2009). To ensure high quality data for analysis, sequence reads containing: ambiguous
bases; homopolymers >7 bp; more than one mismatch in the primer sequence; or an
average per base quality score below 25 within each 15 bp window were removed.
Sequences that only appeared once in the total set were assumed to be a result of
sequencing error and removed from the analysis. Chimeric sequences were removed from
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the data set using the UCHIME algorithm within the mothur program (Edgar et al.,
2011). A random subset of 152,259 sequences from each sample for Patient 2 and donor
and 128,381 sequences from each sample for Patients 3 and 4 and their respective donors
were used to balance read numbers and clustered into operational taxonomic units
(OTUs). Taxonomy was assigned at a cutoff value of >90%, using the Ribosomal
Database Project (RDP) 7 16S rRNA database using the Bayesian method with a
bootstrap algorithm (100 iterations) and a probability cutoff of 0.60 (Cole et al., 2009).
Samples were clustered using the Fast UniFrac algorithm to generate trees and principle
coordinate analysis (PCoA) plots (Hamady et al., 2010). The UniFrac algorithm was run
using the Fast Unifrac program available at www.bmf2.colorado.edu/fastunifrac/.
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RESULTS
Clinical Summary
Each patient in this series had a unique clinical narrative, and individual histories
are provided in Methods and Materials. These four patients developed severe CDI
refractory to standard antibiotic therapy. Subtotal colectomy was considered in all
patients, but was felt to be prohibitively risky or was refused by the patient (Patient 4).
FMT was performed emergently in Patient 1 (Fig. 7.1A) using freshly prepared fecal
material from a pre-screened donor in the medical intensive care unit (MICU). The other
patients received their FMT using previously frozen material. All patients had a prompt
positive clinical response to the procedure. This was especially dramatic in Patient 1
where hemodynamic improvement was evident with lessening vasopressor support,
defervescence, and precipitous fall in white blood cell (WBC) count to near normal levels
over 24 h (Fig. 7.1B). The improvement, however, was not sustained. Symptoms and
signs of CDI returned in Patients 1 and 2 within 3-6 days (Fig. 7.1B and Fig. 7.2A).
Patient 1 underwent subtotal colectomy. Patient 2 was restarted on vancomycin on day 5
after FMT and continued on vancomycin for 2 wk as an outpatient, which was followed
by a second FMT. Going forward, after the experience with these two patients, we
recommended re-initiation of antibiotics after a holding period of several days following
the first FMT, with the plan to repeat the FMT on an outpatient basis after completing the
antibiotic course. This plan was executed on Patient 3, who was started on fidaxomicin
on day 2 following her first FMT, and had the second FMT done on day 14. Patient 4 was
also started on fidaxomicin on day 3 after her FMT, but refused to undergo the second
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FMT. She ultimately succumbed to fulminant CDI, and elected comfort care in a hospice
program.
Fecal Microbiota
Analysis of bacterial composition in fecal samples. The composition of fecal
microbiota in patients before and after each FMT, as well as the donor, was examined by
sequencing the V6 region of the 16S rDNA gene. A total of 13,563,547 sequences were
generated, and 8,510,597 sequences remained after quality filtering and chimera removal.
Sequences were subsampled to obtain the same number for each patient sample, clustered
into operational taxonomic units (OTUs) at 90% sequence identity, and classified using
the Ribosomal Database Project (RDP) 7 (Cole et al., 2009). The most abundant 100
OTUs contributed to more than 80% of the sequences in each sample, suggesting that any
additional OTUs obtained by further sequencing would not greatly affect overall sample
composition.
Decreases in Proteobacteria are associated with recovery and stability of the fecal
microbiome of severe CDI patients treated with FMT. The relative abundance of each
bacterial phylum in fecal samples was assessed in Patients 2, 3, and 4. In Patient 2, the
sample taken before the first FMT (on Day 0) had a composition similar to the donor
sample, with a fecal community dominated by Firmicutes and Bacteroidetes, although
there was a higher relative proportion (20%) of Proteobacteria versus the donor sample
(~5%, Fig. 7.3A). One day following the initial FMT, the fecal community of Patient 2
remained dominated by Firmicutes and Bacteroidetes, though the abundance of
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Proteobacteria increased. However, on the second day following FMT (Day +2) through
just before the second FMT (Day +22/Day 0), the fecal bacterial community was
dominated by Proteobacteria, which comprised over 70-90% of OTUs in each sample.
Concomitantly, the abundance of Firmicutes and Bacteroidetes decreased dramatically.
These changes in the fecal microbiome on Day +2 preceded the return of the patient’s
symptoms on Day +3, and the patient becoming C. difficile toxin-positive on Day +5. In
contrast, following the second FMT (on Day +23/Day +1), the fecal microbiome in this
patient more closely resembled the donor sample, with decreases in Proteobacteria and
increases in Bacteroidetes and Firmicutes, as well as the appearance of the
Verrucomicrobia. These changes persisted the next day (Day +24/Day +2). The patient
developed aspiration pneumonia within a day of collecting this fecal sample and was
started on antibiotics, however despite this, he did not experience recurrent C. difficile
infection.
The fecal microbiota of Patient 3 prior to the first FMT was markedly altered
compared to the donor (Fig. 7.3B). Fecal samples taken one day prior to, and the day of,
FMT (Day -1 and Day 0) were dominated by Proteobacteria, which represented over
90% of the OTUs. In contrast, Firmicutes and particularly Bacteroidetes were present
only in low abundance. However, on day +1 after the first FMT and over the course of
the next 9 days (Days +3, +6, and +9), the relative abundance of Proteobacteria
decreased, with a concomitant increase in the relative abundance of Bacteroidetes and
Verrucomicrobia. In contrast, the relative abundance of Firmicutes did not markedly
change, remaining ≤ 10% of the OTUs from these samples. However, this group returned
following the second FMT and remained relatively abundant (~25%) 15 d later (Day
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+28/Day +15), although the abundance of Proteobacteria remained high compared to the
donor sample.
Similar to Patient 2, a fecal sample from Patient 4 prior to FMT (Day 0), as well
as a flushed colonoscopy sample obtained prior to delivery of the donor’s microbiota
(Day 0 during FMT), had a microbial community similar to the donor, with a relatively
high abundance of Bacteroidetes and Firmicutes and few Proteobacteria (Fig. 7.3C).
Although the Bacteroidetes decreased in this patient 3 days post-procedure (Days +1, +2,
and +3), these samples did not become dominated by Proteobacteria as was seen in
Patients 2 and 3. However, 10 days post-FMT (Day +10), over 90% of OTUs represented
Proteobacteria, while the Firmicutes dramatically decreased and the Bacteriodetes
virtually disappeared. These changes in the fecal microbiome coincided with the patient’s
use of fidaxomicin. Unfortunately, this patient elected not to receive a second FMT, and,
unlike Patients 2 and 3, experienced CDI recurrence.
Lachnospiraceae and Bacteroidaceae are associated with stability of the fecal
microbiome in severe CDI patients. We also compared the relative abundance of
bacterial families in each fecal sample. In Patient 2, the intestinal microbiota prior to the
first FMT (Day 0) was dominated by Enterobacteriaceae and Enterococcaceae, with low
abundance of Lachnospiraceae compared to the donor sample (Fig. 7.4A). Although the
first sample following FMT (Day +1) was characterized by a return of the
Lachnospiraceae, with a decrease in the relative abundance of Enterococcaeae, the fecal
microbiome by Day +2 was still dominated by Enterobacteriaceae, with very low
abundance of the Lachnospiraceae, Porphyromonadaceae, and Bacteroidaceae. This
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pattern persisted until immediately prior to the second FMT (Day +22/Day 0). In
contrast, following the second FMT (Day +23/Day +1, Day +24/Day +2), the fecal
microbiota of Patient 2 showed an increase in the relative abundance of Lachnospiraceae,
Porphyromonadaceae, and Bacteroidaceae, with a dramatic decrease in the abundance of
Enterobacteriaceae. Several other groups found in higher abundance in the donor sample
also increased following the second FMT, including the Ruminococcaceae and
Rikenellaceae.
The fecal microbiome of Patient 3 prior to the first FMT was heavily dominated
by Enterobacteriaceae, which comprised >95% of OTUs (Fig. 7.4B). Between the first
and second FMT (Days +1 through +9), the microbiota slowly shifted, with eventual
increases in groups seen in higher abundance in the donor sample, including
Bacteroidaceae, Porphyromonadaceae, and Rikenellaceae. Only after the second FMT
(Day +28/Day +15), however, did the Lachnospiraceae appear. Interestingly, the fecal
microbiome of Patient 3 after the second FMT still displayed a high relative abundance of
Proteobacteria (Fig. 7.3B), but these were primarily unclassifiable families, rather than
the Enterobacteriaceae.
The relative abundance of bacterial families in the fecal microbiome of Patient 4
revealed differences not seen at the phylum level (Fig. 7.4C). The intestinal microbiota of
Patient 4 before the procedure (Day 0, Day 0 Tx) had slightly increased abundances of
Enterobacteriaceae and Porphyromonadaceae, and lower abundances of Bacteroidaceae
and Lachnospiraceae, relative to the donor. Following FMT (Days +1, +2, and +3), there
was an initial increase in Lachnospiraceae and Sutterellaceae, with decreases in the
relative abundance of Enterobacteriaceae and Porphyromonadaceae, although the
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Bacteroidaceae also appeared to decrease. Interestingly, however, these changes reversed
by 10 days post-FMT (Day +10), with loss of Lachnospiraceae, Bacteroidaceae, and
Porphyromonadaceae, and replacement by Enterobacteriaceae and Sutterellaceae. This
occurred concurrently with the initiation of fidaxomicin treatment 9 days following the
procedure.
Fecal microbiota transplantation alters the overall fecal bacterial community in
severe CDI patients. The Fast UniFrac distance metric, followed by PCoA based on
weighted and normalized UniFrac distances, was used to analyze changes in the
community structure of fecal microbiota in patients following FMT (Hamady et al.,
2010). After the first FMT, there was an observable shift in the fecal bacterial community
of Patient 2, away from the pre-treatment sample (Day 0) and towards the donor sample
on the first day following FMT (Day +1, Fig. 7.5A). However, concurrent with the
changes observed in the relative abundance of bacterial taxa, from Days +2 to +22, the
bacterial community became distinct from both the initial sample and donor sample.
Following the second FMT, the fecal microbial community in Patient 2 continued to
change and was closer to, though still distinct from, the donor’s microbiota.
In contrast, the bacterial communities in samples from Patient 3 were initially
quite distinct from that of the donor’s (Day -1 and Day 0, Fig. 7.5B). Following the initial
FMT, the community shifted closer to the donor along the first principal coordinate, but
appeared to change along the second principal coordinate away from both the donor and
the patient’s pre-FMT samples. Two weeks after the second FMT, the fecal microbial
community of Patient 3 was not shifted substantially closer to the donor communities
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than before the second procedure, though it remained distinct from the pre-FMT
community (Day +28/Day +15).
Changes in the fecal bacterial community in Patient 4 followed a different course
than either Patients 2 or 3. Interestingly, the community was relatively similar in the
donor sample and pre-FMT samples from Patient 4 (Day 0 and Day 0 Tx, Fig. 7.5C).
FMT in this patient did result in a substantial shift in the microbial community, but a shift
away from both pre-procedure and donor samples (Day +1, +2, and +3). However,
concomitant with changes in the relative abundance of phyla and families, a dramatic
shift occurred on Day +10, with the development of a community highly distinct from
any previous sample from this patient or the donor sample.
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DISCUSSION
The case histories described in this report illustrate the common medical
complexity of patients with severe CDI. In addition, review of these histories can identify
early missteps taken in their care, perhaps reflecting a historical perception of CDI as a
relatively mild and manageable complication of antibiotic therapy. However, the recent
emergence of more toxigenic strains of C. difficile and rising mortality associated with
CDI make this assumption no longer tenable (McDonald et al., 2005; Kelly and Lamont,
2008). Severe CDI is a potentially lethal disease, and even the best surgical treatment is
associated with high mortality (Dallal et al., 2002; Koss et al., 2006; Wysowski 2006;
Lamontagne et al., 2007). FMT has the potential to correct the underlying problem
associated with CDI and should be investigated as a much less invasive alternative to
surgery. We observed short-term clinical improvement in our four patients following
FMT. The improvement was particularly impressive in Patient 1 where close monitoring
in the MICU allowed visualization of hemodynamic stabilization within hours of the
procedure. Although FMT appeared sufficient to stabilize the patients for several days,
CDI ultimately returned in Patients 1 and 2. After these two experiences we continued the
double FMT protocol in subsequent cases, where the two procedures are separated by a
two-week course of antibiotics. We did not wait for recurrence of CDI in Patient 3, and
she did well with this protocol. Patient 4 did not complete the recommended treatment
course and ultimately succumbed to fulminant C. difficile colitis associated with
megacolon.
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It is likely that medical complexities of these patients are reflected in the
complicated changes to their fecal microbiota following FMT. Of the three patients
whose fecal microbiota were sequenced, only one (Patient 3) displayed dominance by
members of the phylum Proteobacteria prior to FMT, a trait found in recurrent CDI
patients and other diseases associated with microbial dysbiosis (Swidsinksi et al., 2005;
Frank et al., 2007; Chang et al., 2008; Khoruts et al., 2010; Wang et al., 2012). In
contrast, the fecal communities of Patients 2 and 4 had high relative abundances of
Bacteroidetes and Firmicutes prior to FMT, a pattern commonly found in healthy
individuals, despite these patients’ critical clinical conditions (Turnbaugh et al., 2007).
These findings mimic previous work comparing the fecal microbiota of patients with
initial versus recurrent CDI, suggesting that patients with severe CDI do not always
display the phylum-level dysbiosis seen in recurrent CDI (Chang et al., 2008).
Despite variation in bacterial phyla in the feces of these patients, there are
consistent patterns in family-level abundances. In fecal samples from all three patients, a
relatively high abundance of Enterobacteriaceae and a relatively low abundance of
Lachnospiraceae compared to donor samples were found prior to FMT. In Patients 2 and
3, who received a second FMT, the Enterobacteriaceae decreased and the
Lachnospiraceae increased for more than one day only following the second FMT. In
Patient 3, this is particularly unexpected because she was treated between procedures
with fidaxomicin, an antibiotic shown to spare the Lachnospiraceae (Tannock et al.,
2010; Louie et al., 2012). While similar changes are observable in Patient 4 following the
first FMT, these changes were reversed 10 days following the procedure. In both Patients
2 and 4, the dominance of Enterobacteriaceae and the decrease in Lachnospiraceae
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occurred prior to CDI recurrence. Taken together, these findings suggest that the stability
of the fecal microbiome in patients following FMT for severe CDI may be associated
with the presence of members of the family Lachnospiraceae. In contrast, an unstable
community structure of the fecal microbiome, perhaps indicating risk of CDI recurrence,
may be associated with the dominance of Enterobacteriaceae. These findings reflect
previous data, which suggest that the Enterobacteriaceae are associated with diseases
such as IBD and recurrent CDI (Swidsinski et al., 2005; Frank et al., 2007; Chang et al.,
2008; Khoruts et al., 2010; Wang et al., 2012). In addition, previous results have
indicated that the Lachnospiraceae are associated with the mucosal surface of healthy
individuals and may positively influence gut health, via regulation of the immune system
and production of molecules which act as fuel for colonic epithelial cells (Pryde et al.,
2002; Hamer et al., 2008; Atarashi et al., 2011; Nava and Stappenbeck, 2011).
Furthermore, in a recent mouse model, Lachnospiraceae strains prevented C. difficile
colonization, highlighting the importance of this group in prophylaxis and possibly
treatment of this disease (Reeves et al., 2012). The results presented here are consistent
with a potential role of Lachnospiraceae in patient recovery and microbiome stability in
severe CDI as well.
Recurrence of CDI following initial FMT in these patients differs from our
extensive experience treating multiply recurrent CDI in outpatients by FMT, where one
infusion of donor fecal microbiota is sufficient in approximately 92% of cases (Hamilton
et al., 2012). One possible explanation for this difference is that these hospitalized
patients returned immediately to their beds, likely contaminated with C. difficile, and
succumbed to reinfection before the donor microbiota could fully occupy their niches in
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the recipient’s colon. In fact, we are currently testing the hypothesis that heavy household
contamination may be a major reason for FMT failures in treating multiply recurrent
CDI. The instability of the fecal microbiome following a single FMT in Patients 2-4
found in this work, as indicated by shifts in microbial community structure in PCoA,
suggests that colonization niches may indeed be unoccupied following a single FMT,
allowing for CDI recurrence. Interestingly, Eiseman and colleagues used multiple daily
enemas in treating their critically ill patients with pseudomembranous colitis, a strategy
that may have facilitated stabilization of the colonic microbial community during the first
several days of treatment (Eiseman et al., 1958). In patients with severe CDI, therefore,
although a single FMT may assist in amelioration of life-threatening colitis, two FMT
procedures appear to be superior for stable engraftment of donor microbiota and full
clinical recovery.
In summary, our experience in this case series adds to the limited literature on the
use of FMT for treatment of severe CDI refractory to antibiotic therapy. Notably, a single
FMT only provided temporary clinical stabilization and was not sufficient to achieve
stability of the colonic microbial community. However, this treatment was sufficient to
allow another course of antibiotics and later administration of a second FMT on an
outpatient basis for longer-term results. The standardized, frozen preparation we
described earlier for recurrent CDI decreases practical concerns with this approach,
which typically must be implemented on an urgent basis (Hamilton et al., 2012). Such a
preparation of fecal microbiota should also simplify execution of randomized clinical
trials, which should be performed in treatment of severe CDI to compare against surgical
outcomes.
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Table 7.1 - Primer sequences used in this study.
Primer Name Sequence (5' - 3')
Forward Primer 1 CNACGCGAAGAACCTTANC
Forward Primer 2 CAACGCGAAAAACCTTACC
Forward Primer 3 CAACGCGCAGAACCTTACC
Forward Primer 4 ATACGCGARGAACCTTACC
Forward Primer 5 CTAACCGANGAACCTYACC
Reverse Primer 1 [6bp ID tag]CGACAGCCATGCANCACCT
Reverse Primer 2 [6bp ID tag]CGACAACCATGCANCACCT
Reverse Primer 3 [6bp ID tag]CGACGGCCATGCANCACCT
Reverse Primer 4 [6bp ID tag]CGACGACCATGCANCACCT
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Figure 7.1 - Clinical response of Patient 1 to FMT. A) Pseudomembranous colitis was
noted in images (left to right) of the sigmoid, transverse, and hepatic flexure colon. B)
White blood cell count was tracked daily during hospitalization; times of fecal microbiota
transplantation and colectomy are noted. Legend: FMT = fecal microbiota
transplantation, WBC = white blood cell.
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Figure 7.2 - Clinical response of Patient 2 to FMT. A) White blood cell count (left)
and C-reactive protein (right) were tracked daily during hospitalization. B)
Pseudomembranous colitis was observed in the sigmoid colon prior to first FMT. C)
Resolution of colitis in the same site prior to second FMT. Legend: FMT = fecal
microbiota transplantation; WBC = white blood cell, CRP = C-reactive protein; C. diff.
Neg. = stool samples were negative for C. difficile toxin B by PCR; and C. diff Pos. =
stool samples were positive for C. difficile toxin B by PCR.
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Figure 7.3 – Fecal bacterial phyla undergo change following each FMT. Relative
abundances of bacterial phyla in fecal samples across treatment course in Patient 2 (A),
Patient 3 (B), and Patient 4 (C), as well as donor samples. Colors correspond to phyla
(see key on figure). Legend: Day 0 during FMT = sample taken from colonoscopy flush
prior to FMT; and less abundant taxa = less than 0.5% of total sequences. Numbers
before slash indicate days after FMT 1; numbers after slash indicate days after FMT 2.
Arrows indicate initiation or cessation of antibiotics: VI = vancomycin initiation, VC =
vancomycin cessation, FI = fidaxomicin initiation, FC = fidaxomicin cessation, SI =
trimethoprim-sulfamethoxazole (TMP-SMX) initiation, SC = TMP-SMX cessation (see
Materials and Methods).
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Figure 7.4 – Fecal bacterial families undergo change following each FMT. Relative
abundances of bacterial families in fecal samples across treatment course in Patient 2 (A),
Patient 3 (B), and Patient 4 (C). Colors correspond to families (see key in figure).
Legend: Day 0 during FMT = sample taken from colonoscopy flush prior to FMT; less
abundant taxa = less than 0.5% of total sequences. Numbers before slash indicate days
after FMT 1; numbers after slash indicate days after FMT 2. Arrows indicate initiation or
cessation of antibiotics: VI = vancomycin initiation, VC = vancomycin cessation, FI =
fidaxomicin initiation, FC = fidaxomicin cessation, SI = trimethoprim-sulfamethoxazole
(TMP-SMX) initiation, SC = TMP-SMX cessation (see Materials and Methods).
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Figure 7.5 - Fecal bacterial communities shift relative to donor communities.
Principal coordinate analysis plots generated from weighted, normalized UniFrac
distances for Patient 2 (A), Patient 3 (B), and Patient 4 (C). Legend: Day 0 during FMT =
sample taken from colonoscopy flush prior to FMT; PC = principal coordinate; percent
variation explained follows coordinate; and red circles indicate donor samples. Numbers
before slash indicate days after FMT 1; numbers after slash indicate days after FMT 2.
Arrows indicate initiation or cessation of antibiotics: VI = vancomycin initiation, VC =
vancomycin cessation, FI = fidaxomicin initiation, FC = fidaxomicin cessation, SI =
trimethoprim-sulfamethoxazole (TMP-SMX) initiation, SC = TMP-SMX cessation (see
Materials and Methods).
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Chapter 8
Discussion
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Clostridium difficile infection and fecal microbiota transplantation
Clostridium difficile infection (CDI) is an increasingly common and severe
nosocomial infection (Zilberberg et al., 2008; Miller et al., 2011; Markelov et al., 2011;
Dubberke and Olsen, 2012; Magill et al., 2014; Lessa et al., 2015). With the rise in CDI,
the incidence of recurrences of this infection, where symptoms and the presence of the
pathogen in the stool return after completion of antibiotic therapy, is also on the rise
(Pepin et al., 2005; Kelly and Lamont, 2008; Khoruts and Sadowsky, 2011; Borody and
Khoruts, 2011; Vardakas et al., 2012; Lessa et al., 2015). Unfortunately, each recurrence
drastically increases the chance of further recurrence; initial recurrences occur in 20-30%
of patients treated with recommended antibiotics (Khoruts and Sadowsky, 2011;
Vardakas et al., 2012), while additional recurrences can occur in up to 65% of patients
who have already had one recurrent infection (Khoruts and Sadowsky, 2011). Eventually,
these patients may enter a vicious cycle characterized by repeated antibiotic therapy
followed by recurrence of CDI once antibiotics are halted – a condition known as
recurrent CDI syndrome (R-CDI).
Although most R-CDI patients are refractory towards antibiotic therapy, treatment
via transplantation with fecal material from a healthy donor is increasingly used to treat
these individuals. Compared to standard antibiotic therapy, fecal microbiota
transplantation (FMT) is extremely effective, relieving the symptoms of R-CDI and
preventing further recurrence in more than 90% of patients (Hamilton et al., 2012;
Kassam et al., 2013). Despite the extraordinary efficacy of FMT, however, little is known
about its mechanisms, limiting our ability to rationally design novel therapies for patients
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who do not meet the criteria for or fail FMT, and limiting our understanding of the role
our intestinal microbes play in our health.
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Summary of findings
In this work we have outlined our efforts to identify potential mechanisms behind
FMT, test those mechanisms, and use our understanding of those mechanisms to develop
novel treatments for R-CDI. Several previous efforts have used 16S rRNA gene
sequencing and subsequent bacterial community profiling to understand changes in the
fecal microbiome after the procedure. The results of these efforts have indicated that the
fecal microbiome undergoes significant shifts after FMT: while fecal communities from
patients with R-CDI are dominated by Proteobacteria, following FMT these
communities are predominantly Bacteroidetes and Firmicutes (Khoruts et al., 2010;
Shahinas et al., 2012; Hamilton et al., 2013; van Nood et al., 2013; Song et al., 2013;
Weingarden et al., 2014; Seekatz et al., 2014; Fuentes et al., 2014), similar to the
communities found in donors as well as in healthy individuals (Zoetendal et al., 2008;
Arumugam et al., 2011). However, these studies give very little functional data on the
fecal microbiome, and furthermore focus on the shift from pre-FMT to post-FMT
communities, with little information on the stability and normalization of the fecal
microbiome in the long- and short-term following the procedure.
One previous study has closely examined the dynamics of the fecal microbial
community following FMT (Song et al., 2013). These authors concluded that because
changes in the microbiome were observable after FMT, the community was unstable for
at least six weeks following the procedure (Song et al., 2013). However, it is well-known
that the fecal microbiome can undergo changes in healthy individuals over time
(Dethlefsen et al., 2008; Dethlefsen and Relman, 2011), and therefore simply observing
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changes post-FMT is not an indication that the microbiome has not stabilized. In our
efforts to understand the mechanisms of FMT, we began by examining whether these
changes in the microbiota fell within parameters comparable to changes in healthy
individuals (Chapter 2).
In order to understand the changes in the microbiome following FMT, we
compared microbial community shifts in patients to shifts within donor samples, and
additionally compared patient’s fecal communities to those of healthy individuals as
described in the Human Microbiome Project (Turnbaugh et al., 2007) (Chapter 2). Our
findings revealed that while the composition of the fecal microbiota continued to change
after FMT, the fecal communities of patients remained similar to those found in healthy
individuals. Furthermore, although the patients’ microbiota continued to shift after FMT,
the fecal microbiota of the donor underwent comparable shifts over time. Finally, we
defined two new parameters, normalization and dynamic range, to describe these post-
FMT changes. Neither normalization nor dynamic range were significantly different in
patients compared to the donor. Overall, our findings suggest that although fecal bacterial
communities of patients after FMT continue to change, these changes fall within the
normal variation of healthy individuals.
While these findings provided key insight into the engraftment of fecal bacteria
and may be useful as a biomarker to judge recovery versus recurrence after FMT, they
still do not provide functional data explaining how the engrafted microbiome prevents C.
difficile recurrence. To understand potential functions of the transplanted microbiota, we
performed metabolomics analysis of patient fecal samples before and after transplant,
along with analysis of the fecal bacterial communities (Chapter 3). Our findings revealed
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that, concurrent with recovery of the fecal microbiota, fecal bile acid composition
normalized. Specifically, bile acids present in patients’ fecal samples prior to FMT were
dominated by primary bile acids, produced by the liver, while bile acids present after
FMT as well as in healthy donors were predominantly secondary bile acids, which are
produced from primary bile acids by native colonic bacteria (Wells et al., 2000; Wells et
al., 2003; Ridlon et al., 2006; Hoffman and Hagey, 2008).
Importantly, previous work has identified a possible link between bile acids and
the physiology of Clostridium difficile. Some primary bile acids, notably cholate and its
conjugate taurocholate, have been shown to cause C. difficile spores to germinate
(Wilson, 1983; Sorg and Sonenshein, 2008). In contrast, several secondary bile acids,
including lithocholic acid, inhibit germination (Sorg and Sonenshein, 2009; Sorg and
Sonenshein, 2010). We hypothesized, therefore, that the shift in fecal bile acid
composition we observed after FMT could represent a change from an environment
favorable towards germination towards an environment where germination could not
occur, and therefore was a mechanism explaining the success of FMT.
Despite this enticing hypothesis, the relationship between primary and secondary
bile acids and C. difficile is not completely cut-and-dried. In particular, the primary bile
acid chenodeoxycholic acid (CDCA) can inhibit spore germination (Sorg and
Sonenshein, 2009; Sorg and Sonenshein, 2010), while the secondary bile acid
deoxycholate (DCA) has been shown to induce germination (Wilson, 1983; Sorg and
Sonenshein, 2008). To complicate the situation further, the response of different strains to
CDCA can vary: while spores from most strains are inhibited from germinating with
CDCA, it has no effect on germination in some strains, and in a few strains CDCA can
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itself induce germination (Heeg et al., 2012). Therefore, it was important to test our
hypothesis using combinations of bile acids reflective of the fecal environment before
and after FMT, rather than simply individual bile acids, and it was also necessary to
investigate the response of a variety of strains of C. difficile to these bile acid
combinations.
Our results with bile acid combinations revealed that exposure to fecal bile acids
present before FMT induced germination of C. difficile spores, while exposure to bile
acids present after FMT did not (Chapter 4), supporting our hypothesis. Furthermore, we
demonstrated that the post-FMT bile acid combination significantly inhibited vegetative
growth of C. difficile compared to pre-FMT bile acids. Importantly, our results remained
similar across a variety of C. difficile isolates and strains. These findings suggest that
while individual bile acids may have opposing effects on C. difficile physiology, the
overall fecal bile acid composition of patients with R-CDI allows for C. difficile
germination and growth, while fecal bile acid composition after FMT prevents both
germination and growth. This shift in fecal bile acid composition following FMT,
therefore, likely prevents CDI recurrence and explains the success of the procedure.
Having provided strong evidence for a mechanism underlying FMT, we sought to
use our understanding of this mechanism to rationally design novel therapies for R-CDI.
One secondary bile acid, ursodeoxycholic acid (UDCA), is already approved for clinical
use for bile acid disorders (Poupon, 2010; Lindor et al., 2009) and has been shown in a
limited study to inhibit in vitro C. difficile germination (Sorg and Sonenshein, 2010).
Here we demonstrated that UDCA could inhibit in vitro germination, as well as growth,
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across the multiple strains we examined previously, suggesting that this drug could be
used as a new therapy to prevent recurrence of CDI.
Despite the potential of UDCA, however, the drug has one key flaw: it is
absorbed in the small intestine and enters the enterohepatic circulation, limiting its
intracolonic concentration (Rodrigues et al., 1995; Hofmann and Hagey, 2008). However,
certain derivatives of UDCA, notably C7-sulfated UDCA (7-SUDCA), have been shown
to be minimally absorbed in the small intestine in animal models (Rodrigues et al., 1995).
We therefore tested whether 7-SUDCA, like UDCA, could prevent C. difficile
germination. Our results demonstrated that at concentrations ranging from 2-5 mM, 7-
SUDCA significantly inhibited germination of all tested isolates of C. difficile. As these
concentrations are well below the intracolonic concentrations of the drug in a rat model
(Rodrigues et al., 1995), 7-SUDCA is therefore a promising novel therapeutic to prevent
the recurrence of CDI.
Because our in vitro results suggested that 7-SUDCA could be a novel therapy for
CDI, we next tested the efficacy of this drug in vivo using a mouse model. We
successfully generated a model of CDI which displayed significant weight loss following
infection and maintained productive infection based on C. difficile growth from the feces
up to five days following infection. Using this model, we demonstrated that 7-SUDCA
treatment prevented weight loss and delayed the appearance of the bacterium in the feces.
Although 7-SUDCA was not delivered as initially intended, these efforts indicate that the
drug is likely to be a successful therapy for preventing CDI. Future efforts using this
model will be focused on twice-daily delivery of the drug to ensure more stable
concentrations of 7-SUDCA in the colon, delivery immediately following infection to
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mimic previous work with similar drugs (Howerton et al., 2013), and the addition of a
drug-treated group which is not infected to insure that the abrogation of weight loss with
the drug is not related to weight gain by the drug. While our findings with 7-SUDCA in
vivo are preliminary, they are promising results which suggest that the drug is effective
and that translation into humans is a very real possibility.
Although the use of UDCA itself may be limited due to its efficient uptake into
enterohepatic circulation in the small intestine (Rodrigues et al., 1995; Hofmann and
Hagey, 2008), in patients with altered intestinal anatomy the drug may have utility. C.
difficile infection is associated with 10% of diarrheal symptoms in patients with an ileal
pouch reservoir that is surgically created after a total colectomy (Seril and Shen, 2014).
Unfortunately, FMT may not be a reliable treatment for these patients (Hamilton et al.,
2012; Borody et al., 2014; Patel et al., 2014), possibly because the typical microbiota of
the small intestine and ileal pouch is distinct from that of the colon (Booijink et al., 2010;
Zella et al., 2011; Zoetendal et al., 2012; Young et al., 2013; Yasuda et al., 2015). We
successfully treated one such patient with oral UDCA, finding that in addition to
remaining free of infection more than eight months after halting antibiotics, the
concentrations of UDCA in the patient’s feces were more than sufficient to inhibit
germination of spores generated from the patient’s own isolate of C. difficile (Chapter 6).
Despite our clinical success, however, the fecal microbiota of this patient did not
normalize over three months after beginning UDCA. In particular, the Bacteroidetes
phylum, normally a dominant member of the fecal microbiota (Zoetendal et al., 2008;
Arumugam et al., 2011), remained nearly absent, the α-diversity of the microbiota
remained low, and the overall fecal bacterial communities remained distinct from healthy
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individuals. Unlike patients who successfully recover following FMT (Khoruts et al.,
2010; Shahinas et al., 2012; Hamilton et al., 2013; van Nood et al., 2013; Song et al.,
2013; Weingarden et al., 2014; Seekatz et al., 2014; Fuentes et al., 2014), the microbiota
seems not to have recovered in this patient. Therefore, it may be necessary to continue
oral UDCA treatment to prevent recurrence of CDI.
In addition to exploring novel therapies for R-CDI, we also presented here work
on using FMT for other forms of CDI (Chapter 7). As CDI has increased in incidence, the
incidence of severe or complicated forms of CDI has also risen (McDonald et al., 2005;
Kelly and Lamont, 2008; Merrigan et al., 2010). These forms of CDI are typically
clinically defined, using criteria such as the ATLAS criteria which include age,
temperature, leukocytosis, low serum albumin, and concurrent antibiotic use for other
conditions (Mulherin et al., 2014), though they can also include serious sequelae such as
toxic megacolon or pseudomembranous colitis (Cohen et al., 2010). Unfortunately,
currently recommended therapy for these severe forms of CDI is colectomy, or removal
of the colon (Markelov et al., 2011), which is associated with a postoperative mortality
rate of 35-80% (Dallal et al., 2002; Koss et al., 2006; Wysowski, 2006; Lamontagne et
al., 2007). We examined whether FMT could be used as an alternative therapy to
colectomy for four cases of severe CDI, and found that two sequential FMTs could lead
to lasting cure for the patients. An initial FMT clinically stabilizes the patient, while a
second FMT performed two weeks after the first can insure stable engraftment of donor
microbiota and prevent recurrence of disease.
Although these results suggest that FMT is a useful alternative to colectomy in
severe CDI, analysis of the fecal microbiome of these patients indicates that the
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mechanisms of the procedure may be different than those which prevent R-CDI. While a
single FMT did not result in sustained resistance to CDI recurrence, as indicated by both
the maintained predominance of the Enterobacteriaceae and recurrence of disease
following the procedure, clinical recovery of the patients, including defervesence,
decreased white blood cell count, and hemodynamic stabilization, was noted after the
initial procedure. In addition to non-lasting changes to the Enterobacteriaceae, the
Lachnospiraceae, often associated with recovery in R-CDI patients following FMT
(Hamilton et al., 2013; van Nood et al., 2013; Song et al., 2013; Weingarden et al., 2014;
Seekatz et al., 2014; Fuentes et al., 2014), recovered only temporarily (for 1 day or less)
following initial FMT. Previous results have indicated that the Lachnospiraceae are
associated with the mucosal surface of healthy individuals and may positively influence
gut health, via regulation of the immune system and production of molecules which act as
fuel for colonic epithelial cells (Pryde et al., 2002; Hamer et al., 2008; Atarashi et al.,
2011; Nava and Stappenbeck, 2011). It is possible, therefore, that this brief reappearance
of the Lachnospiraceae may have decreased the inflammatory response in these patients,
allowing for clinical recovery, even if lasting resistance to CDI recurrence was not
achieved.
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Concluding remarks and future directions
Although FMT is an extremely successful treatment for R-CDI, its mechanisms
were heretofore unknown. This work represents our efforts to uncover the mechanisms
behind this treatment and subsequently design novel therapies based on these
mechanisms. These therapies may be used to treat patients who fail FMT, who do not
meet the criteria for FMT, or who choose not to have an FMT. Ultimately, these new
therapies may replace FMT entirely.
Our findings reveal that fecal bile acids play a key role in preventing subsequent
recurrence following FMT (Fig. 8.1). Before FMT, bile acids in the feces are
predominantly primary bile acids, which in combination induce C. difficile germination
and permit vegetative growth. In contrast, after FMT fecal bile acids are dominated by
the secondary bile acids, which in combination do not allow germination and
significantly inhibit vegetative growth. Furthermore, pharmacological manipulation of
these bile acids is capable of preventing C. difficile infection. For patients who develop
R-CDI pouchitis following colectomy, UDCA is already available as a therapy to prevent
recurrence. We have demonstrated in vitro and have preliminary data from a mouse
model of CDI that 7-SUDCA can prevent germination and infection. 7-SUDCA
represents one bile acid derivative that may be useful in patients with normal intestinal
anatomy.
In addition to 7-SUDCA, it is likely that other bile acid analogs may represent
additional therapeutic options. Much of our future work will focus on testing other bile
acid analogs, some of which may have even greater effects on C. difficile. Although 7-
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SUDCA has already been shown to be unabsorbed by the host and non-metabolized by
the colonic microbiota, pharmacokinetic studies will be needed to determine whether
these other analogs are also unabsorbed and non-metabolized.
While we have made significant strides towards non-antibiotic pharmacological
solutions to R-CDI, manipulation of the microbiota remains a viable avenue of treatment.
Our work and the work of others (Buffie et al., 2014) have pointed towards the potential
of bacteria capable of performing 7α-dehydroxylation to produce secondary bile acids in
vivo. While Buffie and colleagues focused on Clostridium scindens, one of the best-
described 7α-dehydroxylating bacteria, it is known that other bacteria in the human colon
possess this metabolic pathway. Future efforts will be focused on uncovering and
understanding these bacteria, and investigating their use in preventing CDI recurrence.
Finally, having demonstrated the efficacy of 7-SUDCA in vitro and in mice, it
will be necessary to translate this novel therapy to the clinic. This will require
multidisciplinary efforts from clinical researchers, microbiologists, medicinal chemists,
and more. Eventually, it is possible that 7-SUDCA or another bile acid analog may
replace FMT entirely, as the ease of oral therapy makes pharmacological solutions
preferable to the procedure. The work presented herein represents the first steps down
this path.
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Figure 8.1 – Model of the mechanism of fecal microbiota transplantation and the
relationship between bile acids and C. difficile infection. R-CDI is characterized by an
abundance of primary bile acids in the feces, which induce germination and allow growth
of C. difficile. In contrast, the feces of healthy individuals, or post-FMT patients, is
dominated by secondary bile acids, which do not induce germination and limit growth of
C. difficile. Predominance by primary bile acids in the feces may be caused or maintained
by the repeated antibiotic treatments R-CDI patients receive, while FMT restores
secondary bile acid metabolism to prevent recurrence of infection. Prevention of
recurrence may also be achieved by directly replacing secondary bile acids using UDCA
or 7-SUDCA. R-CDI: recurrent C. difficile infection; FMT: fecal microbiota
transplantation; UDCA: ursodeoxycholic acid; 7-SUDCA: C7-sulfated UDCA.
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